CLDF Title
Home | Contact Us | Bookmark
HEPATITIS
HBV HCV HDV
CIRRHOSIS
HEPATIC ENCEPHALOPATHY (HE) HEPATORENAL SYNDROME (HRS) THROMBOCYTOPENIA
NASH
CHOLESTATIC
PRIMARY BILIARY CHOLANGITIS (PBC)
HCC PEDIATRIC LIVER DISEASE
About CLDF
Board of Trustees Board of Advisors/Faculty 2020 GI Fellow Board of Advisors CLDF Committees
Centers of Educational Expertise  
Live Events Slide Library Webcasts Abstract Library Committee Members Conference Highlights
 
HCV | Abstract Library
Abstract Library
 
The summaries are free for public use. The Chronic Liver Disease Foundation will continue to add and archive summaries of articles deemed relevant to CLDF by the Board of Trustees and its Advisors.
1.Global adverse events reported for direct-acting antiviral therapies for the treatment of hepatitis C: an analysis of the World Health Organization VigiBase
 

Eur J Gastroenterol Hepatol. 2021 Apr 21. doi: 10.1097/MEG.0000000000002173.Online ahead of print.

Kaleen N Hayes 1, Theresa Burkard, Stefan Weiler, Mina Tadrous, Andrea M Burden

 
 
2.Hepatitis C Virus Testing Among Men With Human Immunodeficiency Virus Who Have Sex With Men: Temporal Trends and Racial/Ethnic Disparities
 

  • Open Forum Infect Dis. 2021 Apr 17;8(4):ofaa645. doi: 10.1093/ofid/ofaa645.eCollection 2021 Apr.

    Jun Li 1, Carl Armon 2, Frank J Palella 3, Ellen Tedaldi 4, Richard M Novak 5, Jack Fuhrer 6, Gina Simoncini 4, Kimberly Carlson 2, Kate Buchacz 1, HIV Outpatient Study (HOPS) Investigators

    Collaborators

  • HIV Outpatient Study (HOPS) Investigators: 

  • Jun Li, Kate Buchacz, Marcus D Durham, Cheryl Akridge, Stacey Purinton, Nabil Rayeed, Selom Agbobil-Nuwoaty, Kalliope Chagaris, Kimberly Carlson, Carl Armon, Linda Battalora, Jonathan Mahnken, Frank J Palella, Saira Jahangir, Conor Daniel Flaherty, Patricia Bustamante, John Hammer, Kenneth S Greenberg, Barbara Widick, Rosa Franklin, Douglas J Ward, Troy Thomas, Cheryl Stewart, Jack Fuhrer, Linda Ording-Bauer, Rita Kelly, Jane Esteves, Ellen M Tedaldi, Ramona A Christian, Faye Ruley, Dania Beadle, Princess Davenport, Richard M Novak, Andrea Wendrow, Stockton Mayer, Mia Scott, Billie Thomas, Loraine Van Slyke, Cynthia Mayer, Terry Beitler, Karen Maroney, Denise Franklin
 
3.Sustained and cumulative impact of an electronic medical record-based alert on a hepatitis C birth cohort screening program
 

J Viral Hepat. 2021 Apr 25. doi: 10.1111/jvh.13524. Online ahead of print.

Claus J Fimmel 1, Mohammad Q Khan 1, Yuliya Belopolsky 1, Polina Imas 1, Anuhya Gampa 1, Amnon Sonnenberg 2
 
4.Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian 'surveillance and treatment of prisoners with hepatitis C' project (SToP-C)
 

Harm Reduct J. 2021 Apr 26;18(1):46. doi: 10.1186/s12954-021-00494-4.

Jake Rance 1, Lise Lafferty 2, Carla Treloar 2, SToP-C Study Group

Collaborators

  • SToP-C Study Group: 

Stuart Loveday, Gregory Dore, Andrew Lloyd, Jason Grebely, Tony Butler, Natasha Martin, Georgina Chambers, Carla Treloar, Marianne Byrne, Roy Donnelly, Colette McGrath, Julia Bowman, Lee Trevethan, Luke Grant, Terry Murrell, Nicky Bath, Mary Harrod, Alison Churchill, Kate Pinnock, Sallie Cairnduff
 
5.Implementation of a Hepatitis C Treatment Program Into a Primary Care Residency Clinic
 

PRiMER. 2021 Jan 22;5:1. doi: 10.22454/PRiMER.2021.532368. eCollection 2021.

Morgan Adams Rhodes 1, Mark Humphrey 1
 
6.Using the Electronic Health Record to Characterize the Hepatitis C Virus Care Cascade
 

Public Health Rep. 2021 Apr 8;333549211005812. doi: 10.1177/00333549211005812.Online ahead of print.

Shannon M Christy 1 2 3 4, Richard R Reich 5, Julie A Rathwell 3 6, Susan T Vadaparampil 1 3 4, Kimberly A Isaacs-Soriano 3 6, Mark S Friedman 2 4, Richard G Roetzheim 1 3 7, Anna R Giuliano 3 4 6
 
7.Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease
 

Nephrol Dial Transplant. 2021 Apr 12;gfab072. doi: 10.1093/ndt/gfab072. Online ahead of print.

Meghan E Sise 1, Thomas McQuaid 2, Paul Martin 3
 
8.Risk factors for loss to follow-up of persons who inject drugs enrolled at syringe services programs in Kentucky
 

Int J Drug Policy. 2021 Apr 10;95:103255. doi: 10.1016/j.drugpo.2021.103255.Online ahead of print.

Jaime Soria 1, Tisha Johnson 2, Jana Collins 3, Greg Corby-Lee 3, James Thacker 3, Connie White 2, Ardis Hoven 3, Alice Thornton 3
 
9.Atherosclerotic Cardiovascular Disease in Individuals with Hepatitis C Viral Infection
 

Curr Cardiol Rep. 2021 Apr 6;23(5):52. doi: 10.1007/s11886-021-01475-6.

Alison L Bailey 1, Saif Al-Adwan 2, Eliea Sneij 3, Nicholas Campbell 3, Matthew E Wiisanen 4
 
10.Predictors of hepatitis C treatment outcomes in a harm reduction-focused primary care program in New York City
 

Harm Reduct J. 2021 Mar 31;18(1):38. doi: 10.1186/s12954-021-00486-4.

Jacob Ziff 1, Trang Vu 2, Danielle Dvir 2, Farah Riazi 2, Wilma Toribio 2, Scott Oster 2, Keith Sigel 2, Jeffrey Weiss 2
 
11.Impact of antiviral therapy with Direct Acting Antiviral Agents (DAAs) on kidney disease in patients with chronic hepatitis C
 

Minerva Gastroenterol (Torino). 2021 Apr 1. doi: 10.23736/S2724-5985.21.02849-X.Online ahead of print.

Fabrizio Fabrizi 1, Roberta Cerutti 2, Carlo M Alfieri 2 3, Ezequiel Ridruejo 4 5
 
12.Hepatitis E Infection in a Longitudinal Cohort of HCV and HCV/HIV Coinfected Persons
 

AIDS Res Hum Retroviruses. 2021 Apr 1. doi: 10.1089/AID.2020.0303. Online ahead of print.

Kenneth E Sherman 1 2, Shyam Kottilil 3, Susan D Rouster 4, Enass A Abdel-Hameed 5, Ceejay L Boyce 6, Heidi L Meeds 7, Norah Terrault 8, M Tarek Shata 9
 
13.Association of exercise participation levels with cardiometabolic health and quality of life in individuals with hepatitis C
 

BMJ Open Gastroenterol. 2021 Mar;8(1):e000591. doi: 10.1136/bmjgast-2020-000591.

Kate Hallsworth 1 2 3, Shion Gosrani 1, Sarah Hogg 1, Preya Patel 1, Aaron Wetten 1, Rachael Welton 1, Stuart McPherson 4 2, Matthew D Campbell 5 6
 
14.High hepatitis C virus seropositivity, viremia, and associated risk factors among trans women living in San Francisco, California
 

PLoS One. 2021 Mar 30;16(3):e0249219. doi: 10.1371/journal.pone.0249219. eCollection 2021.

Christopher J Hernandez 1, Dillon Trujillo 1, Sofia Sicro 1, Joaquin Meza 1, Mackie Bella 1, Emperatriz Daza 1, Francisco Torres 1, Willi McFarland 1 2, Caitlin M Turner 1 2, Erin C Wilson 1 2
 
15.The 2020 Nobel Prize for Medicine or Physiology for the Discovery of Hepatitis C Virus: A Triumph of Curiosity and Persistence
 

Hepatology. 2021 Mar 30. doi: 10.1002/hep.31830. Online ahead of print.

Marc G Ghany 1, Anna S F Lok 2, Jules L Dienstag 3, Stephen M Feinstone 1, Jay H Hoofnagle 4, T Jake Liang 1, Leonard B Seeff 5, David E Cohen 6, Jorge A Bezerra 7, Raymond T Chung 3
 
16.Pharmacokinetics, safety, and efficacy of glecaprevir/pibrentasvir in children with chronic hepatitis C virus: part 2 of the DORA study
 

Hepatology. 2021 Apr 2. doi: 10.1002/hep.31841. Online ahead of print.

Maureen M Jonas 1, Susan Rhee 2, Deirdre A Kelly 3, Antonio Del Valle-Segarra 4, Cornelia Feiterna-Sperling 5, Susan Gilmour 6, Regino P Gonzalez-Peralta 7, Loreto Hierro 8, Daniel H Leung 9, Simon C Ling 10, Yuri Lobzin 11, Steven Lobritto 12, Tatsuki Mizuochi 13, Michael R Narkewicz 14, Vishakha Sabharwal 15, Jessica Wen 16, Hoi Kei Lon 2, John Marcinak 2, Andrew Topp 2, Rakesh Tripathi 2, Etienne Sokal 17
 
17.Risks for acquiring hepatitis C virus among women in the United States
 

Public Health Nurs. 2021 Mar 22. doi: 10.1111/phn.12892. Online ahead of print.

Theresa Watts 1, Diane Lauver 2, Traci Snedden 2, Susan Zahner 2
 
18.Hepatitis C standards of care: A review of good practices since the advent of direct-acting antiviral therapy
 

Clin Res Hepatol Gastroenterol. 2021 Mar 15;45(2):101564.doi: 10.1016/j.clinre.2020.11.001. Online ahead of print.

Jeffrey V Lazarus 1, Camila A Picchio 2, Danielle Guy 2, Soo Aleman 3, Cary James 4, Felice A Nava 5, Anne Øvrehus 6, Juan Turnes 7, John W Ward 8, Andy Ustianowski 9
 
19.Risk Factors Associated With Chronic Liver Enzyme Elevation in Persons With HIV Without Hepatitis B or C Coinfection in the Combination Antiretroviral Therapy Era
 

Open Forum Infect Dis. 2021 Feb 24;8(3):ofab076. doi: 10.1093/ofid/ofab076.eCollection 2021 Mar.

Shannon Wood 1 2 3 4, Seung Hyun Won 3 5, Hsing-Chuan Hsieh 3 5, Tahaniyat Lalani 3 5 6, Karl Kronmann 3 6, Ryan C Maves 3 7, Gregory Utz 3 7, Christina Schofield 3 4, Rhonda E Colombo 3 5 4, Jason F Okulicz 3 8, Jason Blaylock 2 3, Brian K Agan 3 5, Anuradha Ganesan 2 3 5
 
20.Non-Invasive Reliable Methods to Objectify the Positive Influence of Hepatitis C Virus Treatment on Liver Stiffness
 

Gastroenterology Res. 2021 Feb;14(1):31-40. doi: 10.14740/gr1347. Epub 2021 Feb 19.

Florian Bert 1, Jona Theodor Stahmeyer 2, Andra-Livia Parpalea 1, Siegbert Rossol 1

Af
 
21.The Changing Epidemiology of Hepatitis C Virus Infection in the United States During the Years 2010 to 2018
 

Am J Public Health. 2021 Mar 18;e1-e7. doi: 10.2105/AJPH.2020.306149. Online ahead of print.

Deborah Holtzman 1, Alice K Asher 1, Sarah Schillie 1
 
22.Higher Levels of Fibrosis in a Cohort of Veterans with Chronic Viral Hepatitis are Associated with Extrahepatic Cancers
 

J Clin Exp Hepatol. Mar-Apr 2021;11(2):195-200. doi: 10.1016/j.jceh.2020.08.001.Epub 2020 Aug 9.

Ameer Abutaleb 1, Jose Antonio Almario 2, Saleh Alghsoon 2, Ji Ae Yoon 3, Kate Gheysens 2, Shyam Kottilil 4, Eleanor Wilson 4
 
23.Treatment failure with DAA therapy: importance of resistance
 

J Hepatol. 2021 Mar 11;S0168-8278(21)00169-0. doi: 10.1016/j.jhep.2021.03.004.Online ahead of print.

Christoph Sarrazin 1
 
24.Social vulnerability in persons with chronic hepatitis C virus infection is associated with a higher risk of prescription opioid use
 

Sci Rep. 2021 Mar 15;11(1):5883. doi: 10.1038/s41598-021-85283-6.

Adeel A Butt 1 2 3 4, Peng Yan 5, Shashi Kapadia 6, Abdul-Badi Abou-Samra 7, Naveed Z Janjua 8 9, Said Ibrahim 6
 
25.Impact of Behavioral Health Consultation on Hepatitis C Treatment Outcomes at a Federally Qualified Health Center; Philadelphia, PA
 

J Prim Prev. 2021 Apr;42(2):203-215. doi: 10.1007/s10935-021-00627-2. Epub 2021 Mar 18.

Kaitlin Grosgebauer 1, Tyler S Bartholomew 2 3, Katherine Huynh 4, Travis Cos 4 5
 
26.Constructing a middle-range theory to explain the uptake of hepatitis C tests in prison
 

Nurse Res. 2021 Mar 18. doi: 10.7748/nr.2021.e1782. Online ahead of print.

Kathryn Jack 1, Paul Linsley 2
 
27.Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/HCV co-infected women
 

AIDS. 2021 Mar 11. doi: 10.1097/QAD.0000000000002869. Online ahead of print.

Audrey L French 1, Dara Grennan, Elizabeth Daubert, Eric C Seaberg, Marion Peters, Michael Augenbraun, Margaret Fischl, Seble Kassaye, Ricardo Franco, Mark Kuniholm, Adaora A Adimora, Kimberly Workowski, Kathleen M Weber
 
28.Attitudes toward pharmacy-based HCV/HIV testing among people who use drugs in rural Kentucky
 

J Rural Health. 2021 Mar 5. doi: 10.1111/jrh.12564. Online ahead of print.

Michelle Duong 1, Chris Delcher 2, Patricia R Freeman 2, April M Young 3 4, Hannah L F Cooper 5
 
29.Systematic review: Accuracy of the enhanced liver fibrosis test for diagnosing advanced liver fibrosis and cirrhosis
 

J Gastroenterol Hepatol. 2021 Mar 5. doi: 10.1111/jgh.15482. Online ahead of print.

Chetanya Sharma 1, Sara Cococcia 1 2, Nicola Ellis 1, Julie Parkes 3, William Rosenberg 1
 
30.Exploring and understanding HCV patient journeys- HEPCARE Europe project
 

BMC Infect Dis. 2021 Mar 5;21(1):239. doi: 10.1186/s12879-021-05928-9.

Shannon Glaspy 1, Gordana Avramovic 1 2, Tina McHugh 1 2, Cristiana Oprea 3, Julian Surey 4 5, Irina Ianache 3, Juan Macías 6, Alistair Story 7, Walter Cullen 1, John S Lambert 8
 
31.Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry
 

Clin Infect Dis. 2021 Mar 2;ciaa1510. doi: 10.1093/cid/ciaa1510. Online ahead of print.

Fernanda Q Onofrio 1, Curtis Cooper 2, Sergio M Borgia 3, Marie-Louise Vachon 4, Alnoor Ramji 5, Leslie B Lilly 6, Alexander Wong 7, Joshua Booth 1, Izza Sattar 1, Heidy Morales 1, Samuel Lee 8, Brian Conway 9, Jordan J Feld 1
 
32.Where are the children in national hepatitis C policies? A global review of national strategic plans and guidelines
 

JHEP Rep. 2021 Jan 15;3(2):100227. doi: 10.1016/j.jhepr.2021.100227. eCollection 2021 Apr.

Farihah Malik 1, Heather Bailey 2, Polin Chan 3, Intira Jeannie Collins 4, Antons Mozalevskis 5, Claire Thorne 1, Philippa Easterbrook 6
 
33.Lymphocyte Landscape after Chronic Hepatitis C Virus (HCV) Cure: The New Normal
 

Int J Mol Sci. 2020 Oct 10;21(20):7473. doi: 10.3390/ijms21207473.

Alip Ghosh 1, Sara Romani 1, Shyam Kottilil 1, Bhawna Poonia 1
 
34.County-Level Variation in Hepatitis C Virus Mortality and Trends in the United States, 2005-2017
 

Hepatology. 2021 Feb 20. doi: 10.1002/hep.31756. Online ahead of print.

Eric W Hall 1, Sarah Schillie 2, Adam S Vaughan 3, Jeb Jones 1, Heather Bradley 4, Ben Lopman 1, Eli Rosenberg 5, Patrick Sullivan 1
 
35.HCV virology and diagnosis
 

Clin Res Hepatol Gastroenterol. 2021 Feb 23;45(3):101626.doi: 10.1016/j.clinre.2021.101626. Online ahead of print.

Steven Roger 1, Alexandra Ducancelle 1, Hélène Le Guillou-Guillemette 1, Catherine Gaudy 2, Françoise Lunel 3
 
36.Willingness to Participate in Research among Black Patients with Liver Disease: A National Cross-Sectional Study
 

J Viral Hepat. 2021 Mar 4. doi: 10.1111/jvh.13493. Online ahead of print.

F Hunter McGuire 1 2, Kat André 2 3, Minyone L Bradsher 2, Dawn Harrison 4, Richard K Sterling 5, K Rajender Reddy 6, Marina Serper 6, Carol E Golin 1 7, Nancy Reau 8, Joseph K Lim 9, David R Nelson 10, Souvik Sarkar 11, Donna M Evon 2 4
 
37.High HCV cure rates among people who inject drugs and have suboptimal adherence: A patient-centered approach to HCV models of care
 

Int J Drug Policy. 2021 Mar 1;93:103135. doi: 10.1016/j.drugpo.2021.103135.Online ahead of print.

Brianna L Norton 1, Matthew J Akiyama 2, Julia H Arnsten 3, Linda Agyemang 4, Moonseong Heo 5, Alain H Litwin 6
 
38.Hepatitis C treatment in a co-located mental health and alcohol and drug service using a nurse-led model of care
 

J Viral Hepat. 2021 Feb 17. doi: 10.1111/jvh.13487. Online ahead of print.

Brendan L Harney 1 2, Rebecca Brereton 3, Bradley Whitton 1, Danusia Pietrzak 3, Emma Paige 1, Stuart K Roberts 4 5, Susanne Birks 3, Sudeep Saraf 3, Margaret E Hellard 1 2, Joseph S Doyle 1 2
 
39.Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2)
 

Health Psychol Res. 2021 Jan 20;8(3):9450. doi: 10.4081/hpr.2020.9450.eCollection 2020 Dec 30.

Gaetano Bertino 1, Rosalia Ragusa 2, Liberato Simone Corsaro 3, Evelise Frazzetto 1, Vincenzo Messina 4, Lucio Inguscio 5, Carlo Lai 5, Marilena Maglia 6, Andrea Nunnari 7, Pasquale Caponnetto 6
 
40.A Survey of Practices in the United States Regarding Hepatitis C Screening in Pregnant Women
 

Clin Ther. 2021 Feb 5;S0149-2918(21)00020-5. doi: 10.1016/j.clinthera.2021.01.016.Online ahead of print.

Elizabeth A Godar 1, Ravi Jhaveri 2
 
41.Initiation of Low-threshold Buprenorphine in Nontreatment Seeking Patients With Opioid Use Disorder Engaged in Hepatitis C Treatment
 

J Addict Med. 2021 Feb 5. doi: 10.1097/ADM.0000000000000807. Online ahead of print.

Kristi Hill 1, Laura Nussdorf, Julia D Mount, Rachel Silk, Chloe Gross, David Sternberg, Phyllis Bijole, Miriam Jones, Randy Kier, Dana Mccullough, Poonam Mathur, Shyam Kottilil, Henry Masur, Sarah Kattakuzhy, Elana S Rosenthal
 
42.The persistence of underreporting of hepatitis C as an underlying or contributing cause of death, 2011-2017
 

Clin Infect Dis. 2021 Feb 9;ciab108. doi: 10.1093/cid/ciab108. Online ahead of print.

Philip R Spradling 1, Yuna Zhong 1, Anne C Moorman 1, Loralee B Rupp 2, Mei Lu 2, Eyasu H Teshale 1, Mark A Schmidt 3, Yihe G Daida 4, Joseph A Boscarino 5, Stuart C Gordon 2 6
 
43.Direct-Acting Antiviral Treatment Use Remains Low Among Florida Medicaid Beneficiaries With Chronic Hepatitis C
 

Hepatol Commun. 2020 Nov 17;5(2):203-216. doi: 10.1002/hep4.1634. eCollection 2021 Feb.

Haesuk Park 1, Hyun Jin Song 1, Xinyi Jiang 1, Linda Henry 1, Robert L Cook 2, David R Nelson 3
 
44.The impact of electronic medical record system implementation on HCV screening and continuum of care: a systematic review
 

Ann Hepatol. 2021 Feb 4;24:100322. doi: 10.1016/j.aohep.2021.100322. Online ahead of print.

Lauren Barter 1, Curtis L Cooper 2
 
45.Screening for Sexually Transmitted Infections During Hepatitis C Treatment to Predict Reinfection Among People With HIV
 

Open Forum Infect Dis. 2020 Dec 30;8(2):ofaa643. doi: 10.1093/ofid/ofaa643.eCollection 2021 Feb.

Lucas A Hill 1, Natasha K Martin 2, Francesca J Torriani 2, Sonia Jain 3, Huifang Qin 4, Wm Christopher Mathews 4, Edward R Cachay 2
 
46.The Impact of Hepatitis C and Liver Disease on Risk of Complications After Total Hip and Knee Arthroplasty: Analysis of Administrative Data From Louisiana and Texas
 

Arthroplast Today. 2021 Feb 2;7:200-207. doi: 10.1016/j.artd.2020.12.016. eCollection 2021 Feb.

Brett Salomon 1, Peter C Krause 2, Vinod Dasa 2, Lizheng Shi 3, Deryk Jones 4, Andrew G Chapple 5
 
47.Hepatitis C direct-acting antiviral outcomes in patients 75 years and older
 

JGH Open. 2020 Dec 18;5(2):253-257. doi: 10.1002/jgh3.12480. eCollection 2021 Feb.

Parmvir Parmar 1 2, Stephen D Shafran 3, Sergio M Borgia 4, Karen Doucette 3, Curtis L Cooper 1 2
 
48.Deinduction of P-glycoprotein resulting in delayed viral response during hepatitis C treatment
 

J Clin Pharm Ther. 2021 Feb 3. doi: 10.1111/jcpt.13374. Online ahead of print.

Jennifer E Stark 1, Jennifer L Cole 1
 
49.Global prevalence of hepatitis C virus in women of childbearing age in 2019: a modelling study
 

Lancet Gastroenterol Hepatol. 2021 Mar;6(3):169-184. doi: 10.1016/S2468-1253(20)30359-9.Epub 2021 Jan 28.

Ellen Dugan 1, Sarah Blach 1, Mia Biondi 2, Zongzhen Cai 1, Mindi DePaola 1, Chris Estes 1, Jordan Feld 3, Ivane Gamkrelidze 1, Shyamasundaran Kottilil 4, Siya Ma 1, Poonam Mathur 1, Shauna Montoya 1, Devin Razavi-Shearer 1, Kathryn Razavi-Shearer 1, Sarah Robbins-Scott 1, Jonathan Schmelzer 1, Homie Razavi 5
 
50.Outcomes of Hepatitis C Virus Seropositive Donors to Hepatitis C Virus Seronegative Liver Recipients: A Large Single Center Analysis
 

Ann Hepatol. 2021 Jan 27;100318. doi: 10.1016/j.aohep.2021.100318. Online ahead of print.

Lindsay A Sobotka 1, Khalid Mumtaz 1, Michael R Wellner 1, Sean G Kelly 1, Lanla F Conteh 1, A James Hanje 1, Austin Schenk 2, Ashraf El-Hinnawi 2, Sylvester Black 2, Kenneth Washburn 2, Todd Pesavento 3, Reem Daloul 3, Anthony J Michaels 4
 
51.A drug repurposing screen identifies hepatitis C antivirals as inhibitors of the SARS-CoV2 main protease
 

PLoS One. 2021 Feb 1;16(2):e0245962. doi: 10.1371/journal.pone.0245962. eCollection 2021.

Jeremy D Baker 1 2, Rikki L Uhrich 2, Gerald C Kraemer 3, Jason E Love 4, Brian C Kraemer 1 2 5 6
 
52.Relationship between hepatitis C virus (HCV) IgG index values and quantitative HCV RNA results in HCV IgG-reactive serum samples
 

Diagn Microbiol Infect Dis. 2021 Jan 19;100(1):115311. doi: 10.1016/j.diagmicrobio.2021.115311.Online ahead of print.

Harry E Prince 1, Elizabeth M Marlowe 2, Dale S Schwab 2
 
53.Delays and Gaps in Progressing Through the Hepatitis C Virus Cascade of Care: An Underserved Safety-net Hospital Experience
 

Chantal Gomes 1, Dina Ginzberg 1, Robert J Wong 2 3
 
54.Mortality is Not Increased in SARS-CoV-2 Infected Persons With Hepatitis C Virus Infection
 

Liver Int. 2021 Feb 3. doi: 10.1111/liv.14804. Online ahead of print.

Adeel A Butt 1 2, Peng Yan 1, Rashid A Chotani 3 4, Obaid S Shaikh 1 5
 
55.Applicability of a new specialty pharmacy-reported measure describing completion of therapy for hepatitis C
 

J Manag Care Spec Pharm. 2021 Feb;27(2):263-267. doi: 10.18553/jmcp.2021.27.2.263.

Clay Bolduc 1, Kenneth McCall 3rd 2, Kirsten Stickney 3, Alycia Gelinas 3, Eileen Levesque 3
 
56.Cost-effectiveness of syringe service programs, medications for opioid use disorder, and combination programs in hepatitis C harm reduction among opioid injection drug users: a public payer perspective using a decision tree
 

J Manag Care Spec Pharm. 2021 Feb;27(2):137-146. doi: 10.18553/jmcp.2021.27.2.137.

Stephen C Ijioma 1, Vasco M Pontinha 1, David A Holdford 1, Norman V Carroll 1
 
57.Hepatitis B Virus Reactivation in Cancer Patients Receiving Direct-Acting Antivirals for Hepatitis C Virus Infection
 

J Viral Hepat. 2021 Feb 1. doi: 10.1111/jvh.13478. Online ahead of print.

Haley Pritchard 1 2 3, Jessica P Hwang 4, Georgios Angelidakis 2, Marcel Yibirin 2, Lan Wang 5, Ethan Miller 5, Harrys A Torres 2 5
 
58.Pharmaceutical citizenship in an era of universal access to hepatitis C treatment: Situated potentials and limits
 

Health (London). 2021 Jan 28;1363459320988887. doi: 10.1177/1363459320988887.Online ahead of print.

Jake Rance 1, Tim Rhodes 1 2, Kari Lancaster 1

Health (London). 2021 Jan 28;1363459320988887. doi: 10.1177/1363459320988887.Online ahead of print.

Jake Rance 1, Tim Rhodes 1 2, Kari Lancaster 1

 
 
59.Long-Term Patient Centered Outcomes in Cirrhotic Patients with Chronic Hepatitis C After Achieving Sustained Virologic Response
 

Clin Gastroenterol Hepatol. 2021 Jan 22;S1542-3565(21)00076-8.doi:10.1016/j.cgh.2021.01.026. Online ahead of print.

Zobair M Younossi 1, Andrei Racila 2, Andrew Muir 3, Marc Bourliere 4, Alessandra Mangia 5, Rafael Esteban 6, Stefan Zeuzem 7, Massimo Colombo 8, Michael Manns 9, George V Papatheodoridis 10, Maria Buti 6, Anand Chokkalingam 11, Anuj Gaggar 11, Fatema Nader 12, Issah Younossi 12, Linda Henry 12, Maria Stepanova 12
 
60.Experiences of an HCV Patient engagement group: a seven-year journey
 

Res Involv Engagem. 2021 Jan 25;7(1):7. doi: 10.1186/s40900-021-00249-2.

UNC Chapel Hill HCV Patient Engagement Group; Scott Kixmiller 1, Anquenette P Sloan 2, Summer Wadsworth 2, Finton Brown 2, Lourdes Chaney 3, Larry Houston 2, Kim Thomas 4
 
61.Hepatitis C Virus Transmission Clusters in Public Health and Correctional Settings, Wisconsin, USA, 2016-2017 1
 

Emerg Infect Dis. 2021 Feb;27(2):480-489. doi: 10.3201/eid2702.202957.

Karli R Hochstatter, Damien C Tully, Karen A Power, Ruth Koepke, Wajiha Z Akhtar, Audrey F Prieve, Thomas Whyte, David J Bean, David W Seal, Todd M Allen, Ryan P Westergaard
 
62.Identifying the Hidden Population: Former Intravenous Drug Users Who Are No Longer in Contact with Services. "Ask a Friend"
 

Diagnostics (Basel). 2021 Jan 25;11(2):170. doi: 10.3390/diagnostics11020170.

Sarah R Donaldson 1 2, Andrew Radley 1 2, John F Dillon 1 3
 
63.Assessment of health-related quality of life and health utilities in Australian patients with cirrhosis
 

JGH Open. 2020 Dec 10;5(1):133-142. doi: 10.1002/jgh3.12462. eCollection 2021 Jan.

Steven M McPhail 1 2, Samath Amarasena 3, Katherine A Stuart 4, Kelly Hayward 5, Rohit Gupta 6, David Brain 1 2, Gunter Hartel 7, Tony Rahman 6, Paul J Clark 8, Christina M Bernardes 6, Richard Skoien 3, Benjamin Mckillen 3, Andrew Lee 8, Leshni Pillay 9, Lei Lin 6, Myat Myat Khaing 6, Leigh Horsfall 4 5, Elizabeth E Powell 4 5, Patricia C Valery 7
 
64.Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington
 

Drug Alcohol Depend. 2021 Jan 11;220:108525. doi: 10.1016/j.drugalcdep.2021.108525.Online ahead of print.

Maria A Corcorran 1, Judith I Tsui 2, John D Scott 3, Julia C Dombrowski 4, Sara N Glick 4
 
65.Impact of a Nurse Care Coordinator Supporting a Clinical Pharmacist Practitioner in Further Managing HCV-Infected Patients
 

Gastroenterol Nurs. 2021 Jan 12. doi: 10.1097/SGA.0000000000000578. Online ahead of print.

Anita Yang 1, Debbie Zachary, Jane Giang
 
66.Hepatitis C virus infection and polysubstance use among young adult people who inject drugs in a rural county of New Mexico
 

Drug Alcohol Depend. 2021 Jan 11;220:108527. doi: 10.1016/j.drugalcdep.2021.108527.Online ahead of print.

Katherine Wagner 1, Yuna Zhong 2, Eyasu Teshale 2, Kirsten White 1, Erin L Winstanley 3, Jennifer Hettema 4, Karla Thornton 5, Birgitta Bisztray 1, Philip Fiuty 6, Kimberly Page 7
 
67.Why do patients with chronic hepatitis C drink alcohol? An examination of pain, depression, and drinking motives
 

J Viral Hepat. 2021 Jan 21. doi: 10.1111/jvh.13474. Online ahead of print.

Julius M Wilder 1 2, Donna M Evon 3, Rae Jean Proeschold-Bell 4 5, Jia Yao 4 5, Malik Muhammed Sohail 4, Donna Niedzwiecki 6, Christina Makarushka 4 5, Terra Hodge 1, Andrew J Muir 1 2
 
68.HIV, HCV, and HBV incidence and residual risk in US blood donors before and after implementation of the 12-month deferral policy for men who have sex with men
 

Transfusion. 2021 Jan 18. doi: 10.1111/trf.16250. Online ahead of print.

Whitney R Steele 1, Roger Y Dodd 1, Edward P Notari 1, James Haynes 1, Steven A Anderson 2, Alan E Williams 2, Rita Reik 3, Debra Kessler 4, Brian Custer 5, Susan L Stramer 1, Transfusion-Transmissible Infections Monitoring System (TTIMS)
 
69.Liver Abnormalities after Elimination of HCV Infection: Persistent Epigenetic and Immunological Perturbations Post-Cure
 

Pathogens. 2021 Jan 7;10(1):E44. doi: 10.3390/pathogens10010044.

Stephen J Polyak 1 2 3, I Nicholas Crispe 1 4, Thomas F Baumert 5 6
 
70.Hepatitis C Antiviral Treatment Decreases All-Cause Complications After Total Joint Arthroplasty Regardless of the Presence of Fibrosis
 

J Arthroplasty. 2021 Jan 8;S0883-5403(20)31285-7. doi: 10.1016/j.arth.2020.12.025.Online ahead of print.

Ella Cornell 1, David Novikov 2, Ruijia Niu 2, Kevin Staatz 1, Ran Schwarzkopf 3, Eric L Smith 4
 
71.Adherence to Direct-Acting Antiviral Therapy in People Actively Using Drugs and Alcohol: The INCLUD Study
 

Open Forum Infect Dis. 2020 Nov 19;8(1):ofaa564. doi: 10.1093/ofid/ofaa564.eCollection 2021 Jan.

Kristina M Brooks 1, Jose R Castillo-Mancilla 2, Mary Morrow 3, Samantha MaWhinney 3, Sarah E Rowan 2 4, David Wyles 2 4, Joshua Blum 4, Ryan Huntley 1, Lana M Salah 1, Arya Tehrani 1, Lane R Bushman 1, Peter L Anderson 1, Jennifer J Kiser 1
 
72.Beyond a
 

Int J Drug Policy. 2021 Jan 13;103042. doi: 10.1016/j.drugpo.2020.103042. Online ahead of print.

Kate Seear 1, Suzanne Fraser 2, Adrian Farrugia 3, Kylie Valentine 4
 
73.Incidence and Impact of Persistent Viremia on SVR Rates in Patients Receiving Direct-Acting Antiviral Therapy
 

Open Forum Infect Dis. 2020 Nov 26;7(12):ofaa569. doi: 10.1093/ofid/ofaa569.eCollection 2020 Dec.

Alicia B Carver 1, Autumn D Zuckerman 1, Joshua DeClercq 2, Leena Choi 2, Cody A Chastain 3
 
74.Patient-Reported Outcomes 12 Months After Hepatitis C Treatment with Direct-Acting Antivirals: Results from the PROP UP Study
 

Liver Int. 2021 Jan 2. doi: 10.1111/liv.14781. Online ahead of print.

Marina Serper 1, Donna M Evon 2, Jipcy Amador 3, Paul W Stewart 3, Souvik Sarkar 4, Anna S Lok 5, Richard K Sterling 6, Bryce B Reeve 7, Carol E Golin 8, K Rajender Reddy 1, Joseph K Lim 9, Nancy Reau 10, David R Nelson 11, Adrian M Di Bisceglie 12, Michael W Fried 2
 
75.Progress towards hepatitis C virus elimination in high-income countries: an updated analysis
 

Liver Int. 2021 Jan 2. doi: 10.1111/liv.14779. Online ahead of print.

Ivane Gamkrelidze 1, Jean-Michel Pawlotsky 2, Jeffrey V Lazarus 3, Jordan J Feld 4, Stefan Zeuzem 5, Yanjun Bao 6, Ana Gabriela Pires Dos Santos 6, Yuri Sanchez Gonzalez 6, Homie Razavi 1
 
76.Sex Differences in Extrahepatic Outcomes After Antiviral Treatment for Hepatitis C
 

Am J Gastroenterol. 2020 Dec 24;Publish Ahead of Print. doi: 10.14309/ajg.0000000000001095.Online ahead of print.

Jia Li 1, Stuart C Gordon, Yueren Zhou, Joseph A Boscarino, Mark A Schmidt, Yihe G Daida, Loralee B Rupp, Sheri Trudeau, Mei Lu, CHeCS Investigators
 
77.Drug Design Strategies to Avoid Resistance in Direct-Acting Antivirals and Beyond
 

Chem Rev. 2021 Jan 7. doi: 10.1021/acs.chemrev.0c00648. Online ahead of print.

Ashley N Matthew 1, Florian Leidner 1, Gordon J Lockbaum 1, Mina Henes 1, Jacqueto Zephyr 1, Shurong Hou 1, Desaboini Nageswara Rao 1, Jennifer Timm 1, Linah N Rusere 1, Debra A Ragland 1, Janet L Paulsen 1, Kristina Prachanronarong 1, Djade I Soumana 1, Ellen A Nalivaika 1, Nese Kurt Yilmaz 1, Akbar Ali 1, Celia A Schiffer 1
 
78.HPTN 078: High Prevalence of HCV Antibodies Among Urban U.S. Men Who Have Sex with Men (MSM) Independent of HIV Status
 

Clin Infect Dis. 2020 Dec 21;ciaa1869.doi: 10.1093/cid/ciaa1869. Online ahead of print.

Risha Irvin 1, Theresa Gamble 2, Jowanna Malone 1, Zhe Wang 3, Ethan Wilson 3, James P Hughes 4, Jason Farley 1, Kenneth H Mayer 5, Carlos Del Rio 6, D Scott Batey 7, Vanessa Cummings 1, Robert H Remien 8, Chris Beyrer 1, Chloe L Thio 1
 
79.Novel Hepatitic C Virus (HCV) Diagnosis and Treatment Delivery Systems: Facilitating HCV Elimination by Thinking Outside the Clinic
 

J Infect Dis. 2020 Nov 27;222(Supplement_9):S758-S772. doi: 10.1093/infdis/jiaa366.

Sahar Bajis 1, Tanya L Applegate 1, Jason Grebely 1, Gail V Matthews 1, Gregory J Dore 1
 
80.We Must Do Better: Addressing HCV Treatment Barriers in Persons Who Inject Drugs in the United States
 

J Infect Dis. 2020 Nov 27;222(Supplement_9):S773-S781. doi: 10.1093/infdis/jiaa574.

Stacey B Trooskin 1 2, Gregory Dore 3, Jay Kostman 1
 
81.Prevalence and incidence of hepatitis C virus infection in men who have sex with men: a systematic review and meta-analysis
 

Lancet Gastroenterol Hepatol. 2021 Jan;6(1):39-56. doi: 10.1016/S2468-1253(20)30303-4.Epub 2020 Nov 18.

Fengyi Jin 1, Gregory J Dore 2, Gail Matthews 2, Niklas Luhmann 3, Virginia Macdonald 3, Sahar Bajis 2, Rachel Baggaley 3, Bradley Mathers 3, Annette Verster 3, Andrew E Grulich 2
 
82.Direct-Acting Antivirals and Organ Transplantation: Is There Anything We Can
 

J Infect Dis. 2020 Nov 27;222(Supplement_9):S794-S801. doi: 10.1093/infdis/jiaa420.

Matthew R Kappus 1 2, Cameron R Wolfe 1 2, Andrew J Muir 1 2
 
83.Nontargeted Hepatitis C Screening in an Urban Emergency Department in New York City
 

J Emerg Med. 2020 Nov 16;S0736-4679(20)30970-7. doi: 10.1016/j.jemermed.2020.09.034.Online ahead of print.

Ethan A Cowan 1, Amreen Dinani 2, Samantha Brandspiegel 1, Clare O'Brien-Lambert 1, Joseph Zaheer 1, Erick Eiting 1, George Loo 1, Yvette Calderon 1
 
84.Hepatitis C Seroprevalence Among Consecutive Labor and Delivery Admissions in Two New York City Hospitals
 

Open Forum Infect Dis. 2020 Oct 23;7(11):ofaa514. doi: 10.1093/ofid/ofaa514.eCollection 2020 Nov.

Tatyana Kushner 1 2, Claire Park 2, Dana Masand 2, Brian Wagner 3, Marie Grace 4, Emma Rosenbluth 1 2, Clara Rodriquez-Rivas 1 2, Hernis de la Cruz 5, Jessica Overbey 5, Rhoda Sperling 2 6
 
85.Failure on voxilaprevir, velpatasvir, sofosbuvir and efficacy of rescue therapy
 

J Hepatol. 2020 Nov 18;S0168-8278(20)33770-3. doi: 10.1016/j.jhep.2020.11.017.Online ahead of print.

Julia Dietz 1, Velia Chiara Di Maio 2, Adolfo de Salazar 3, Dolores Merino 4, Johannes Vermehren 1, Stefania Paolucci 5, Andreas E Kremer 6, Magdalena Lara 7, Maria Rodriguez Pardo 8, Heinz Zoller 9, Elisabetta Degasperi 10, Kai-Henrik Peiffer 1, Laura Sighinolfi 11, Francisco Téllez 12, Christiana Graf 1, Valeria Ghisetti 13, Jonas Schreiber 14, Elisa Fernández-Fuertes 15, Lucio Boglione 16, Leopoldo Muñoz-Medina 17, Rudolf Stauber 18, William Gennari 19, Blanca Figueruela 20, Jesús Santos 21, Pietro Lampertico 10, Stefan Zeuzem 1, Francesca Ceccherini-Silberstein 2, Federico García 3, Christoph Sarrazin 22
 
86.Changing Urban-Rural Disparities in the Utilization of Direct-Acting Antiviral Agents for Hepatitis C in U.S. Medicare Patients, 2014-2017
 

Am J Prev Med. 2020 Nov 18;S0749-3797(20)30435-9. doi: 10.1016/j.amepre.2020.08.031.Online ahead of print.

Ping Du 1, Xi Wang 2, Lan Kong 2, Thomas Riley 3rd 3, Jeah Jung 4
 
87.Reasons for Not Seeking Hepatitis C Treatment among People Who Inject Drugs
 

Subst Use Misuse. 2020 Nov 18;1-10. doi: 10.1080/10826084.2020.1846198.Online ahead of print.

Leith Morris 1, Linda Selvey 1, Owain Williams 1, Charles Gilks 1, Andrew Smirnov 1 2
 
88.Factors associated with hepatitis C and HIV testing uptake among men who inject image and performance enhancing drugs
 

Drug Alcohol Rev. 2020 Nov 8. doi: 10.1111/dar.13198. Online ahead of print.

Vivian D Hope 1, James McVeigh 2, Emma Begley 1, Rachel Glass 3, Claire Edmundson 3, Ellen Heinsbroek 3, Joseph Kean 4, John Campbell 5, Mark Whitfield 1, Gareth Morgan 6, Dean Acreman 7, Josie Smith 7
 
89.Exploring patient willingness to accept hepatitis C-infected kidneys for transplantation
 

BMC Nephrol. 2020 Nov 10;21(1):473. doi: 10.1186/s12882-020-02114-y.

Gretchen C Edwards 1, Maren E Shipe 2, Lindsay Smith 3, Christianna Gamble 3, David Shaffer 4, Beatrice P Concepcion 5, Rachel Forbes 4
 
90.Recurrence of Hepatocellular Carcinoma in Hepatitis C Virus (HCV) Liver Transplant Recipients Treated with Pretransplant Direct-Acting Antiviral (DAA) Therapy
 

Gastrointest Tumors. 2020 Oct;7(4):134-143. doi: 10.1159/000510341. Epub 2020 Sep 14.

Nicholas Lim 1, Dupinder Singh 1, Scott Jackson 2, John R Lake 1
 
91.Routine Screening and Linkage to Care for Hepatitis C Virus in an Urban Safety-Net Health System, 2017-2019
 

Public Health Rep. 2020 Nov 11;33354920969179. doi: 10.1177/0033354920969179.Online ahead of print.

Bijou R Hunt 1, Christopher Ahmed 1, Kimberly Ramirez-Mercado 1, Christopher Patron 1, Nancy R Glick 1 2
 
92.Multicenter, Double-Blind, Randomized Trial of Emricasan in Hepatitis C Treated Liver Transplant Recipients with Residual Fibrosis or Cirrhosis
 

Liver Transpl. 2020 Nov 8. doi: 10.1002/lt.25934. Online ahead of print.

Ethan W Weinberg 1, Michael P Curry 2, Catherine T Frenette 3, Fredric G Regenstein 4, Eugene R Schiff 5, Zachary D Goodman 6, James Mac Robinson 7, Jean L Chan 7, Joanne C Imperial 7, K Rajender Reddy 1
 
93.Direct-acting antiviral Hepatitis C treatment cascade and barriers to treatment initiation among US men and women with and without HIV
 

J Infect Dis. 2020 Nov 3;jiaa686. doi: 10.1093/infdis/jiaa686. Online ahead of print.

Danielle F Haley 1, Andrew Edmonds 2, Catalina Ramirez 3, Audrey L French 4, Phyllis Tien 5, Chloe L Thio 6, Mallory D Witt 7, Eric C Seaberg 8, Michael W Plankey 9, Mardge H Cohen 10, Adaora A Adimora 11
 
94.Estimating the Year Each State in the United States Will Achieve the World Health Organization
 

Adv Ther. 2020 Nov 3;1-18. doi: 10.1007/s12325-020-01535-3. Online ahead of print.

Mark Sulkowski 1, Wei-Han Cheng 2, Steven Marx 2, Yuri Sanchez Gonzalez 2, John Strezewski 2, Nancy Reau 3
 
95.The hepatitis C virus care cascade in the New York City jail system during the direct acting antiviral treatment era, 2014-2017
 

EClinicalMedicine. 2020 Oct 5;27:100567. doi: 10.1016/j.eclinm.2020.100567.eCollection 2020 Oct.

Justin Chan 1, Fatos Kaba 1, Jessie Schwartz 2, Angelica Bocour 2, Matthew J Akiyama 3, Zachary Rosner 1, Ann Winters 2, Patricia Yang 1, Ross MacDonald 1
 
96.PERCEPTIONS OF NETWORK BASED RECRUITMENT FOR HEPATITIS C TESTING AND TREATMENT AMONG PERSONS WHO INJECT DRUGS: A QUALITATIVE EXPLORATION
 

Int J Drug Policy. 2020 Nov 4;88:103019. doi: 10.1016/j.drugpo.2020.103019.Online ahead of print.

Kathleen M Ward 1, Sean D McCormick 2, Mark Sulkowski 3, Carl Latkin 4, Geetanjali Chander 5, Oluwaseun Falade-Nwulia 6
 
97.A platform in the use of medicines to treat chronic hepatitis C (PLATINUM C): protocol for a prospective treatment registry of real-world outcomes for hepatitis C
 

BMC Infect Dis. 2020 Oct 29;20(1):802. doi: 10.1186/s12879-020-05531-4.

Jessica Ramsay 1, Julie Marsh 1, Alisa Pedrana 2 3, Nada Andric 4, Richard Norman 5, Wendy Cheng 6 7 8, Steve Webb 3 9, Nikolajs Zeps 10, Matthew Bellgard 11, Todd Graves 12, Margaret Hellard 2 3 13 14 15, Tom Snelling 16 17 18 19 20
 
98.Early Outcomes of Multivisceral Transplant using Hepatitis C Positive Donors
 

Ann Thorac Surg. 2020 Oct 26;S0003-4975(20)31736-7. doi: 10.1016/j.athoracsur.2020.08.044.Online ahead of print.

William G McMaster Jr 1, Zakiur M Rahaman 2, Maren E Shipe 3, Eric N Quintana 4, Emily M Sandhaus 5, Sarah S Smith 6, Jerod E Crockett 7, Rachel C Forbes 8, Kelly H Schlendorf 9, Ashish S Shah 10
 
99.Low Adherence Achieves High HCV Cure Rates Among People Who Inject Drugs Treated With Direct-Acting Antiviral Agents
 

Open Forum Infect Dis. 2020 Aug 26;7(10):ofaa377. doi: 10.1093/ofid/ofaa377.eCollection 2020 Oct.

Brianna L Norton 1, Matthew J Akiyama 1, Linda Agyemang 1, Moonseong Heo 2, Irene- Pericot-Valverde 3, Alain H Litwin 3 4 5
 
100.Immune system control of hepatitis C virus infection
 

Curr Opin Virol. 2020 Oct 30;46:36-44. doi: 10.1016/j.coviro.2020.10.002.Online ahead of print.

Johnasha D Stuart 1, Eduardo Salinas 1, Arash Grakoui 2
 
101.Outcomes of Hepatitis C Virus Treatment in the New York City Jail Population: Successes and Challenges Facing Scale up of Care
 

Open Forum Infect Dis. 2020 Jun 30;7(7):ofaa263. doi: 10.1093/ofid/ofaa263.eCollection 2020 Jul.

Justin Chan 1, Jessie Schwartz 2, Fatos Kaba 1, Angelica Bocour 2, Matthew J Akiyama 1 3, Laura Hobstetter 1, Zachary Rosner 1, Ann Winters 2, Patricia Yang 1, Ross MacDonald 1
 
102.The use of organs from hepatitis C virus-viremic donors into uninfected recipients
 

Curr Opin Organ Transplant. 2020 Dec;25(6):620-625. doi: 10.1097/MOT.0000000000000826.

Jeffrey A Kahn 1
 
103.Applying a diffusion of innovations framework to the scale-up of direct-acting antiviral therapies for hepatitis C virus infection: Identified challenges for widespread implementation
 

Int J Drug Policy. 2020 Oct 12;86:102964. doi: 10.1016/j.drugpo.2020.102964.Online ahead of print.

Alison D Marshall 1, Max Hopwood 2, Jason Grebely 3, Carla Treloar 2
 
104.Sustained Sobriety: A Qualitative Study of Persons with HIV and Chronic Hepatitis C Coinfection and a History of Problematic Drinking
 

AIDS Behav. 2020 Oct 16. doi: 10.1007/s10461-020-03067-x. Online ahead of print.

Abigail Howell 1, Audrey Lambert 2 3, Megan M Pinkston 4, Claire E Blevins 4, Jumi Hayaki 5, Debra S Herman 4, Ethan Moitra 4, Michael D Stein 3, H Nina Kim 6
 
105.Review of Clinically Relevant Drug Interactions with Next Generation Hepatitis C Direct-acting Antiviral Agents
 

J Clin Transl Hepatol. 2020 Sep 28;8(3):322-335. doi: 10.14218/JCTH.2020.00034.Epub 2020 Jul 30.

Jenny Hong 1, Robert C Wright 1, Nilu Partovi 1 2, Eric M Yoshida 3 4, Trana Hussaini 1 2 3
 
106.Update on Hepatitis C Epidemiology: Unaware and Untreated Infected Population Could Be the Key to Elimination
 

SN Compr Clin Med. 2020 Oct 18;1-8. doi: 10.1007/s42399-020-00588-3.Online ahead of print.

Cristina Stasi 1 2, Caterina Silvestri 1, Fabio Voller 1
 
107.Reduced Independence in Daily Living Is Associated with the Gut Microbiome in People with HIV and HCV
 

mSystems. 2020 Oct 13;5(5):e00528-20. doi: 10.1128/mSystems.00528-20.

Bryn C Taylor # 1, Kelly C Weldon # 2 3, Ronald J Ellis 4 5, Donald Franklin 6, Daniel McDonald 7, Gregory Humphrey 7, MacKenzie Bryant 7, Julia Toronczak 7, Tara Schwartz 7, Jennifer Iudicello 6, Robert Heaton 6, Igor Grant 6, Sara Gianella 8
 
108.Addressing the Syndemic of HIV, Hepatitis C, Overdose, and COVID-19 Among People Who Use Drugs: The Potential Roles for Decriminalization and Safe Supply
 

J Stud Alcohol Drugs. 2020 Sep;81(5):556-560.

Matthew Bonn 1, Adam Palayew 2, Sofia Bartlett 3, Thomas D Brothers 4, Natasha Touesnard 1, Mark Tyndall 5
 
109.Management of Hepatitis C in Children and Adolescents
 

J Pediatric Infect Dis Soc. 2020 Oct 12;piaa114. doi: 10.1093/jpids/piaa114. Online ahead of print.

Victoria A Statler 1, Claudia Espinosa 2
 
110.Supportive Interventions During Treatment of Chronic Hepatitis C: A Review of the Literature
 

Gastroenterol Nurs. Sep/Oct 2020;43(5):E172-E183. doi: 10.1097/SGA.0000000000000488.

Donald E Bailey Jr 1, Donna M Zucker
 
111.The role of social capital in facilitating hepatitis C treatment scale-up within a treatment-as-prevention trial in the male prison setting
 

Addiction. 2020 Oct 2. doi: 10.1111/add.15277. Online ahead of print.

Lise Lafferty 1, Jake Rance 1, Gregory J Dore 2, Andrew R Lloyd 2, Carla Treloar 1
 
112.Exploring Patient-Reported Costs Related to Hepatitis C on the Medical Crowdfunding Page GoFundMe®
 

Pharmacoecon Open. 2020 Sep 30. doi: 10.1007/s41669-020-00232-9. Online ahead of print.

T Joseph Mattingly 2nd 1, Karen Li 2, Arnold Ng 2, Tieu-Long Ton-Nu 2, Jennifer Owens 3
 
113.Escape from planned obsolescence: Hepatitis C, the cirrhotic liver, and clonal expansions
 

J Exp Med. 2020 Mar 2;217(3):e20191070. doi: 10.1084/jem.20191070.

Andrea D Branch 1
 
114.T cell immunity to hepatitis C virus: Lessons for a prophylactic vaccine
 

J Hepatol. 2020 Sep 28;S0168-8278(20)33665-5. doi: 10.1016/j.jhep.2020.09.022.Online ahead of print.

Robert Thimme 1
 
115.Characteristics of Adults With Hepatitis C Virus: Evidence From the National Health and Nutrition Examination Survey 2011-2012
 

Gastroenterol Nurs. Sep/Oct 2020;43(5):363-374. doi: 10.1097/SGA.0000000000000459.

Sheila A Williams 1, Lisa C Lindley
 
116.Misclassification Error-Adjusted Prevalence of Injection Drug Use Among Infective Endocarditis Hospitalizations in the United States: A Serial Cross-Sectional Analysis of the 2007-2016 National Inpatient Sample
 

Am J Epidemiol. 2020 Sep 30;kwaa207. doi: 10.1093/aje/kwaa207. Online ahead of print.

Kaitlin M McGrew 1, Tabitha Garwe 1, S Reza Jafarzadeh 2, Douglas A Drevets 3 4, Yan Daniel Zhao 1, Mary B Williams 1 5, Hélène Carabin 1 6 7 8
 
117.EASL recommendations on treatment of hepatitis C: Final update of the series
 

J Hepatol. 2020 Nov;73(5):1170-1218. doi: 10.1016/j.jhep.2020.08.018.Epub 2020 Sep 15.

European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guidelines Panel: Chair:; EASL Governing Board representative:; Panel members:
 
118.In the era of direct-acting antivirals, liver transplant delisting due to clinical improvement for hepatitis C remains infrequent
 

Clin Gastroenterol Hepatol. 2020 Sep 21;S1542-3565(20)31294-5.doi: 10.1016/j.cgh.2020.09.033. Online ahead of print.

Therese Bittermann 1, K Rajender Reddy 2
 
119.Impact Of Direct Acting Antiviral Agents On Liver Function In Patients With Chronic Hepatitis C Virus Infection
 

J Viral Hepat. 2020 Sep 26. doi: 10.1111/jvh.13408. Online ahead of print.

Philip J Johnson 1, Sarah Berhane 1, Alex J Walker 2, Fiona H Gordon 3, Steven D Ryder 4 5, Stuart McPherson 6, Aravamuthan Sreedharan 7, Andrew A Ustianowski 8, Kosh Agarwal 9, David Mutimer 10, Takeshi Kumada 11, Hidenori Toyoda 12, William L Irving 5, HCV Research UK
 
120.Depression in Individuals Coinfected with HIV and HCV Is Associated with Systematic Differences in the Gut Microbiome and Metabolome
 

mSystems. 2020 Sep 29;5(5):e00465-20. doi: 10.1128/mSystems.00465-20.

Bryn C Taylor 1, Kelly C Weldon 2 3, Ronald J Ellis 4 5, Donald Franklin 6, Tobin Groth 7, Emily C Gentry 2, Anupriya Tripathi 2 7 8, Daniel McDonald 8, Gregory Humphrey 8, MacKenzie Bryant 8, Julia Toronczak 8, Tara Schwartz 8, Michelli F Oliveira 9, Robert Heaton 6, Igor Grant 6, Sara Gianella 10, Scott Letendre 9 11, Austin Swafford 3, Pieter C Dorrestein 2 3 8, Rob Knight 12 8 13 14
 
121.Detection of Recurrent Hepatitis C Viremia Using Surveillance Data, New York City
 

J Public Health Manag Pract. 2020 Sep 9. doi: 10.1097/PHH.0000000000001150.Online ahead of print.

Kevin Guerra 1, Angelica Bocour, Miranda S Moore, Ann Winters
 
122.Protocol for a systematic review of treatment adherence for HIV, hepatitis C and tuberculosis among homeless populations
 

Syst Rev. 2020 Sep 13;9(1):211. doi: 10.1186/s13643-020-01470-y.

Luke Johnson 1 2, Dan Lewer 3, Robert W Aldridge 4, Andrew C Hayward 1, Alistair Story 1
 
123.The Economic Value of Improved Productivity from Treatment of Chronic Hepatitis C Virus Infection: A Retrospective Analysis of Earnings, Work Loss, and Health Insurance Data
 

Adv Ther. 2020 Nov;37(11):4709-4719. doi: 10.1007/s12325-020-01492-x. Epub 2020 Sep 14.

Mark Sulkowski 1, Raluca Ionescu-Ittu 2, Dendy Macaulay 3, Yuri Sanchez-Gonzalez 4
 
124.Hepatitis C virus infections among people aged 15-44, United States, 2009-2018
 

Public Health Nurs. 2020 Sep 15. doi: 10.1111/phn.12808. Online ahead of print.

Theresa Watts 1, Diane Lauver 2, Ajay K Sethi 3, Traci Snedden 2, Susan Zahner 2
 
125.Will peer-based interventions improve hepatitis C virus treatment uptake among young people who inject drugs?
 

Can J Public Health. 2020 Sep 16. doi: 10.17269/s41997-020-00413-3. Online ahead of print.

Jessica Jacob 1 2, Lianping Ti 1 2, Rod Knight 3 4
 
126.Emerging Viral and Bacterial Infections: Within an Era of Opioid Epidemic
 

Infect Dis Ther. 2020 Sep 11. doi: 10.1007/s40121-020-00335-0.Online ahead of print.

Jessica F Jones 1, Jamie Legaspi 2, Eric Chen 2, Kelly Lee 3, Jennifer Le 3
 
127.Retreatment of Hepatitis C Infection With Direct-Acting Antivirals
 

Fed Pract. 2020 Jul;37(7):316-319.

Marisel Segarra-Newnham 1, Nathalie See 1, Gail Fox-Seaman 1
 
128.Selecting a theoretical framework to explore the social and cognitive uncertainty that hepatitis C treatment represents for people who inject drugs
 

Appl Nurs Res. 2020 Aug 3;151339. doi: 10.1016/j.apnr.2020.151339. Online ahead of print.

Greg Carlson 1, Tracy E Crane 2, Ruth E Taylor-Piliae 3
 
129.Cholesterol sensing by CD81 is important for hepatitis C virus entry
 

J Biol Chem. 2020 Sep 8;jbc.RA120.014761. doi: 10.1074/jbc.RA120.014761.Online ahead of print.

Machaela Palor 1, Lenka Stejskal 1, Piya Mandal 1, Annasara Lenman 2, Maria Pia Alberione 3, Jared Kirui 4, Rebecca Moeller 4, Stefan Ebner 5, Felix Meissner 5, Gisa Gerold 6, Adrian J Shepherd 7, Joe Grove 1
 
130.Housing Stability and Hepatitis C Infection for Young Adults Who Inject Drugs: Examining the Relationship of Consistent and Intermittent Housing Status on HCV Infection Risk
 

J Urban Health. 2020 Sep 8. doi: 10.1007/s11524-020-00445-7. Online ahead of print.

Meghan D Morris 1, Irene H Yen 2, Steve Shiboski 3, Jennifer L Evans 3, Kimberly Page 4
 
131.Prevalence of Hepatitis C Virus Infection in the Veteran Population Undergoing Total Joint Arthroplasty: An Update
 

J Arthroplasty. 2020 Aug 18;S0883-5403(20)30909-8. doi: 10.1016/j.arth.2020.08.023.Online ahead of print.

Cdr Bennett H Shapiro 1, Ramsey C Cheung 2, Nicholas J Giori 3
 
132.Hepatitis C Virus Incidence in a Cohort in Medication-Assisted Treatment for Opioid Use Disorder in New York City
 

J Infect Dis. 2020 Sep 2;222(Supplement_5):S322-S334. doi: 10.1093/infdis/jiz659.

Ashly E Jordan 1 2 3, Charles M Cleland 2 4, Katarzyna Wyka 1, Bruce R Schackman 5, David C Perlman 2 6, Denis Nash 1
 
133.Health Department Efforts to Increase Hepatitis C RNA Testing Among People Appearing Out of Care: Comparison of Outreach Approaches, New York City, 2017
 

Public Health Rep. 2020 Sep 4;33354920952068. doi: 10.1177/0033354920952068.Online ahead of print.

Rachel Webster 1, Miranda S Moore 1, Angelica Bocour 1, Nirah Johnson 1, Ann Winters 1
 
134.Treatment of Chronic Hepatitis C in Young Children Reduces Adverse Outcomes and Is Cost-Effective Compared to Deferring Treatment to Adulthood
 

J Pediatr. 2020 Sep 2;S0022-3476(20)31124-0. doi: 10.1016/j.jpeds.2020.08.088.Online ahead of print.

Emma Greenaway 1, Alexander Haines 2, Simon C Ling 3, Murray Krahn 4
 
135.Comparing direct acting antivirals for hepatitis C using observational data - Why and how?
 

Pharmacol Res Perspect. 2020 Oct;8(5):e00650. doi: 10.1002/prp2.650.

Jim Young 1 2 3, Stanley Wong 4 5, Naveed Z Janjua 4 5, Marina B Klein 1 2 6
 
136.Insights into the unique characteristics of hepatitis C virus genotype 3 revealed by development of a robust sub-genomic DBN3a replicon
 

J Gen Virol. 2020 Sep 8. doi: 10.1099/jgv.0.001486. Online ahead of print.

Joseph C Ward 1, Sebastian Bowyer 1, Shucheng Chen 1, Guilherme Rodrigues Fernandes Campos 2 1, Santseharay Ramirez 3 4, Jens Bukh 3 4, Mark Harris 1
 
137.Persistent Challenges in the Hepatitis C Virus Care Continuum for Patients in a Central Texas Public Health System
 

Open Forum Infect Dis. 2020 Aug 7;7(8):ofaa322. doi: 10.1093/ofid/ofaa322.eCollection 2020 Aug.

Shane W Reader 1, Hyun-Seok Kim 2, Hashem B El-Serag 2, Aaron P Thrift 1
 
138.Screening Emergency Admissions at Risk of Chronic Hepatitis C (SEARCH) to diagnose or
 

J Viral Hepat. 2020 Sep 1. doi: 10.1111/jvh.13393. Online ahead of print.

David Stephen Prince 1 2, Joseph Louis Pipicella 1 3, Melissa Fraser 1, Frank Alvaro 1 4, Michael Maley 1 2 4, Hong Foo 1 4 5, Paul MacConachie Middleton 1 2 3 6 7, Scott Anthony Davison 1 2, Greg John Dore 8, Geoff William McCaughan 7 9, Miriam Tania Levy 1 2 3
 
139.Hepatitis C Virus
 

Ann Intern Med. 2020 Sep 1;173(5):ITC33-ITC48. doi: 10.7326/AITC202009010.
 
140.Late presenters among minority patients with chronic hepatitis C infection in the USA
 

Int J Public Health. 2020 Sep;65(7):1181-1191. doi: 10.1007/s00038-020-01467-3.Epub 2020 Aug 29.

Calvin Q Pan 1 2, Charles Rabinovich 3, Vijay Gayam 4, Milana Normatov 3, Bazhena Fidman 3, Dan Wang 5
 
141.Rates and Characteristics of SARS-CoV-2 Infection in Persons with Hepatitis C Virus Infection
 

Liver Int. 2020 Oct 2. doi: 10.1111/liv.14681. Online ahead of print.

Adeel A Butt 1 2 3, Peng Yan 1
 
142.Hepatic benefits of HCV cure
 

J Hepatol. 2020 Aug 7;S0168-8278(20)30530-4. doi: 10.1016/j.jhep.2020.08.006.Online ahead of print.

Vincenza Calvaruso 1, Antonio Craxì 2
 
143.Hepatitis C in 2020: A North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition Position Paper
 

J Pediatr Gastroenterol Nutr. 2020 Sep;71(3):407-417. doi: 10.1097/MPG.0000000000002814.

Daniel H Leung 1, James E Squires 2, Ravi Jhaveri 3, Nanda Kerkar 4, Chuan-Hao Lin 5, Parvathi Mohan 6, Karen F Murray 7, Regino P Gonzalez-Peralta 8, Eve A Roberts 9, Shikha S Sundaram 10
 
144.Increased cardiovascular risk and reduced quality of life are highly prevalent among individuals with hepatitis C
 

BMJ Open Gastroenterol. 2020 Aug;7(1):e000470. doi: 10.1136/bmjgast-2020-000470.

Stuart McPherson 1 2, Shion Gosrani 3, Sarah Hogg 3, Preya Patel 3, Aaron Wetten 3, Rachael Welton 3, Kate Hallsworth 3 2, Matthew Campbell 4 5
 
145.Alcohol Use Disorder and Hepatitis C Prevention and Care in People Who Inject Drugs: The State of Play
 

Semin Liver Dis. 2020 Aug 26. doi: 10.1055/s-0040-1716343. Online ahead of print.

Fabienne Marcellin 1, Antoine Jaquet 2 3, Jeffrey V Lazarus 4, Patricia Molina 5, Patrizia Carrieri 1
 
146.Cost-effectiveness of using hepatitis C viremic hearts for transplantation into HCV-negative recipients
 

Am J Transplant. 2020 Aug 10. doi: 10.1111/ajt.16245. Online ahead of print.

Cathy Logan 1, Ily Yumul 2, Javier Cepeda 1, Victor Pretorius 3, Eric Adler 4, Saima Aslam 1, Natasha K Martin 1 5
 
147.Identification of Risk Factors for Testing of Hepatitis C in Non-Birth Cohort Patients: Is Universal Screening Necessary?
 

J Addict Med. 2020 Jul 20. doi: 10.1097/ADM.0000000000000702. Online ahead of print.

Amanda Smart 1, Alexander Geboy, Peter Basch, Whitney Nichols, Alexander Zeymo, Idene Perez, Maria Hafeez, Ilan Fleisher, Stephen Fernandez, Dawn Fishbein
 
148.A Patient Decision Support Tool for Hepatitis C Virus and CKD Treatment
 

Kidney Med. 2019 Jul 11;1(4):200-206. doi: 10.1016/j.xkme.2019.06.003.eCollection Jul-Aug 2019.

Nerissa George 1, AnnMarie Liapakis 2, Kevin M Korenblat 3, Tingting Li 4, David Roth 5, Jerry Yee 6, Kevin J Fowler 7, Lehman Howard 8, Jingxia Liu 1, Mary C Politi 1
 
149.Identifying ED patients with previous abnormal HIV or hepatitis C test results who may require additional services
 

Am J Emerg Med. 2020 May 11;38(9):1831-1833. doi: 10.1016/j.ajem.2020.05.020.Online ahead of print.

Andrew H Ruffner 1, Rachel M Ancona 2, Catherine Hamilton 3, Francisco J Fernandez 4, Kiran A Faryar 5, Bennett H Lane 6, Michael S Lyons 7
 
150.Pharmacology Update for the Treatment of Hepatitis C Virus
 

Nurs Clin North Am. 2020 Sep;55(3):347-359.doi: 10.1016/j.cnur.2020.06.008.Epub 2020 Jul 16.

Leslie Hopkins 1, Travis Dunlap 2, Holly Cline 2
 
151.Impact of routine opt-out HIV/HCV screening on testing uptake at a syringe services program: An interrupted time series analysis
 

Int J Drug Policy. 2020 Jul 27;84:102875. doi: 10.1016/j.drugpo.2020.102875.Online ahead of print.

Tyler S Bartholomew 1, Hansel E Tookes 2, David P Serota 2, Czarina N Behrends 3, David W Forrest 4, Daniel J Feaster 5
 
152.Screening for Hepatitis C Virus: How Universal Is Universal?
 

Clin Ther. 2020 Jul 22;S0149-2918(20)30322-2. doi: 10.1016/j.clinthera.2020.06.012.Online ahead of print.

Ravi Jhaveri 1
 
153.Simplification of Care for Chronic Hepatitis C Virus Infection
 

Semin Liver Dis. 2020 Jul 28.doi: 10.1055/s-0040-1713657. Online ahead of print.

Jean-Michel Pawlotsky 1, Christian B Ramers 2, John F Dillon 3, Jordan J Feld 4, Jeffrey V Lazarus 5
 
154.A model of the economic benefits of global hepatitis C elimination: an investment case
 

Lancet Gastroenterol Hepatol. 2020 Jul 27;S2468-1253(20)30008-X.

doi: 10.1016/S2468-1253(20)30008-X. Online ahead of print.

Nick Scott 1, Christian Kuschel 2, Alisa Pedrana 3, Sophia Schroeder 3, Jessica Howell 4, Alexander Thompson 5, David P Wilson 3, Margaret Hellard 6
 
155.Global hepatitis C elimination: an investment framework
 

Lancet Gastroenterol Hepatoldoi: 10.1016/S2468-1253(20)30010-8. Online ahead of print.

 

Alisa Pedrana 1, Jessica Howell 2, Nick Scott 3, Sophia Schroeder 3, Christian Kuschel 4, Jeffrey V Lazarus 5, Rifat Atun 6, Ricardo Baptista-Leite 7, Ellen 't Hoen 8, Sharon J Hutchinson 9, Lisa Aufegger 10, Raquel Peck 11, Annette H Sohn 12, Tracy Swan 13, Mark Thursz 14, Olufunmilayo Lesi 15, Manik Sharma 16, John Thwaites 17, David P Wilson 3, Margaret Hellard 18
 
156.Testing and Clinical Management of Health Care Personnel Potentially Exposed to Hepatitis C Virus - CDC Guidance, United States, 2020 MMWR
 

Recomm Rep. 2020 Jul 24;69(6):1-8. doi: 10.15585/mmwr.rr6906a1.

MMWR Recomm Rep. 2020 Jul 24;69(6):1-8. doi: 10.15585/mmwr.rr6906a1.

 

Anne C Moorman, Marie A de Perio, Ronald Goldschmidt, Carolyn Chu, David Kuhar, David K Henderson, Susanna Naggie, Saleem Kamili, Philip R Spradling, Stuart C Gordon, Mark B Russi, Eyasu H Teshale
 
157.Estimating the Consensus hepatitis C Cascade of Care among people who inject drugs in Australia: Pre and post availability of direct acting antiviral therapy
 

Int J Drug Policy. 2020 Jul 6;83:102837. doi: 10.1016/j.drugpo.2020.102837.Online ahead of print.

Jenny Iversen 1, Gregory J Dore 2, Mitchell Starr 3, Beth Catlett 4, Philip Cunningham 3, Louise Geddes 2, Lisa Maher 2
 
158.Achieving Hepatitis C Elimination By Using Person-Centered, Nurse-Led Models of Care: A Discussion of Four International Case Studies
 

Gastroenterol Nurs. Jul/Aug 2020;43(4):303-309. doi: 10.1097/SGA.0000000000000458.

Jacqueline A Richmond 1, Lesley Gallagher, Lucy McDonald, Margaret O'Sullivan, Christine Fitzsimmons, Alisa Pedrana
 
159.Low Yield of Hepatitis C Infection in an Outreach Screening Program in Harris County, Texas
 

Open Forum Infect Dis. 2020 Jun 2;7(7):ofaa191. doi: 10.1093/ofid/ofaa191. eCollection 2020 Jul.

Hyun-Seok Kim 1, Rosalia Guerrero 2, Shane W Reader 3, Maria Daheri 4, Maya Balakrishnan 1, Catherine L Troisi 2, Hashem B El-Serag 1, Aaron P Thrift 3 5
 
160.Hepatitis C antibody screening and determinants of initial and duplicate screening in the baby boomer patients of six urban primary care clinics
 

PLoS One. 2020 Jul 9;15(7):e0235778. doi: 10.1371/journal.pone.0235778. eCollection 2020.

Dagan Coppock 1, Edgar Chou 2, Edward Gracely 3, Robert Gross 4, Dong Heun-Lee 1
 
161.Post-transplant survey to assess patient experiences with donor-derived HCV infection
 

Transpl Infect Dis. 2020 Jul 7;e13402. doi: 10.1111/tid.13402. Online ahead of print.

Katya Prakash 1, Claudia Ramirez-Sanchez 1, Sydney I Ramirez 1, Cathy Logan 1, Nancy Law 1, Kristin Mekeel 2, Victor Pretorius 2, Saima Aslam 1
 
162.Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience
 

Transplant Proc. 2020 Jul 4;S0041-1345(20)32581-1. doi:10.1016/j.transproceed.2020.06.005.Online ahead of print.

Eloi Chevallier 1, Matthias Büchler 2, Sophie Caillard 3, Nicolas Bouvier 4, Charlotte Colosio 5, Joseph Rivalan 6, Johnny Sayegh 7, Dominique Bertrand 8, Yannick Le Meur 9, Antoine Thierry 10, Cyril Garrouste 11, Jean-Philippe Rerolle 12, Lionel Rostaing 13, Philippe Gatault 2
 
163.Fibrosis improvement in patients with HCV treated with direct-acting antivirals
 

Eur J Gastroenterol Hepatol. 2020 Jul 3. doi: 10.1097/MEG.0000000000001821.Online ahead of print.

James McPhail 1, Omar T Sims 2 3 4 5 6, Yuqi Guo 7, David Wooten 1, John S Herndon 1, Omar I Massoud 8
 
164.Treatment outcomes in hepatitis C virus genotype 1a infected patients with and without baseline NS5A resistance-associated substitutions
 

Liver Int. 2020 Jul 8. doi: 10.1111/liv.14591. Online ahead of print.

Julia Dietz 1, Johannes Vermehren 1, Katrin Matschenz 2, Peter Buggisch 2, Hartwig Klinker 3, Julian Schulze Zur Wiesch 4, Holger Hinrichsen 5, Kai-Henrik Peiffer 1, Christiana Graf 1, Thomas Discher 6, Janina Trauth 6, Jörn M Schattenberg 7, Felix Piecha 4, Stefan Mauss 8, Claus Niederau 9, Tobias Müller 10, Christoph Neumann-Haefelin 11, Christoph P Berg 12, Stefan Zeuzem 1, Christoph Sarrazin 1 13, European HCV Resistance Study Group
 
165.Trends in Indicators of Injection Drug Use, Indian Health Service, 2010-2014 : A Study of Health Care Encounter Data
 

Public Health Rep. Jul/Aug 2020;135(4):461-471. doi: 10.1177/0033354920937284.Epub 2020 Jul 7.

Mary E Evans 1 2 3, Marissa Person 4, Brigg Reilley 5, Jessica Leston 5, Richard Haverkate 6, Jeffrey T McCollum 6, Andria Apostolou 6 7, Michele K Bohm 1, Michelle Van Handel 8, Danae Bixler 9, Andrew J Mitsch 2, Dana L Haberling 4, Sarah M Hatcher 3 5, Thomas Weiser 10, Kim Elmore 2, Eyasu H Teshale 9, Paul J Weidle 2, Philip J Peters 2, Kate Buchacz 2
 
166.The Inflammatory Relationship between Hepatitis C Virus with Coronary and Carotid Atherosclerosis
 

Cardiol Rev. 2020 Jun 18. doi: 10.1097/CRD.0000000000000314. Online ahead of print.

Michael Broker 1, Shalom Z Frager 2, Nayan S Patel 3, Edward Lebovics 2, William H Frishman 1
 
167.Transplanting Livers From "HCV-Positive" Donors To HCV-Negative Recipients: Increased Experience But Many Unanswered Questions
 

Am J Gastroenterol. 2020 Jul;115(7):1022-1023.doi: 10.14309/ajg.0000000000000649.

Nathalie Pena Polanco 1, David Goldberg 1
 
168.Impact of Early Initiation of Direct-Acting Antiviral Therapy in Thoracic Organ Transplantation From Hepatitis C Virus Positive Donors
 

Semin Thorac Cardiovasc Surg. 2020 Jul 2;S1043-0679(20)30236-7.doi: 10.1053/j.semtcvs.2020.06.045. Online ahead of print.

Deane E Smith 1, Stacey Chen 2, Anthony Fargnoli 1, Tyler Lewis 3, Aubrey C Galloway 1, Zachary N Kon 1, Nader Moazami 1
 
169.Eight Weeks of Treatment With Glecaprevir/Pibrentasvir Is Safe and Efficacious in an Integrated Analysis of Treatment-Naïve Patients With Hepatitis C Virus Infection
 

Clin Gastroenterol Hepatol. 2020 Jul 1;S1542-3565(20)30907-1. doi: 10.1016/j.cgh.2020.06.044.Online ahead of print.

Eli Zuckerman 1, Julio A Gutierrez 2, Douglas E Dylla 3, Victor de Ledinghen 4, Andrew J Muir 5, Michael Gschwantler 6, Massimo Puoti 7, Florin Caruntu 8, Jihad Slim 9, Frederik Nevens 10, Samuel Sigal 11, Stanley Cohen 12, Linda M Fredrick 3, Ana Gabriela Pires Dos Santos 3, Lino Rodrigues Jr 3, John F Dillon 13
 
170.Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals
 

Int J Antimicrob Agents. 2020 Jun 26;106067. doi: 10.1016/j.ijantimicag.2020.106067.Online ahead of print.

M Pisaturo 1, M Starace 1, C Minichini 1, S De Pascalis 2, L Occhiello 1, A Di Fraia 1, V Messina 3, V Sangiovanni 4, E Claar 5, N Coppola 6, CampC Network
 
171.Educating Primary Care Providers and Associate Care Providers About Hepatitis C Screening of Baby Boomers: a Multi-practice Study
 

J Cancer Educ. 2020 Jun 25. doi: 10.1007/s13187-020-01805-2. Online ahead of print.

Bertha E Flores 1, Andrea A Fernandez 1, Chen-Pin Wang 2 3, Raudel Bobadilla 3, Ludivina Hernandez 3, Mamta K Jain 4, Barbara J Turner 5
 
172.Co-Located hepatitis C virus infection treatment within an opioid treatment program promotes opioid agonist treatment retention
 

Drug Alcohol Depend. 2020 Jun 12;213:108116. doi: 10.1016/j.drugalcdep.2020.108116.Online ahead of print.

Brooke Severe 1, Jeanette M Tetrault 2, Lynn Madden 2, Robert Heimer 3
 
173.Finding undiagnosed patients with hepatitis C infection: an application of artificial intelligence to patient claims data
 

Sci Rep. 2020 Jun 29;10(1):10521. doi: 10.1038/s41598-020-67013-6.

Orla M Doyle 1, Nadejda Leavitt 2, John A Rigg 3
 
174.The impact of universal access to direct-acting antiviral therapy on the hepatitis C cascade of care among individuals attending primary and community health services
 

PLoS One. 2020 Jun 30;15(6):e0235445.doi: 10.1371/journal.pone.0235445. eCollection 2020.

Michael W Traeger 1 2, Alisa E Pedrana 1 2, Daniela K van Santen 1 2, Joseph S Doyle 1 3, Jessica Howell 1 4, Alexander J Thompson 4, Carol El-Hayek 1, Jason Asselin 1, Victoria Polkinghorne 1, Dean Membrey 5, Fran Bramwell 5, Allison Carter 6, Rebecca Guy 6, Mark A Stoové 1 2 7, Margaret E Hellard 1 2 3, EC Victoria Partnership and the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood-borne Viruses and Sexually Transmitted Infections (ACCESS)
 
175.Cost-effectiveness analysis of an outreach model of Hepatitis C Virus (HCV) assessment to facilitate HCV treatment in primary care
 

PLoS One. 2020 Jun 17;15(6):e0234577.doi: 10.1371/journal.pone.0234577. eCollection 2020.

David Brain 1 2, Jonathan Mitchell 3 4, James O'Beirne 3 4
 
176.Baseline prevalence and correlates of HIV and HCV infection among people who inject drugs accessing a syringe services program; Miami, FL
 

Harm Reduct J. 2020 Jun 10;17(1):40. doi: 10.1186/s12954-020-00385-0.

Tyler S Bartholomew 1, Jason Onugha 1, Corinne Bullock 1, Carolina Scaramutti 1, Hardik Patel 1, David W Forrest 2, Daniel J Feaster 1, Hansel E Tookes 3
 
177.Hepatitis C cascade of care at an integrated community facility for people who inject drugs
 

J Subst Abuse Treat. 2020 Jul;114:108025. doi: 10.1016/j.jsat.2020.108025. Epub 2020 May 4.

Leith Morris 1, Linda Selvey 2, Owain Williams 2, Charles Gilks 2, Amanda Kvassy 3, Andrew Smirnov 4
 
178.Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study
 

Lancet Gastroenterol Hepatol. 2020 Jun 9;S2468-1253(19)30417-0.doi: 10.1016/S2468-1253(19)30417-0. Online ahead of print.

Eric Lawitz 1, Charles S Landis 2, Steven L Flamm 3, Maurizio Bonacini 4, Grisell Ortiz-Lasanta 5, Jonathan Huang 6, Jie Zhang 7, Brian J Kirby 7, Shampa De-Oertel 7, Robert H Hyland 7, Anu O Osinusi 7, Diana M Brainard 7, Richard Robson 8, Benedict J Maliakkal 6, Stuart C Gordon 9, Edward J Gane 10
 
179.Real World Cost-of-Illness Evidence in Hepatitis C Virus: A systematic review
 

Pharmacoeconomics. 2020 Jun 12. doi: 10.1007/s40273-020-00933-3.Online ahead of print.

T Joseph Mattingly 2nd 1, Bryan L Love 2, Bilal Khokhar 3
 
180.Hepatitis C and Treatment in Patients with Chronic Kidney Disease
 

Dis Mon. 2020 Jun 15;101017. doi: 10.1016/j.disamonth.2020.101017.Online ahead of print.

Abhijay Jalota 1, Brian K Lindner 2, Beje Thomas 3, Edgar V Lerma 4
 
181.Glycemic Control after Initiating Direct-Acting Antiviral Agents in Patients with Hepatitis C Virus and Type 2 Diabetes Mellitus Using the United States Integrated Healthcare System
 

J Res Pharm Pract. 2020 Mar 28;9(1):16-23. doi: 10.4103/jrpp.JRPP_19_110.eCollection Jan-Mar 2020.

Alicia Halim Wong 1, John Sie 1, Angela Chen 1, Basuki Gunawan 2, Joanie Chung 3, Nazia Rashid 4
 
182.Impact of an Open Access Nationwide Treatment Model on Hepatitis C Virus Antiviral Drug Resistance
 

Hepatol Commun. 2020 Apr 6;4(6):904-915. doi: 10.1002/hep4.1496. eCollection 2020 Jun.

Mark W Douglas 1 2 3, Enoch S E Tay 1 4, Dao Sen Wang 1, Adrian T L Ong 1 2, Caroline Wilson 1, Amy Phu 1, Jen Kok 4, Dominic E Dwyer 3 4, Rowena A Bull 5, Andrew R Lloyd 5, Tanya L Applegate 5, Gregory J Dore 5, Anita Y Howe 6, Richard Harrigan 7, Jacob George 1 3
 
183.Sustained Virologic Suppression After 4 Weeks of Ledipasvir/Sofosbuvir in Human Immunodeficiency Virus (HIV)/Hepatitis C Virus (HCV) Co-Infection
 

Am J Case Rep. 2020 Jun 4;21:e923326. doi: 10.12659/AJCR.923326.

Joshua P Havens 1 2, Nichole N Regan 1, Sara H Bares 1
 
184.High prevalence of injection drug use and blood-borne viral infections among patients in an urban emergency department
 

PLoS One. 2020 Jun 4;15(6):e0233927. doi: 10.1371/journal.pone.0233927. eCollection 2020.

Erik S Anderson 1, Carly Russell 1, Kellie Basham 1, Martha Montgomery 1, Helen Lozier 1, Abigail Crocker 1, Marisa Zuluaga 1, Douglas A E White 1
 
185.Hepatitis C Virus Infection and Chemotherapy in Breast Cancer: A Retrospective Chart Analysis
 

Oncologist. 2020 Jun 2. doi: 10.1634/theoncologist.2020-0172. Online ahead of print.

Saptaparni Ghosh 1, Minghua L Chen 2, Janice Weinberg 3, Tsion Fikre 4, Naomi Y Ko 4
 
186.Pretreatment Assessment of Psychosocial Readiness Is Not Associated with Improved Treatment Outcomes in a Safety-Net HCV Treatment Clinic
 

South Med J. 2020 Jun;113(6):261-266.doi: 10.14423/SMJ.0000000000001099.

Zoë Kopp 1, Lesley Miller 1, Sara Turbow 1
 
187.Proportion and Characterization of Co-infections of HIV and Hepatitis C or Hepatitis B among People with HIV in Alabama, 2007-2016
 

South Med J. 2020 Jun;113(6):298-304. doi: 10.14423/SMJ.0000000000001104.

Charlene Siza 1, Danae Bixler 1, Sherri Davidson 1
 
188.How do people in prison feel about opt-out hepatitis C virus testing?
 

J Viral Hepat. 2020 Jun 2.doi: 10.1111/jvh.13338. Online ahead of print.

Kathryn Jack 1, Paul Linsley 2, Brian James Thomson 1, William Lucien Irving 1
 
189.Prevalence and staging of non-alcoholic fatty liver disease among patients with heart failure with preserved ejection fraction
 

Sci Rep. 2020 Jul 24;10(1):12440. doi: 10.1038/s41598-020-69013-y.

Alexandria Miller 1, Jennifer McNamara 2, Scott L Hummel 2 3, Matthew C Konerman 2, Monica A Tincopa 4
 
190.Comparing Treatment Response Between Older and Younger Patients with Chronic Hepatitis C Virus Infection on Direct-acting Antiviral Agents
 

R I Med J (2013). 2020 Jun 1;103(5):35-40.

Alyssa K Francis 1, Francesca L Beaudoin 2, Safiya S Naidjate 3, Christine Berard-Collins 4, Andrew R Zullo 5
 
191.Novel Models to Identify Census Tracts for Hepatitis C Screening Interventions
 

J Am Board Fam Med. May-Jun 2020;33(3):407-416. doi: 10.3122/jabfm.2020.03.190305.

Thomas Ludden 1, Lindsay Shade 2, Jeremy Thomas 2, Brisa Urquieta de Hernandez 2, Sveta Mohanan 2, Mark W Russo 2, Michael Leonard 2, Philippe J Zamor 2, Charity G Patterson 2, Hazel Tapp 2
 
192.Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a
 

Adv Ther. 2020 Jul;37(7):3299-3310. doi: 10.1007/s12325-020-01389-9. Epub 2020 May 25.

Philip Rosenthal 1, Michael R Narkewicz 2, Betty B Yao 3, Christopher D Jolley 4, Steven J Lobritto 5, Jessica Wen 6, Jean P Molleston 7, Evelyn K Hsu 8, Maureen M Jonas 9, Jiuhong Zha 3, Li Liu 3, Daniel H Leung 10
 
193.Real-world utility of HCV core antigen as an alternative to HCV RNA testing: Implications for viral load and genotype
 

J Viral Hepat. 2020 Jun 1. doi: 10.1111/jvh.13337. Online ahead of print.

Kevin G Pollock 1, Scott A McDonald 2, Rory Gunson 3, Allan McLeod 4, April Went 4, David J Goldberg 3, Sharon J Hutchinson 3, Stephen T Barclay 1 5
 
194.Direct acting antiviral HCV treatment does not influence renal function
 

Matt Driedger 1, Chrissi Galanakis 2, Curtis Cooper 1
 
195.Public Health Clinic-Based Hepatitis C Treatment
 

Am J Prev Med. 2020 May 16;S0749-3797(20)30146-X. doi:10.1016/j.amepre.2020.03.006.Online ahead of print.

Amanda M Rosecrans 1, Aneesha Cheedalla 2, Sarah T Rives 3, Lisa A Scotti 3, Robert E Harris 3, Adena H Greenbaum 4, Risha R Irvin 2, Boatemaa A Ntiri-Reid 5, Holly T Brown 3, Karen E Alston 3, Jaeson A Smith 4, Kathleen R Page 3, Oluwaseun O Falade-Nwulia 2
 
196.Peer outreach point-of-care testing as a bridge to hepatitis C care for people who inject drugs in Toronto, Canada
 

Int J Drug Policy. 2020 Jun;80:102755. doi: 10.1016/j.drugpo.2020.102755. Epub 2020 May 14.

Jennifer Broad 1, Kate Mason 1, Mary Guyton 2, Bernadette Lettner 3, John Matelski 4, Jeff Powis 5
 
197.English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed
 

Kathryn Drysdale 1 2, Yevedzo Ntuli 1 3, Jonathan Bestwick 4, William Gelson 5, Kosh Agarwal 3, Daniel Forton 6, David Mutimer 7, Ahmed M Elsharkawy 7, Ceri Townley 8, Faizel Mahomed 9, Graham R Foster 1 2

Aliment Pharmacol Ther. 2020 Jul;52(1):168-181. doi: 10.1111/apt.15780. Epub 2020 May 22.
 
198.Ethical and Practical Issues Associated with the Possibility of Using Controlled Human Infection Trials in Developing a Hepatitis C Virus Vaccine
 

Clin Infect Dis. 2020 May 22;ciaa640. doi: 10.1093/cid/ciaa640. Online ahead of print.

Andrea Cox 1 2, Mark Sulkowski 1, Jeremy Sugarman 1 2 3

Affiliations collapse
 
199.Impact of the Centers for Disease Control and Prevention Recommendation and State Law on Birth Cohort Hepatitis C Screening of New York City Medicaid Recipients
 

Am J Prev Med. 2020 Jun;58(6):832-838. doi: 10.1016/j.amepre.2019.12.024.

Angelica Bocour 1, Miranda S Moore 2, Ann Winters 2
 
200."Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs
 

Int J Drug Policy. 2020 Jul;81:102766. doi: 10.1016/j.drugpo.2020.102766. Epub 2020 May 13.

Trevor Goodyear 1, Lianping Ti 2, Patrizia Carrieri 3, Will Small 4, Rod Knight 5
 
201.Resistance-associated Substitutions in Patients With Chronic Hepatitis C Virus Genotype 4 Infection
 

J Viral Hepat. 2020 May 12. doi: 10.1111/jvh.13322. Online ahead of print.

Julia Dietz 1 2, Olga V Kalinina 3 4, Johannes Vermehren 1 2, Kai-Henrik Peiffer 1 2, Katrin Matschenz 5, Peter Buggisch 5, Claus Niederau 6, Jörn M Schattenberg 7, Beat Müllhaupt 8, Sabine Yerly 9, Marc Ringelhan 10, Roland M Schmid 10, Christoph Antoni 11, Tobias Müller 12, Julian Schulze Zur Wiesch 13 14, Felix Piecha 13, Darius Moradpour 15, Katja Deterding 16 17 18, Heiner Wedemeyer 16 17 18, Christophe Moreno 19, Thomas Berg 20, Christoph P Berg 21, Stefan Zeuzem 1 2, Christoph Welsch 1 2, Christoph Sarrazin 1 2 22, European HCV Resistance Study Group
 
202.Standard Versus Extended Duration Direct-Acting Antiviral Therapy in Hepatitis C Patients With Slow Response to Treatment
 

Ann Pharmacother. 2020 May 14;1060028020921166. doi: 10.1177/1060028020921166.Online ahead of print.

Ashley H McKnight 1, Mary L Townsend 1, Mohamed G Hashem 1, Susanna Naggie 1 2 3, Lawrence P Park 1 2 4, Rachel B Britt 1
 
203.HCV DAA Therapy in Persons With HIV-HCV Genotype 1 Coinfection Results in High Rate of Sustained Virologic Response and Heterogeneity in Normalization of Soluble Markers of Immune Activation
 

J Infect Dis. 2020 May 15;jiaa254.doi: 10.1093/infdis/jiaa254. Online ahead of print.

Donald D Anthony 1, Mark S Sulkowski 2, Laura M Smeaton 3, Sofi Damjanovska 1, Carey L Shive 1, Corinne M Kowal 1, Daniel E Cohen 4, Debika Bhattacharya 5, Beverly L Alston-Smith 6, Ashwin Balagopal 2, David L Wyles 7
 
204.High Prevalence of Hepatitis C Infection Among Adult Patients at Four Urban Emergency Departments - Birmingham, Oakland, Baltimore, and Boston, 2015-2017
 

MMWR Morb Mortal Wkly Rep. 2020 May 15;69(19):569-574 doi: 10.15585/mmwr.mm6919a1.

James W Galbraith, Erik S Anderson, Yu-Hsiang Hsieh, Ricardo A Franco, John P Donnelly, Joel B Rodgers, Elissa M Schechter-Perkins, William W Thompson, Noele P Nelson, Richard E Rothman, Douglas A E White

Free PMC article
 
205.Impact of Treatment With Direct Acting Antiviral Drugs on Glycemic Control in Patients With Hepatitis C and Diabetes Mellitus
 

Int J Hepatol. 2020 Jan 13;2020:6438753. doi: 10.1155/2020/6438753. eCollection 2020.

Pradeep Kumar Mada 1 2, Matthew E Malus 3, Arvin Parvathaneni 4, Bing Chen 3, Gabriel Castano 5, Sharon Adley 2, Maureen Moore 2, Michinari Hieda 6, Mohammed J Alam 2, Mark Feldman 1, John William King 2
 
206.Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation
 

Gastroenterol Clin North Am. 2020 Jun;49(2):253-277.doi: 10.1016/j.gtc.2020.01.005. Epub 2020 Mar 29.

Marianne Martinello 1, Sahar Bajis 2, Gregory J Dore 2
 
207.Hepatitis C: How Good Are Real-Life Data and Do Generics Work
 

Gastroenterol Clin North Am. 2020 Jun;49(2):279-299.doi: 10.1016/j.gtc.2020.01.006. Epub 2020 Mar 29.

Ashley N Tran 1, Joseph K Lim 2
 
208.Hepatitis C: Does Successful Treatment Alter the Natural History and Quality of Life?
 

Gastroenterol Clin North Am. 2020 Jun;49(2):301-314.doi: 10.1016/j.gtc.2020.01.007. Epub 2020 Mar 29.

Humberto C Gonzalez 1, Stuart C Gordon 2
 
209.Hepatitis C Screening Rates and Care Cascade in a Large US Insured Population, 2010-2016: Gaps to Elimination
 

Popul Health Manag. 2020 May 11. doi: 10.1089/pop.2019.0237. Online ahead of print.

Josephine Nhu Tran 1, Robert J Wong 2, Janet S Lee 3, Tim Bancroft 1, Ami R Buikema 1, Jie Ting 3, Norah Terrault 4
 
210.Global Epidemiology of Viral Hepatitis
 

Gastroenterol Clin North Am. 2020 Jun;49(2):179-189.doi: 10.1016/j.gtc.2020.01.001.

Homie Razavi 1
 
211.Eliciting Patient Views on the Allocation of Limited Healthcare Resources: A Deliberation on Hepatitis C Treatment in the Veterans Health Administration
 

BMC Health Serv Res. 2020 May 1;20(1):369. doi: 10.1186/s12913-020-05211-8.

Akbar K Waljee 1 2 3, Kerry A Ryan 4, Chris D Krenz 4, George N Ioannou 5 6, Lauren A Beste 6 7, Monica A Tincopa 8, Sameer D Saini 9 8 10, Grace L Su 9 8, Maria E Arasim 9, Patti T Roman 9, Brahmajee K Nallamothu 9 10 11, Raymond De Vries 4
 
212.Bayesian Network Modelling Study to Identify Factors Influencing the Risk of Cardiovascular Disease in Canadian Adults With Hepatitis C Virus Infection
 

MJ Open. 2020 May 5;10(5):e035867. doi: 10.1136/bmjopen-2019-035867.

Alaa Badawi 1 2, Giancarlo Di Giuseppe 3 4, Alind Gupta 5, Abbey Poirier 6, Paul Arora 3
 
213.Assessment of Treatment Strategies to Achieve Hepatitis C Elimination in Canada Using a Validated Model
 

Open. 2020 May 1;3(5):e204192. doi: 10.1001/jamanetworkopen.2020.4192.

Mawuena Binka 1, Naveed Z Janjua 1 2 3, Jason Grebely 2 4, Chris Estes 5, Dena Schanzer 2, Jisoo A Kwon 4, Naglaa H Shoukry 2 6, Jeffrey C Kwong 2 7, Homie Razavi 5, Jordan J Feld 2 8, Mel Krajden 1 2 3
 
214.Direct-Acting Antivirals Improve Overall Survival in Interventional Oncology Patients With Hepatitis C and Hepatocellular Carcinoma
 

Vasc Interv Radiol. 2020 Jun;31(6):953-960. doi: 10.1016/j.jvir.2019.12.809. Epub 2020 May 4.

William M Kamp 1, Cortlandt M Sellers 1, Stacey Stein 2, Joseph K Lim 3, Hyun S Kim 4
 
215.Impact of a Digital Medicine Programme on Hepatitis C Treatment Adherence and Efficacy in Adults at High Risk for Non-Adherence
 

Aliment Pharmacol Ther. 2020 Jun;51(12):1384-1396. doi: 10.1111/apt.15707. Epub 2020 Apr 30.

Mark Sulkowski 1, Annie F Luetkemeyer 2, David L Wyles 3, Claudia Martorell 4, Andrew Muir 5, Ilan Weisberg 6, Stuart C Gordon 7, Richard McLain 8, Gregory Huhn 3 8
 
216.Japan Society of Hepatology Guidelines for the Management of Hepatitis C Virus Infection: 2019 Update
 

Hepatol Res. 2020 Apr 28. doi: 10.1111/hepr.13503. Online ahead of print.

Drafting Committee for Hepatitis Management Guidelines, the Japan Society of Hepatology
 
217.The Prevalence and Impact of Hepatic Steatosis on Response to Direct-Acting Antiviral Therapy in HIV-HCV Coinfection
 

Biology (Basel). 2020 Apr 24;9(4):87. doi: 10.3390/biology9040087.

Leigh P Johnson 1, Richard K Sterling 1 2 3
 
218.Utilization and Effectiveness of elbasvir/grazoprevir and Adoption of Resistance-Associated Substitutions Testing in Real-World Treatment of Hepatitis C Virus Genotype 1A Infection: Results From the German Hepatitis C-Registry
 

Eur J Gastroenterol Hepatol. 2020 May 15. doi: 10.1097/MEG.0000000000001759.Online ahead of print.

Holger Hinrichsen 1, Albrecht Stoehr 2, Markus Cornberg 3, Hartwig Klinker 4, Renate Heyne 5, Christine John 6, Karl-Georg Simon 7, Veronika Guenther 8, Karen Martin 8, Vanessa Witte 8, Stefan Zeuzem 9
 
219.Hepatocellular Carcinoma Mechanisms Associated With Chronic HCV Infection and the Impact of Direct-Acting Antiviral Treatment
 

J Hepatocell Carcinoma. 2020 Apr 15;7:45-76. doi: 10.2147/JHC.S221187.eCollection 2020.

Srikanta Dash 1 2 3, Yucel Aydin 1, Kyle E Widmer 2, Leela Nayak 2
 
220.Antibody Responses in Hepatitis C Infection
 

Cold Spring Harb Perspect Med. 2020 Apr 27;a036962.doi: 10.1101/cshperspect.a036962.Online ahead of print.

Mansun Law 1
 
221.Hepatitis C Prevalence and Risk Factors in Georgia, 2015: Setting a Baseline for Elimination
 

BMC Public Health. 2019 May 10;19(Suppl 3):480. doi: 10.1186/s12889-019-6784-3.

Liesl M Hagan 1, Ana Kasradze 2, Stephanie J Salyer 3, Amiran Gamkrelidze 2, Maia Alkhazashvili 2, Gvantsa Chanturia 2, Nazibrola Chitadze 2, Roena Sukhiashvili 2, Marina Shakhnazarova 2, Steven Russell 3, Curtis Blanton 3, Giorgi Kuchukhidze 2, Davit Baliashvili 2, Susan Hariri 4, Stephen Ko 4 5, Paata Imnadze 2, Jan Drobeniuc 4, Juliette Morgan 3 6, Francisco Averhoff 4
 
222.An Evaluation of the Hepatitis C Testing, Care and Treatment Program in the Country of Georgia's Corrections System, December 2013 - April 2015
 

BMC Public Health. 2019 May 10;19(Suppl 3):466. doi: 10.1186/s12889-019-6783-4.

Aaron M Harris 1, Otar Chokoshvili 2, Joshua Biddle 3, Kostantine Turashvili 4, Maia Japaridze 5, Irma Burjanadze 6, Tengiz Tsertsvadze 2, Lali Sharvadze 2, Marine Karchava 2, Archil Talakvadze 7, Ketevan Chakhnashvili 4, Tamta Demurishvili 4, Paata Sabelashvili 8, Monique Foster 9 10, Liesl Hagan 9, Maia Butsashvili 11, Juliette Morgan 5 12, Francisco Averhoff 9
 
223.HCV Knowledge, Disclosure Practices, and Risk Perceptions Among Gay and Bisexual Men Who Do and Do Not Engage in Group Sex While Using Drugs
 

AIDS Care. 2020 Apr 26;1-4. doi: 10.1080/09540121.2020.1757023. Online ahead of print.

Loren Brener 1, Dean A Murphy 2, Elena Cama 1, Joel Murray 3, Neil Fraser 4, Jeanne Ellard 5
 
224.Excess Weight Gain After Cure of Hepatitis C Infection With Direct-Acting Antivirals
 

J Gen Intern Med. 2020 Apr 27. doi: 10.1007/s11606-020-05782-6. Online ahead of print.

Albert Do 1, Denise A Esserman 2, Supriya Krishnan 3 4, Joseph K Lim 5 4, Tamar H Taddei 5 4, Ronald G Hauser 3rd 4 6, Janet P Tate 3 4, Vincent Lo Re 3rd 7 8, Amy C Justice 3 4
 
225.Cost-effectiveness of Universal Hepatitis C Screening in Pregnant Women: A Systematic Review
 

J Clin Gastroenterol. 2020 Apr 21. doi: 10.1097/MCG.0000000000001360. Online ahead of print.

Sammy Saab 1 2 3, Ravina Kullar 4, Haydar Khalil 1, Prabhu Gounder 5
 
226.Cost-Effectiveness of Antenatal Rescreening Among Pregnant Women for Hepatitis C in the United States
 

Clin Infect Dis. 2020 Apr 13;ciaa362.doi: 10.1093/cid/ciaa362. Online ahead of print.

Antoine Chaillon 1, Adriane Wynn 2, Tatyana Kushner 3, Nancy Reau 4, Natasha K Martin 1 5
 
227.HCC Recurrence in HCV-infected Patients After Liver Transplantation: SiLVER Study Reveals Benefits of Sirolimus in Combination With CNIs - A Post-Hoc Analysis
 

Transpl Int. 2020 Apr 21. doi: 10.1111/tri.13621. Online ahead of print.

Jens M Werner 1, Matthias Hornung 1, Rubertha Krah 1, Markus Götz 1, Andreas A Schnitzbauer 1 2, Hans J Schlitt 1, Edward K Geissler 1 3, International SiLVER study group
 
228.Per-Contact Infectivity of Hepatitis C Virus Acquisition in Association With Receptive Needle Sharing Exposures in a Prospective Cohort of Young Adult People Who Inject Drugs in San Francisco, California
 

Forum Infect Dis. 2020 Mar 16;7(4):ofaa092. doi: 10.1093/ofid/ofaa092.eCollection 2020 Apr.

Yuridia Leyva 1, Kimberly Page 2, Stephen Shiboski 3, Judith A Hahn 4, Jennifer Evans 3, Erik Erhardt 5
 
229.Hepatitis C Virus in Pregnancy: A Systematic Review of the Literature
 

Am J Perinatol. 2020 Apr 22. doi: 10.1055/s-0040-1709672. Online ahead of print.

Alexandra Andes 1, Kerry Ellenberg 1, Amanda Vakos 1, James Collins 1, Kimberly Fryer 2
 
230.Preemptive Treatment With Elbasvir and Grazoprevir for Hepatitis C-Viremic Donor to Uninfected Recipient Kidney Transplantation
 

Kidney Int Rep. 2020 Jan 13;5(4):459-467.doi: 10.1016/j.ekir.2020.01.001. eCollection 2020 Apr.

Meghan E Sise 1, Ian A Strohbehn 2, Donald F Chute 2, Jenna Gustafson 2, Vivianna M Van Deerlin 3, Jennifer R Smith 3, Caren Gentile 3, David Wojciechowski 4, Winfred W Williams 1, Nahel Elias 5, Raymond T Chung 2
 
231.CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020
 

MMWR Recomm Rep. 2020 Apr 10;69(2):1-17. doi: 10.15585/mmwr.rr6902a1.

Sarah Schillie 1, Carolyn Wester 1, Melissa Osborne 1, Laura Wesolowski 1, A Blythe Ryerson 1
 
232.Assessing the Effectiveness of Strategies in US Birth Cohort Screening for Hepatitis C Infection
 

J Clin Transl Hepatol. 2020 Mar 28;8(1):25-41. doi: 10.14218/JCTH.2019.00059.Epub 2020 Mar 24.

Cynthia J Tsay 1, Joseph K Lim 2
 
233.Maternal Hepatitis B or Hepatitis C Virus Carrier Status and Long-Term Infectious Morbidity of the Offspring: A Population-Based Cohort Study
 

J Viral Hepat. 2020 Apr 9.doi: 10.1111/jvh.13300. Online ahead of print.

Naim Abu Freha 1, Tamar Wainstock 2, Liat Poupko 3, Avni Yonat Shemer 4, Ruslan Sergienko 2, Eyal Sheiner 5
 
234.Viral Eradication Restores Normal Iron Status in Chronic Hepatitis C Patients With Abnormal Iron Studies
 

Ann Hepatol. 2020 Mar 17;S1665-2681(20)30024-7.doi: 10.1016/j.aohep.2020.03.002.Online ahead of print.

Yazan Hasan 1, Kyle Brown 2
 
235.Outcomes of Liver Transplantation by Insurance Types in the United States
 

Am J Manag Care. 2020 Apr 1;26(4):e121-e126. doi: 10.37765/ajmc.2020.42839.

Maria Stepanova, Saleh Al Qahtani, Alita Mishra, Issah Younossi, Chapy Venkatesan, Zobair M Younossi 1
 
236.Outcomes of Liver Transplantation by Insurance Types in the United States
 

Am J Manag Care. 2020 Apr 1;26(4):e121-e126. doi: 10.37765/ajmc.2020.42839.

Maria Stepanova, Saleh Al Qahtani, Alita Mishra, Issah Younossi, Chapy Venkatesan, Zobair M Younossi 1
 
237.KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C
 

Am J Kidney Dis. 2020 May;75(5):665-683. doi: 10.1053/j.ajkd.2019.12.016. Epub 2020 Apr 9.

David Roth 1, Roy D Bloom 2, Miklos Z Molnar 3, Peter P Reese 4, Deirdre Sawinski 5, Meghan E Sise 6, Norah A Terrault 7
 
238.Effectiveness of 8-Week Glecaprevir/Pibrentasvir for Treatment-Naïve, Compensated Cirrhotic Patients With Chronic Hepatitis C Infection
 

Adv Ther. 2020 May;37(5):2267-2274. doi: 10.1007/s12325-020-01301-5. Epub 2020 Apr 11.

Steven L Flamm 1, Jens Kort 2, Steven E Marx 3, John Strezewski 2, Douglas E Dylla 2, Bruce Bacon 4, Michael P Curry 5, Naoky Tsai 6, Nicole Wick 7
 
239.CDC Recommendations for Hepatitis C Screening Among Adults - United States, 2020
 

MMWR Recomm Rep. 2020 Apr 10;69(2):1-17. doi: 10.15585/mmwr.rr6902a1.

Sarah Schillie 1, Carolyn Wester 1, Melissa Osborne 1, Laura Wesolowski 1, A Blythe Ryerson 1
 
240.Vital Signs: Newly Reported Acute and Chronic Hepatitis C Cases - United States, 2009-2018
 

MMWR Morb Mortal Wkly Rep. 2020 Apr 10;69(14):399-404.doi: 10.15585/mmwr.mm6914a2.

A Blythe Ryerson 1, Sarah Schillie 1, Laurie K Barker 1, Benjamin A Kupronis 1, Carolyn Wester 1
 
241.Factors Influencing Treatment Outcome in Hepatitis C Virus Minority Patients at an Inner-City Hospital: A STROBE-complaint Article
 

Zaki A Sherif 1, Mehdi Nouraie 2, Rehana Begum 2 3, Ali Afsari 4 5, Babak Shokrani 5, Edward Lee 5 6, Adeyinka O Laiyemo 2 3, Hassan Brim 4 6, Hassan Ashktorab 2 4
 
242.Simeprevir, Daclatasvir, and Sofosbuvir for Hepatitis C Virus-Infected Patients: Long-term Follow-Up Results From the Open-Label, Phase II IMPACT Study
 

Health Sci Rep. 2020 Feb 22;3(2):e145. doi: 10.1002/hsr2.145. eCollection 2020 Jun.

Eric Lawitz 1, Fred Poordad 1, Julio A Gutierrez 2, Maria Beumont 3, Greet Beets 3, Ann Vandevoorde 3, Pieter Van Remoortere 4, Donghan Luo 4, Leen Vijgen 3, Veerle Van Eygen 3, Mohamed Gamil 3
 
243.Elbasvir and Grazoprevir for Hepatitis C Virus Genotype 1 Infection in People With Recent Injecting Drug Use (DARLO-C): An Open-Label, Single-Arm, Phase 4, Multicentre Trial
 

Health Sci Rep. 2020 Mar 15;3(2):e151. doi: 10.1002/hsr2.151. eCollection 2020 Jun.

Jason Grebely 1, Phillip Read 2, Evan B Cunningham 1, Martin Weltman 3, Gail V Matthews 1 4, Adrian Dunlop 5, Mark Montebello 6, Marianne Martinello 1 4, Rosie Gilliver 2, Philippa Marks 1, Tanya L Applegate 1, Gregory J Dore 1 4, DARLO-C Study Group
 
244.Infective Endocarditis Among Persons Aged 18-64 Years With HIV, Hepatitis C Infection, or Opioid Use Disorder - United States, 2007-2017
 

Clin Infect Dis. 2020 Apr 9;ciaa372. doi: 10.1093/cid/ciaa372. Online ahead of print.

Cecillia Y Wong 1, Weiming Zhu 2, Gerard P Aurigemma 1, Nathan Furukawa 2, Eyasu H Teshale 3, Ya-Lin A Huang 2, Philip J Peters 2, Karen W Hoover 2
 
245.The Emergency Department as a Setting-Specific Opportunity for Population-Based Hepatitis C Screening: An Economic Evaluation
 

Liv Int. 2020 Apr 8. doi: 10.1111/liv.14458. Online ahead of print.

Andrew B Mendlowitz 1 2, David Naimark 3, William W L Wong 4, Camelia Capraru 5, Jordan J Feld 5, Wanrudee Isaranuwatchai 2 6, Murray Krahn 1 7
 
246.Ombitasvir/paritaprevir/ritonavir & Dasabuvir ± Ribavirin Following Protease Inhibitors Failure - A Prospective Multi-Centre Trial
 

BMC Infect Dis. 2020 Apr 3;20(1):264. doi: 10.1186/s12879-020-4921-3.

Liat Deutsch 1 2, Inbal Houri 1 2, Ziv Ben-Ari 2 3, Amir Shlomai 2 4, Ella Veitsman 2 3, Oranit Cohen-Ezra 2 3, Assaf Issachar 2 4, Orna Mor 5 6, Yael Gozlan 5, Rafael Bruck 1 2, Yoram Menachem 1 2, Shira Zelber-Sagi 1 7, Helena Katchman 1 2, Oren Shibolet 8 9
 
247.How to Think With Models and Targets: Hepatitis C Elimination as a Numbering Performance
 

Int J Drug Policy. 2020 Mar 31;102694. doi: 10.1016/j.drugpo.2020.102694. Online ahead of print.

Tim Rhodes 1, Kari Lancaster 2
 
248.Is Alzheimer's Disease a Liver Disease of the Brain?
 

Alzheimers Dis. 2020 Apr 2.doi: 10.3233/JAD-190848. Online ahead of print.

Margaret F Bassendine 1 2, Simon D Taylor-Robinson 2, Michael Fertleman 2 3, Michael Khan 4, Dermot Neely 1 5
 
249.Low Uptake of Direct-acting Antiviral Therapy Among Hepatitis C Patients With Advanced Liver Disease and Access to Care, 2014-2017
 

J Clin Gastroenterol. 2020 Apr 3. doi: 10.1097/MCG.0000000000001344. Online ahead of print.

Philip R Spradling 1, Jian Xing 1, Loralee B Rupp 2, Anne C Moorman 1, Stuart C Gordon 2 3, Mei Lu 2, Eyasu H Teshale 1, Joseph A Boscarino 4, Mark A Schmidt 5, Yihe G Daida 6, Scott D Holmberg 1, Chronic Hepatitis Cohort Study (CHeCS) Investigators
 
250.Use of Electronic Health Records at Federally Qualified Health Centers: A Potent Tool to Increase Viral Hepatitis Screening and Address the Climbing Incidence of Liver Cancer
 

Cancer Educ. 2020 Apr 2. doi: 10.1007/s13187-020-01741-1. Online ahead of print.

Christina Pham 1, Mo-Kyung Sin 2
 
251. Antibody Avidity-Based Approach to Estimate Population-Level Incidence of Hepatitis C
 

Hepatol. 2020 Mar 30;S0168-8278(20)30190-2. doi: 10.1016/j.jhep.2020.03.028.Online ahead of print.

Denali Boon 1, Veronica Bruce 2, Eshan U Patel 3, Jeffery Quinn 3, Aylur K Srikrishnan 4, Saravanan Shanmugam 4, Syed Iqbal 4, Pachamuthu Balakrishnan 4, Matthew Sievers 3, Gregory D Kirk 3, David L Thomas 3, Thomas C Quinn 5, Andrea L Cox 3, Kimberly A Page 2, Sunil S Solomon 6, Shruti H Mehta 3, Oliver Laeyendecker 5
 
252.Association Between Statin Use, Intensity and Acute Liver Injury in Human Immunodeficiency Virus, Hepatitis C Virus, and Uninfected US Veterans
 

 J Cardiovasc Drugs. 2020 Apr 1. doi: 10.1007/s40256-020-00404-2. Online ahead of print.

S S Sutton 1 2, Joseph Magagnoli 3 4, Tammy H Cummings 2, James W Hardin 2 5
 
253.Health of Special Immigrant Visa Holders From Iraq and Afghanistan After Arrival Into the United States Using Domestic Medical Examination Data, 2014-2016: A Cross-Sectional Analysis
 

PLoS Med. 2020 Mar 31;17(3):e1003083. doi: 10.1371/journal.pmed.1003083.eCollection 2020 Mar.

Gayathri S Kumar 1, Clelia Pezzi 1, Simone Wien 1, Blain Mamo 2, Kevin Scott 3, Colleen Payton 3, Kailey Urban 2, Stephen Hughes 4, Lori Kennedy 5, Nuny Cabanting 6, Jessica Montour 7, Melissa Titus 8, Jenny Aguirre 9, Breanna Kawasaki 5, Rebecca Ford 10, Emily S Jentes 1
 
254.Influence of Interferon-free Direct-acting Antiviral Therapy on Primary Hepatocellular Carcinoma Recurrence: A Landmark Time Analysis and Time-dependent Extended Cox Proportional Hazards Model Analysis
 

Intern Me. 2020;59(7):901-907. doi: 10.2169/internalmedicine.3382-19. Epub 2020 Apr 1.

Satoshi Miuma 1, Junya Miyamoto 2, Naota Taura 1, Masanori Fukushima 1, Ryu Sasaki 1, Masafumi Haraguchi 1, Hidetaka Shibata 1, Shuntaro Sato 2, Hisamitsu Miyaaki 1, Kazuhiko Nakao 1
 
255. Prescription Opioid Injection Among Young People Who Inject Drugs in New York City: A Mixed-Methods Description and Associations With Hepatitis C Virus Infection and Overdose
 

Harm Reduct J. 2020 Mar 30;17(1):22. doi: 10.1186/s12954-020-00367-2.

Pedro Mateu-Gelabert 1, Honoria Guarino 2, Jon E Zibbell 3, Jennifer Teubl 4, Chunki Fong 2, Elizabeth Goodbody 2, Brian Edlin 5, Carli Salvati 2, Samuel R Friedman 6
 
256.Measuring Hepatitis C Virus Elimination as a Public Health Threat: Beyond Global Targets
 

J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13294. Online ahead of print.

Daniela K van Santen 1 2 3, Rachel Sacks-Davis 1 3, Joseph S Doyle 1 4, Nick Scott 1 3, Maria Prins 2 5, Margaret Hellard 1 4 6
 
257.The Impact of SVR From Direct-Acting Antiviral- And Interferon-Based Treatments for HCV on Hepatocellular Carcinoma Risk
 

J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13295. Online ahead of print.

Naveed Z Janjua 1 2, Stanley Wong 1, Maryam Darvishian 1 2 3, Zahid A Butt 1 2, Amanda Yu 1, Mawuena Binka 1, Maria Alvarez 1, Ryan Woods 3, Eric M Yoshida 4, Alnoor Ramji 4, Jordan Feld 5, Mel Krajden 1 6
 
258.Hepatitis C: Looking Into the Future
 

Expert Rev Gastroenterol Hepatol. 2020 Mar 27;1-8.

 doi: 10.1080/17474124.2020.1746641.Online ahead of print.

Omar Massoud 1
 
259.Comparison of Recommendations for Treatment of Chronic Hepatitis C Virus Infection in Children and Adolescents: A Position Paper of the Global Federation of International Societies of International Societies of Pediatric Gastroenterology, Hepatology and Nutrition (FISPGHAN)
 

J Pediatr Gastroenterol Nutr. 2020 Mar 20.

 doi: 10.1097/MPG.0000000000002710.Online ahead of print.

Giuseppe Indolfi 1, Björn Fischler 2, Regino P Gonzalez-Peralta 3, Mirta Ciocca 4, Gilda Porta 5, Mohan Neelam 6, Mohammed El-Guindi 7, Deirdre Kelly 8, Yen-Hsuan Ni 9, Anupan Sibal 10, Daniel H Leung 11, Mei Hwei Chang 12, Hepatitis Expert Team of the Federation of International Societies of Pediatric Gastroenterology, Hepatology, and Nutrition (FISPGHAN)
 
260.Population Impact of Direct-Acting Antiviral Treatment on New Presentations of Hepatitis C-related Decompensated Cirrhosis: A National Record-Linkage Study
 

Gut. 2020 Mar 26;gutjnl-2019-320007. doi: 10.1136/gutjnl-2019-320007. Online ahead of print.

Sharon J Hutchinson 1 2, Heather Valerio 3 2, Scott A McDonald 3 2, Alan Yeung 3 2, Kevin Pollock 3 2, Shanley Smith 3 2, Stephen Barclay 3 4, John F Dillon 5, Raymond Fox 6, Peter Bramley 7, Andrew Fraser 8 9, Nicholas Kennedy 10, Rory N Gunson 11, Kate Templeton 12, Hamish Innes 3 2, Allan McLeod 2, Amanda Weir 2, Peter C Hayes 13, David Goldberg 3 2
 
261.New hepatitis C diagnoses in Ontario, Canada are associated with the local prescription patterns of a controlled-release opioid
 

Meyer M1,2,3, Bondy L4, Koivu S5, Koval J2, Scarffe AD3,6, Silverman MS4. J Viral Hepat. 2020 Mar 18. doi: 10.1111/jvh.13292. [Epub ahead of print]
 
262.Hepatitis C: looking into the future
 

Massoud O1. Expert Rev Gastroenterol Hepatol. 2020 Mar 27:1-8. doi: 10.1080/17474124.2020.1746641. [Epub ahead of print]
 
263.Sustained Improvements in Markers of Liver Disease Severity After Hepatitis C Treatment
 

Wong RJ1, Jain MK2,3, Therapondos G4, Shiffman ML5, Kshirsagar O6, Clark C3, Thamer M6. J Clin Exp Hepatol. 2020 Mar-Apr;10(2):114-123. doi: 10.1016/j.jceh.2019.09.001. Epub 2019 Sep 20.
 
264.T-Cell Immunity against the Hepatitis C Virus: A Persistent Research Priority in an Era of Highly Effective Therapy
 

Smith S1,2, Honegger JR1,2, Walker C1,2. Cold Spring Harb Perspect Med. 2020 Mar 23. pii: a036954. doi: 10.1101/cshperspect.a036954. [Epub ahead of print]
 
265.Hepatitis C virus treatment response to ledipasvir/sofosbuvir among patients coinfected with HIV and HCV: Real world data in a black population
 

Banga J1, Nizami S1, Slim J2, Nagarakanti S3, Portilla M1, Swaminathan S1. Medicine (Baltimore). 2020 Mar;99(11):e19140. doi: 10.1097/MD.0000000000019140.
 
266.Australia needs to increase testing to achieve hepatitis C elimination
 

Scott N1, Sacks-Davis R1, Wade AJ1, Stoove M1, Pedrana A1, Doyle JS1, Thompson AJ2, Wilson DP1, Hellard ME1. Med J Aust. 2020 Mar 13. doi: 10.5694/mja2.50544. [Epub ahead of print]
 
267.The Urgent Need for Hepatitis C Screening in Pregnant Women: A Call to Action
 

Saab S1, Kullar R, Gounder P. Obstet Gynecol. 2020 Apr;135(4):773-777. doi: 10.1097/AOG.0000000000003704.
 
268.Present and future management of viral hepatitis B and C in children
 

Clemente MG1, Antonucci R2, Sotgiu G2, Dettori M2, Piana A2, Vajro P3. Clin Res Hepatol Gastroenterol. 2020 Mar 12. pii: S2210-7401(20)30043-7. doi: 10.1016/j.clinre.2020.02.010. [Epub ahead of print]
 
269. Hepatitis C Virus Antibody Screening in a Cohort of Pregnant Women: Identifying Seroprevalence and Risk Factors
 

Prasad M1, Saade GR, Sandoval G, Hughes BL, Reddy UM, Mele L, Salazar A, Varner MW, Gyamfi-Bannerman C, Thorp JM Jr, Tita ATN, Swamy GK, Chien EK, Casey BM, Peaceman AM, El-Sayed YY, Iams JD, Gibbs RS, Sibai B, Wiese N, Kamili S, Macones GA; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) Maternal-Fetal Medicine Units (MFMU) Network. Obstet Gynecol. 2020 Apr;135(4):778-788. doi: 10.1097/AOG.0000000000003754.
 
270.Reinfection following successful direct-acting antiviral therapy for hepatitis Cinfection among people who inject drugs
 

Cunningham EB1, Hajarizadeh B1, Amin J1,2, Hellard M3,4, Bruneau J5, Feld JJ6, Cooper C7, Powis J8, Litwin AH9, Marks P1, Dalgard O10, Conway B11, Moriggia A12,13, Stedman C14, Read P1,15, Bruggmann P16, Lacombe K17, Dunlop A18, Applegate TL1, Matthews GV1,19, Fraser C20, Dore GJ1,19, Grebely J1. Clin Infect Dis. 2020 Mar 12. pii: ciaa253. doi: 10.1093/cid/ciaa253. [Epub ahead of print]
 
271.Modeling the role of incarceration in HCV transmission and prevention amongst people who inject drugs in rural Kentucky
 

Stone J1, Fraser H2, Young AM3, Havens JR4, Vickerman P2. Int J Drug Policy. 2020 Mar 6:102707. doi: 10.1016/j.drugpo.2020.102707. [Epub ahead of print]
 
272.A Phylogenetic Analysis of HCV Transmission, Relapse, and Reinfection Among People Who Inject Drugs Receiving Opioid Agonist Therapy
 

Akiyama MJ1, Lipsey D1, Ganova-Raeva L2, Punkova L2, Agyemang L1, Sue A2, Ramachandran S2, Khudyakov Y2, Litwin AH3. J Infect Dis. 2020 Mar 9. pii: jiaa100. doi: 10.1093/infdis/jiaa100. [Epub ahead of print]
 
273.Transplant Outcomes in Older Patients with Nonalcoholic Steatohepatitis Compared to Alcohol-Related Liver Disease and Hepatitis C
 

Henson JB1, Wilder JM2,3, Kappus MR2, Barbas AS4, Moylan CA2, Niedzwiecki D5, Muir AJ2,3, Berg CL2, Patel YA2. Transplantation. 2020 Mar 6. doi: 10.1097/TP.0000000000003219. [Epub ahead of print]
 
274.Hepatitis C Virus Prevalence in 50 U.S. States and D.C. by Sex, Birth Cohort, and Race: 2013-2016
 

Bradley H1, Hall EW2, Rosenthal EM3, Sullivan PS2, Ryerson AB4, Rosenberg ES3. Hepatol Commun. 2020 Jan 14;4(3):355-370. doi: 10.1002/hep4.1457. eCollection 2020 Mar.
 
275.Are we on the precipice of a new epidemic? Risk for hepatitis C among HIV-negative men-, trans women-, and trans men- who have sex with men in the United States
 

Grov C1,2, Westmoreland DA2, Carrico AW3,4, Nash D1,2. AIDS Care. 2020 Mar 15:1-9. doi: 10.1080/09540121.2020.1739204. [Epub ahead of print]
 
276.Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct-acting antiviral therapy-Results from the German Hepatitis C-Registry
 

Knop V1, Mauss S2, Goeser T3, Geier A4, Zimmermann T5, Herzer K6, Postel N7, Friedrich-Rust M1, Hofmann WP8; German Hepatitis C-Registry9. J Viral Hepat. 2020 Feb 24. doi: 10.1111/jvh.13280. [Epub ahead of print]
 
277.A vulnerability assessment for the HCV infections associated with injection drug use
 

Sharareh N1, Hess R2, White S3, Dunn A4, Singer PM5, Cochran J6. Prev Med. 2020 Feb 22;134:106040. doi: 10.1016/j.ypmed.2020.106040. [Epub ahead of print]
 
278.Examination of using alcohol to cope, depressive symptoms, and perceived social support in persons with HIV and Hepatitis C
 

Moitra E1, Anderson BJ2, Herman DS1,2, Hayaki J3, Pinkston MM1,4, Kim HN5,6, Stein MD7. AIDS Care. 2020 Feb 25:1-8. doi: 10.1080/09540121.2020.1734177. [Epub ahead of print]
 
279.Cost effectiveness of an intervention to increase uptake of hepatitis C virus testing and treatment (HepCATT): cluster randomised controlled trial in primary care
 

Roberts K1, Macleod J1,2, Metcalfe C1,3, Hollingworth W1, Williams J4,5, Muir P6, Vickerman P1,2, Clement C2, Gordon F7, Irving W8, Waldron CA9, North P6, Moore P6, Simmons R5,10, Miners A4,5, Horwood J1,2, Hickman M11,2. BMJ. 2020 Feb 26;368:m322. doi: 10.1136/bmj.m322.
 
280.Increasing uptake of hepatitis C virus infection case-finding, testing, and treatment in primary care: evaluation of the HepCATT (Hepatitis C Assessment Through to Treatment) trial
 

Horwood J1, Clement C2, Roberts K2, Waldron CA3, Irving WL4, Macleod J5, Hickman M6. Br J Gen Pract. 2020 Feb 24. pii: bjgp20X708785. doi: 10.3399/bjgp20X708785. [Epub ahead of print]Horwood J1, Clement C2, Roberts K2, Waldron CA3, Irving WL4, Macleod J5, Hickman M6. Br J Gen Pract. 2020 Feb 24. pii: bjgp20X708785. doi: 10.3399/bjgp20X708785. [Epub ahead of print]
 
281.Socio-demographic and ecological factors associated with anti-HCV prevalence in people who inject drugs: A systematic review
 

Colledge S1, Leung J2, Grebely J3, Degenhardt L4, Peacock A4, Hickman M5, Vickerman P5, Stone J5, Trickey A5, Larney S4. Drug Alcohol Depend. 2020 Feb 6;209:107899. doi: 10.1016/j.drugalcdep.2020.107899. [Epub ahead of print]
 
282.Minimal Compared With Standard Monitoring During Sofosbuvir-Based Hepatitis CTreatment: A Randomized Controlled Trial
 

Davis JS1,2, Young M1, Marshall C3, Tate-Baker J3, Madison M3, Sharma S3, Silva C1, Jones T1, Davies J2,3. Open Forum Infect Dis. 2020 Jan 19;7(2):ofaa022. doi: 10.1093/ofid/ofaa022. eCollection 2020 Feb.
 
283.Cost-effectiveness of Using Kidneys From HCV-Viremic Donors for Transplantation Into HCV-Uninfected Recipients
 

Eckman MH1, Woodle ES2, Thakar CV3, Alloway RR3, Sherman KE4. Am J Kidney Dis. 2020 Feb 5. pii: S0272-6386(19)31163-1. doi: 10.1053/j.ajkd.2019.11.005. [Epub ahead of print]
 
284.The association between etiology of hepatocellular carcinoma and race-ethnicity in Florida
 

Pinheiro PS1, Medina HN2, Callahan KE3, Jones PD4, Brown CP5, Altekruse SF6, McGlynn KA7, Kobetz EN8. Liver Int. 2020 Feb 22. doi: 10.1111/liv.14409. [Epub ahead of print]
 
285.Diagnostic Accuracy of Non-Invasive Tests to Detect Advanced Hepatic Fibrosis in Patients With Hepatitis C and End-Stage Renal Disease
 

Schmoyer CJ1, Kumar D2, Gupta G2, Sterling RK3. Clin Gastroenterol Hepatol. 2020 Feb 18. pii: S1542-3565(20)30189-0. doi: 10.1016/j.cgh.2020.02.019. [Epub ahead of print]
 
286.Hepatitis C Virus Vaccine: Challenges and Prospects
 

Duncan JD1,2,3, Urbanowicz RA1,2,3, Tarr AW1,2,3, Ball JK1,2,3. Vaccines (Basel). 2020 Feb 17;8(1). pii: E90. doi: 10.3390/vaccines8010090.
 
287.Micro-elimination of hepatitis C virus
 

Hollande C1, Parlati L1, Pol S1. Liver Int. 2020 Feb;40 Suppl 1:67-71. doi: 10.1111/liv.14363
 
288.Hepatitis C elimination - Macro-elimination
 

Kåberg M1,2, Weiland O1. Liver Int. 2020 Feb;40 Suppl 1:61-66. doi: 10.1111/liv.14352.
 
289.Increased-risk donors and solid organ transplantation: current practices and opportunities for improvement
 

Brown CS1, Wakam GK, Englesbe MJ. Curr Opin Organ Transplant. 2020 Apr;25(2):139-143. doi: 10.1097/MOT.0000000000000735
 
290.Case Management and Capacity Building to Enhance Hepatitis C Treatment Uptake at Community Health Centers in a Large Urban Setting
 

Boodram B1, Kaufmann M, Aronsohn A, Hamlish T, Peregrine Antalis E, Kim K, Wolf J, Rodriguez I, Millman AJ, Johnson D. Fam Community Health. 2020 Apr/Jun;43(2):150-160. doi: 10.1097/FCH.0000000000000253
 
291.HCV infection and non-Hodgkin lymphomas: an evolving story
 

Defrancesco I1, Zerbi C1, Rattotti S2, Merli M3, Bruno R4,5, Paulli M1,6, Arcaini L7,8. Clin Exp Med. 2020 Feb 12. doi: 10.1007/s10238-020-00615-6. [Epub ahead of print]
 
292.Respect women, promote health and reduce stigma: ethical arguments for universal hepatitis C screening in pregnancy
 

Gross MS1, Ruth AR2, Rasmussen SA3,4. J Med Ethics. 2020 Feb 13. pii: medethics-2019-105692. doi: 10.1136/medethics-2019-105692. [Epub ahead of print]
 
293.Discontinuation of new hepatitis C drugs among Medicare patients
 

Jung J1, Du P, Feldman R, Riley T 3rd. Am J Manag Care. 2020 Feb;26(2):84-88. doi: 10.37765/ajmc.2020.42397
 
294.Hepatitis C Testing Among Perinatally Exposed Infants
 

Lopata SM1,2, McNeer E3,4, Dudley JA5, Wester C6, Cooper WO7,3,5, Carlucci JG7,8, Espinosa CM9,10, Dupont W4,5, Patrick SW7,2,3,5. Pediatrics. 2020 Mar;145(3). pii: e20192482. doi: 10.1542/peds.2019-2482. Epub 2020 Feb 14.
 
295.Hepatitis C vaccine: 10 good reasons for continuing
 

Roingeard P1, Beaumont E1. Hepatology. 2020 Feb 15. doi: 10.1002/hep.31182. [Epub ahead of print]
 
296.Treatment-failure to direct antiviral HCV regimens in real world: frequency, patient characteristics and rescue therapy - data from the German hepatitis C registry (DHC-R)
 

Schmitt A1, Günther R2, Mauss S3, Boeker KHW4, Buggisch P5, Hillenbrand H6, John C7, Klinker H8, Pathil A9,10, Simon KG11, Serfert Y12, Niederau C13, Vermehren J10, Wedemeyer H12,14,15, Sarrazin C1,10. Z Gastroenterol. 2020 Feb 10. doi: 10.1055/a-1068-3056. [Epub ahead of print]
 
297.The Next Frontier: Universal HCV Screening in pregnant women
 

Saab S1, Kullar R2, Amini C3, Gounder P4. Am J Obstet Gynecol. 2020 Feb 7. pii: S0002-9378(20)30133-2. doi: 10.1016/j.ajog.2020.01.058. [Epub ahead of print]
 
298.Network-based recruitment of people who inject drugs for hepatitis C testing and linkage to care
 

Falade-Nwulia O1, Ward KM1, McCormick S1, Mehta SH2, Pitts SR3, Katz S1, Chander G1, Thomas DL1, Sulkowski M1, Latkin CA2. J Viral Hepat. 2020 Feb 11. doi: 10.1111/jvh.13274. [Epub ahead of print]
 
299.A financial incentive program to improve appointment attendance at a safety-net hospital-based primary care hepatitis C treatment program
 

Lee KS1,2, Quintiliani L1,3, Heinz A4, Johnson NL3, Xuan Z3, Truong V2, Lasser KE1,2,3. PLoS One. 2020 Feb 11;15(2):e0228767. doi: 10.1371/journal.pone.0228767. eCollection 2020
 
300.Alcohol Use and Long-Term Outcomes Among U.S. Veterans Who Received Direct-Acting Antivirals for Hepatitis C Treatment
 

Kim NJ1, Pearson M1, Vutien P1, Su F1, Moon AM2, Berry K3, Green PK3, Williams EC3,4, Ioannou GN1,5. Hepatol Commun. 2020 Jan 2;4(2):314-324. doi: 10.1002/hep4.1464. eCollection 2020 Feb.
 
301.HIV and Hepatitis C Virus Infection Testing Among Commercially Insured Persons Who Inject Drugs, United States, 2010-2017
 

Bull-Otterson L1, Huang YA2, Zhu W3, King H4, Edlin BR1, Hoover KW2. J Infect Dis. 2020 Jan 30. pii: jiaa017. doi: 10.1093/infdis/jiaa017. [Epub ahead of print]
 
302.Exploring Awareness of HCV Among Sexual-Minority Black Generation Millennials and Gen Z: a Qualitative Study
 

D'Anna L1, Washington TA2, Cabudol M3, Canjura C3, Owens J3; PPOWER Project Team. J Racial Ethn Health Disparities. 2020 Jan 31. doi: 10.1007/s40615-019-00684-8. [Epub ahead of print]
 
303.Community viral load and hepatitis C virus infection: Community viral load measures to aid public health treatment efforts and program evaluation
 

Jordan AE1, Perlman DC2, Cleland CM3, Wyka K4, Schackman BR5, Nash D4. J Clin Virol. 2020 Jan 27;124:104285. doi: 10.1016/j.jcv.2020.104285. [Epub ahead of print]
 
304.Impact of hepatitis C virus clearance by direct-acting antiviral treatment on the incidence of major cardiovascular events: A prospective multicentre study
 

Adinolfi LE1, Petta S2, Fracanzani AL3, Coppola C4, Narciso V5, Nevola R6, Rinaldi L6, Calvaruso V2, Staiano L4, Di Marco V2, Marrone A6, Pafundi PC6, Solano A5, Lombardi R3, Sasso FC6, Saturnino M4, Rini F2, Guerrera B6, Troina G2, Giordano M6, Craxì A2. Atherosclerosis. 2020 Jan 21;296:40-47. doi: 10.1016/j.atherosclerosis.2020.01.010. [Epub ahead of print]
 
305.Concurrent Initiation of Hepatitis C and Opioid Use Disorder Treatment in People Who Inject Drugs
 

Rosenthal ES1,2, Silk R1,2, Mathur P1,2, Gross C1,2, Eyasu R1,2, Nussdorf L2,3, Hill K2,3, Brokus C2,3, D'Amore A2,3, Sidique N2,3, Bijole P4, Jones M4, Kier R4, McCullough D4, Sternberg D4, Stafford K1, Sun J3, Masur H2,3, Kottilil S1,2, Kattakuzhy S1,2. Clin Infect Dis. 2020 Feb 3. pii: ciaa105. doi: 10.1093/cid/ciaa105. [Epub ahead of print]
 
306.Quality improvement in hepatitis C screening and treatment in a primary care resident clinic
 

Doering T1, Williamson S1, Gadalla M1. J Community Hosp Intern Med Perspect. 2019 Dec 14;9(6):471-472. doi: 10.1080/20009666.2019.1698230. eCollection 2019.
 
307.Hepatitis C Diagnosis and Treatment, Impact on Engagement and Behaviour of People Who Inject Drugs, a service evaluation, the Hooked C project
 

Caven M1, Robinson EM1,2, Eriksen AJ3, Fletcher EH1,3, Dillon JF1,2. J Viral Hepat. 2020 Jan 29. doi: 10.1111/jvh.13269. [Epub ahead of print]
 
308.Cost-effectiveness of transplanting lungs and kidneys from donors with potential hepatitis C exposure or infection
 

Scott N1,2, Snell G3, Westall G3, Pilcher D4,5, Raggatt M6,7, Walker RG8,9, Hellard M6,4,7, Peleg AY7,10, Doyle J6,7. Sci Rep. 2020 Jan 29;10(1):1459. doi: 10.1038/s41598-020-58215-z.
 
309.A Co-localized Hepatitis C Virus Clinic in a Primary Care Practice Improves Linkage to Care in a High Prevalence Population
 

Adamson PC1, Miceli J2, Shiferaw B3, Villaneuva MS2, Canterino JE4. Am J Med. 2020 Jan 24. pii: S0002-9343(20)30039-5. doi: 10.1016/j.amjmed.2019.12.028. [Epub ahead of print]
 
310.Success of Direct-Acting, Antiviral-Based Therapy for Chronic Hepatitis C Is Not Affected by Type 2 Diabetes
 

Niccum BA1, Stine JG2, Wynter JA3, Kelly V3, Caldwell SH3, Shah NL3. Clin Diabetes. 2020 Jan;38(1):40-46. doi: 10.2337/cd18-0112.
 
311.Comparison of three therapeutic regimens for genotype-3 hepatitis C virus infection in a large real-life multicentre cohort
 

Soria A1, Fava M1,2, Bernasconi DP3, Lapadula G1, Colella E1, Valsecchi MG3, Migliorino GM1, D'Ambrosio R4, Landonio S5, Schiavini M5, Spinetti A6, Carriero C6, Degasperi E4, Cologni G7, Gatti F8, Viganò P8, Hasson H9, Uberti-Foppa C10, Pasulo L7, Baiguera C11, Rossotti R11, Vinci M11, Puoti M11, Giorgini A12, Menzaghi B13, Lombardi A14, Pan A15, Aghemo A16, Grossi PA17, Boldizzoni R18, Colombo S18, Viganò M19, Rumi MG19, Del Poggio P20, Valenti L21, Giglio O22, De Bona A12, d'Arminio Monforte A12, Colombo A22, Spinelli O22, Pigozzi MG6, Molteni C23, Bonfanti P23, Terreni N24, Perini P25, Capretti A26, Bella D27, Liani C27, Polo S27, Aimo G27, Pagnucco L14, Bhoori S28, Centenaro R29, Graffeo M30, Ciaccio A31, Dionigi E32, Lazzaroni S33, Carderi I34, Di Marco M35, Rizzardini G5, Noventa F36, Lampertico P4, Fagiuoli S7. Liver Int. 2020 Jan 22. doi: 10.1111/liv.14386. [Epub ahead of print]
 
312.Electronic medical record alert activation increase hepatitis C and HIV screening rates in primary care practices within a large healthcare system
 

Tapp H1, Ludden T1, Shade L1, Thomas J1, Mohanan S1, Leonard M2. Prev Med Rep. 2020 Jan 7;17:101036. doi: 10.1016/j.pmedr.2019.101036. eCollection 2020 Mar.
 
313.Social values for health technology assessment in Canada: a scoping review of hepatitis C screening, diagnosis and treatment
 

O'Keefe-Markman C1, Lea KD2, McCabe C3,4, Hyshka E1,5, Bubela T6. BMC Public Health. 2020 Jan 20;20(1):89. doi: 10.1186/s12889-020-8190-2.
 
314.Effect of Needle Exchange Program on Maternal Hepatitis C Virus Prevalence
 

Rossi RM1,2, Brady MJ1, Hall ES3,4, Warshak CR1,2. Am J Perinatol. 2020 Jan 21. doi: 10.1055/s-0039-3402753. [Epub ahead of print]
 
315.Global prevalence of hepatitis C virus in children in 2018: a modelling study
 

Schmelzer J1, Dugan E1, Blach S1, Coleman S1, Cai Z1, DePaola M1, Estes C1, Gamkrelidze I1, Jerabek K1, Ma S1, Montoya S1, Razavi-Shearer D1, Razavi-Shearer K1, Robbins-Scott S1, Razavi H2, El Sayed MH3. Lancet Gastroenterol Hepatol. 2020 Jan 16. pii: S2468-1253(19)30385-1. doi: 10.1016/S2468-1253(19)30385-1. [Epub ahead of print]
 
316.Long-Term Safety and Efficacy Results in Hepatitis C Virus Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin in the TOPAZ-I and TOPAZ-II Trials
 

Poordad F1, Castro RE2, Asatryan A3, Aguilar H4, Cacoub P5,6, Dieterich D7, Marinho RT8, Carvalho A9, Siddique A10, Hu YB11, Charafeddine M12, Bondin M11, Khan N11, Cohen DE11, Felizarta F13. J Viral Hepat. 2020 Jan 18. doi: 10.1111/jvh.13261. [Epub ahead of print]
 
317.The Growing Problem of Hepatitis C Virus Infection: The Case of West Virginia
 

Phillips M1, Abboud J, Abodunde B, Paul DP 3rd, Coustasse A. Health Care Manag (Frederick). 2020 Jan/Mar;39(1):2-11. doi: 10.1097/HCM.0000000000000278.
 
318.Management of Hepatitis C in the Older Adult
 

Chahine EB, Guirguis EH, Derrick CB. Sr Care Pharm. 2020 Jan 1;35(1):13-28.
 
319.Control of HCV Infection by Natural Killer Cells and Macrophages
 

Rosen HR1,2, Golden-Mason L1,2. Cold Spring Harb Perspect Med. 2019 Dec 23. pii: a037101. doi: 10.1101/cshperspect.a037101. [Epub ahead of print]
 
320.Effects of Sofosbuvir-Based Hepatitis C Treatment Regimens on Calcineurin Inhibitor Dosing in Liver and Kidney Transplant Recipients
 

Laub M1, Harris M, Sanoff S, Berg C, Byrns J. Exp Clin Transplant. 2019 Dec 24. doi: 10.6002/ect.2019.0289. [Epub ahead of print]
 
321.A cost-effectiveness analysis of primary versus hospital-based specialist care for direct acting antiviral hepatitis C treatment
 

Palmer AY1, Wade AJ2, Draper B3, Howell J4, Doyle JS5, Petrie D6, Thompson AJ7, Wilson DP8, Hellard ME9, Scott N3. nt J Drug Policy. 2019 Dec 20;76:102633. doi: 10.1016/j.drugpo.2019.102633. [Epub ahead of print]
 
322.Dynamic modeling of hepatitis C transmission among people who inject drugs
 

Stocks T1, Martin LJ2, Kühlmann-Berenzon S2, Britton T3. Epidemics. 2019 Dec 11;30:100378. doi: 10.1016/j.epidem.2019.100378. [Epub ahead of print]
 
323.Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population
 

Choi DT1, Puenpatom A2, Yu X1, Erickson KF1, Kanwal F3, El-Serag HB3, Kramer JR4. Antiviral Res. 2019 Dec 17;174:104698. doi: 10.1016/j.antiviral.2019.104698. [Epub ahead of print]
 
324.Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure
 

Chen Q1, Perales C1, Soria ME2, García-Cehic D1, Gregori J3, Rodríguez-Frías F4, Buti M1, Crespo J5, Calleja JL6, Tabernero D4, Vila M7, Lázaro F8, Rando-Segura A7, Nieto-Aponte L7, Llorens-Revull M1, Cortese MF7, Fernandez-Alonso I2, Castellote J9, Niubó J10, Imaz A11, Xiol X9, Castells L1, Riveiro-Barciela M1, Llaneras J1, Navarro J12, Vargas-Blasco V1, Augustin S1, Conde I13, Rubín Á13, Prieto M13, Torras X14, Margall N15, Forns X16, Mariño Z16, Lens S16, Bonacci M17, Pérez-Del-Pulgar S16, Londoño MC16, García-Buey ML18, Sanz-Cameno P18, Morillas R19, Martró E20, Saludes V20, Masnou-Ridaura H19, Salmerón J21, Quíles R21, Carrión JA22, Forné M23, Rosinach M23, Fernández I24, García-Samaniego J25, Madejón A25, Castillo-Grau P26, López-Núñez C27, Ferri MJ28, Durández R29, Sáez-Royuela F30, Diago M31, Gimeno C32, Medina R32, Buenestado J33, Bernet A34, Turnes J35, Trigo-Daporta M36, Hernández-Guerra M37, Delgado-Blanco M38, Cañizares A39, Arenas JI40, Gomez-Alonso MJ6, Rodríguez M41, Deig E42, Olivé G43, Río OD43, Cabezas J5, Quiñones I44, Roget M45, Montoliu S46, García-Costa J47, Force L48, Blanch S49, Miralbés M50, López-de-Goicoechea MJ51, García-Flores A52, Saumoy M11, Casanovas T9, Baliellas C9, Gilabert P9, Martin-Cardona A9, Roca R9, Barenys M53, Villaverde J9, Salord S9, Camps B9, Silvan di Yacovo M9, Ocaña I12, Sauleda S54, Bes M54, Carbonell J2, Vargas-Accarino E2, Ruzo SP2, Guerrero-Murillo M2, Von Massow G2, Costafreda MI55, López RM7, González-Moreno L18, Real Y18, Acero-Fernández D27, Viroles S27, Pamplona X27, Cairó M23, Ocete MD32, Macías-Sánchez JF43, Estébanez A5, Quer JC46, Mena-de-Cea Á38, Otero A38, Castro-Iglesias Á38, Suárez F38, Vázquez Á38, Vieito D38, López-Calvo S38, Vázquez-Rodríguez P38, Martínez-Cerezo FJ56, Rodríguez R47, Macenlle R47, Cachero A57, Mereish G57, Mora-Moruny C58, Fábregas S58, Sacristán B59, Albillos A60, Sánchez-Ruano JJ61, Baluja-Pino R62, Fernández-Fernández J62, González-Portela C62, García-Martin C63, Sánchez-Antolín G64, Andrade RJ65, Simón MA66, Pascasio JM67, Romero-Gómez M68, Antonio Del-Campo J68, Domingo E69, Esteban R1, Esteban JI70, Quer J71. Antiviral Res. 2019 Dec 16;174:104694. doi: 10.1016/j.antiviral.2019.104694. [Epub ahead of print]
 
325.Cost burden of hepatitis C virus treatment in commercially insured patients
 

Lu CY1, Ross-Degnan D, Zhang F, LeCates R, Lupton C, Sherman M, Wagner A. Am J Manag Care. 2019 Dec 1;25(12):e379-e387.
 
326.Expanding the use of hepatitis C positive donors and keeping recipient safety at the forefront
 

Terrault NA1, Sher L2. Am J Transplant. 2019 Dec 15. doi: 10.1111/ajt.15745. [Epub ahead of print]
 
327.Expanding Heart Transplant in the Era of Direct-Acting Antiviral Therapy for Hepatitis C
 

Schlendorf KH1, Zalawadiya S1, Shah AS1, Perri R1, Wigger M1, Brinkley DM1, Danter MR1, Menachem JN1, Punnoose LR1, Balsara K1, Sacks SB1, Ooi H1, Awad JA1, Sandhaus E1, Schwartz C1, O'Dell H1, Carver AB1, Edmonds CL1, Ruzevich-Scholl S1, Lindenfeld J1. JAMA Cardiol. 2019 Dec 18. doi: 10.1001/jamacardio.2019.4748. [Epub ahead of print]
 
328.Unreported alcohol use was common but did not impact hepatitis C cure in HIV-infected persons who use drugs
 

Irvin R1, Chander G1, Ward KM1, Manogue S1, Falade-Nwulia O1, Moon J1, Sutcliffe CG2, Brinkley S1, Haselhuhn T1, Katz S1, Herne K1, Arteaga L1, Thomas DL1, Mehta SH2, Sulkowski MS1. J Viral Hepat. 2019 Dec 18. doi: 10.1111/jvh.13251. [Epub ahead of print]
 
329."Take Charge, Get Cured": Pilot testing a targeted mHealth treatment decision support tool for methadone patients with hepatitis C virus for acceptability and promise of efficacy
 

Jessop AB1, Bass SB2, Brajuha J2, Alhajji M2, Burke M3, Gashat MT3, Wellington C2, Ventriglia N2, Coleman J2, D'Avanzo P2. J Subst Abuse Treat. 2020 Feb;109:23-33. doi: 10.1016/j.jsat.2019.11.001. Epub 2019 Nov 6.
 
330.Associations of Liver Disease with Alcohol Use among People Living with HIV and the Role of Hepatitis C: The New Orleans Alcohol Use in HIV Study
 

Ferguson TF1,2, Rosen E1,2, Carr R3, Brashear M1,4, Simon L1,5, Theall KP1,4, Ronis MJ1,6, Welsh DA1,7, Molina PE1,5. Alcohol Alcohol. 2019 Dec 8. pii: agz089. doi: 10.1093/alcalc/agz089. [Epub ahead of print]
 
331.HCV Eradication: A Duty of the State, an Option for the Individual
 

Craxì L1,2. Adv Exp Med Biol. 2019 Dec 6. doi: 10.1007/5584_2019_452. [Epub ahead of print]
 
332.Securing sustainable funding for viral hepatitis elimination plans
 

Hatzakis A1, Lazarus JV2, Cholongitas E3, Baptista-Leite R4,5, Boucher C6, Busoi CS7, Deuffic-Burban S8,9, Chhatwal J10, Esmat G11,12, Hutchinson S13,14, Malliori MM15, Maticic M16,17, Mozalevskis A18, Negro F19, Papandreou GA20, Papatheodoridis GV21, Peck-Radosavljevic M22, Razavi H23, Reic T24, Schatz E25, Tozun N26, Younossi Z27, Manns MP28. Liver Int. 2019 Dec 5. doi: 10.1111/liv.14282. [Epub ahead of print]
 
333.Systematic review with meta-analysis: effectiveness of direct-acting antiviral treatment for hepatitis C in patients with hepatocellular carcinoma
 

He S1, Lockart I2,3, Alavi M1, Danta M2,3, Hajarizadeh B1, Dore GJ1,3. Aliment Pharmacol Ther. 2020 Jan;51(1):34-52. doi: 10.1111/apt.15598. Epub 2019 Dec 6.
 
334.Hepatitis C drug prescriptions and Medicaid policies--four states, Indian health care system, USA 2018
 

Reilley B1, Miller M2, Hudson M3, Haverkate R2, Leston J4. Int J Equity Health. 2019 Dec 4;18(1):190. doi: 10.1186/s12939-019-1101-4.
 
335.HCV NAT positive solid organ allografts transplanted into HCV negative recipients: A real-world experience
 

Kapila N1,2, Menon KVN3, Al-Khalloufi K4, Vanatta JM4, Murgas C4, Reino D4, Ebaid S4, Shaw JJ4, Agrawal N4, Rhazouani S4, Navas V4, Sheffield C4, Rahman AU1, Castillo M5, Miller C3, Quintini C3, Zervos XB4. Hepatology. 2019 Oct 28. doi: 10.1002/hep.31011. [Epub ahead of print]
 
336.Hepatitis C Behind and Beyond Bars: Targeting the US Prison Population and Changing North Carolina Prisoner Health Policy
 

Ocal S1, Muir AJ2, Naggie S3. N C Med J. 2019 Nov-Dec;80(6):352-355. doi: 10.18043/ncm.80.6.352.
 
337.Efficacy of Retreatment After Failed Direct-acting Antiviral Therapy in Patients With HCV Genotype 1-3 Infections
 

Dietz J1, Spengler U2, Müllhaupt B3, Schulze Zur Wiesch J4, Piecha F4, Mauss S5, Seegers B6, Hinrichsen H6, Antoni C7, Wietzke-Braun P8, Peiffer KH1, Berger A9, Matschenz K10, Buggisch P10, Backhus J11, Zizer E11, Boettler T12, Neumann-Haefelin C12, Semela D13, Stauber R14, Berg T15, Berg C16, Zeuzem S1, Vermehren J1, Sarrazin C17; European HCV Resistance Study Group. Clin Gastroenterol Hepatol. 2019 Nov 6. pii: S1542-3565(19)31260-1. doi: 10.1016/j.cgh.2019.10.051. [Epub ahead of print]
 
338.Rates of hepatitis B and C in patients with schizophrenia: A meta-analysis
 

Lluch E1, Miller BJ2. Gen Hosp Psychiatry. 2019 Nov - Dec;61:41-46. doi: 10.1016/j.genhosppsych.2019.10.007. Epub 2019 Oct 23.
 
339.The Elimination of Hepatitis C as a Public Health Threat
 

Hellard M1,2,3,4, Schroeder SE1,2, Pedrana A1,2, Doyle J1,3, Aitken C1,2. Cold Spring Harb Perspect Med. 2019 Nov 11. pii: a036939. doi: 10.1101/cshperspect.a036939. [Epub ahead of print]
 
340.Hepatitis C Virus Screening and Care: Complexity of Implementation in Primary Care Practices Serving Disadvantaged Populations
 

Turner BJ1, Rochat A2, Lill S2, Bobadilla R2, Hernandez L2, Choi A3, Guerrero JA4. Ann Intern Med. 2019 Dec 3. doi: 10.7326/M18-3573. [Epub ahead of print]
 
341.Hepatitis C Virus Infection In Indigenous Populations: A Systematic Review Of The United States And Canada
 

Bruce V1, Eldredge J2, Leyva Y3, Mera J4, English K5, Page K1. Epidemiol Rev. 2019 Nov 29. pii: mxz015. doi: 10.1093/epirev/mxz015. [Epub ahead of print]
 
342.Hepatitis C-Related Mortality Among American Indian/Alaska Native Persons in the Northwestern United States, 2006-2012
 

Hatcher SM1,2, Joshi S2, Robinson BF1, Weiser T2,3. Public Health Rep. 2020 Jan;135(1):66-73. doi: 10.1177/0033354919887748. Epub 2019 Nov 25.
 
343.Improved Hepatitis C Cure Cascade Outcomes Among Urban Baby Boomers in the Direct-Acting Antiviral Era
 

Dupont SC1, Fluker SA2, Quairoli KM3, Body C4, Okosun I5, Lom J2, Miller LS2. Public Health Rep. 2020 Jan;135(1):107-113. doi: 10.1177/0033354919888228. Epub 2019 Nov 22.
 
344.Eight weeks of sofosbuvir/velpatasvir for genotype 3 hepatitis C in previously untreated patients with significant (F2/3) fibrosis
 

Boyle A1,2, Marra F1,2, Peters E3, Datta S4, Ritchie T5, Priest M6, Heydtmann M7, Barclay ST8,9. J Viral Hepat. 2019 Nov 22. doi: 10.1111/jvh.13239. [Epub ahead of print]
 
345.Loss to follow-up: A significant barrier in the treatment cascade with direct-acting therapies
 

Darvishian M1,2,3,4, Wong S1, Binka M1, Yu A1, Ramji A2, Yoshida EM5, Wong J1,2, Rossi C1,2, Butt ZA1,2, Bartlett S1,2, Pearce ME1,2, Samji H1,6, Cook D1, Alvarez M1, Chong M1, Tyndall M1,2, Krajden M1,2, Janjua NZ1,2. J Viral Hepat. 2019 Oct 30. doi: 10.1111/jvh.13228. [Epub ahead of print]
 
346.Viral Hepatitis: Etiology, Epidemiology, Transmission, Diagnostics, Treatment, and Prevention
 

Lanini S1, Ustianowski A2, Pisapia R3, Zumla A4, Ippolito G3. Infect Dis Clin North Am. 2019 Dec;33(4):1045-1062. doi: 10.1016/j.idc.2019.08.004.
 
347.Correlates of hepatitis C viral clustering among people who inject drugs in Baltimore
 

Hackman J1, Falade-Nwulia O2, Patel EU3, Mehta SH2, Kirk GD4, Astemborski J2, Ray SC5, Thomas DL4, Laeyendecker O6. Infect Genet Evol. 2019 Oct 24;77:104078. doi: 10.1016/j.meegid.2019.104078. [Epub ahead of print]
 
348.Rationale and design of a randomized pragmatic trial of patient-centered models of hepatitis Ctreatment for people who inject drugs: The HERO study
 

Litwin AH1, Jost J2, Wagner K3, Heo M4, Karasz A5, Feinberg J6, Kim AY7, Lum PJ8, Mehta SH9, Taylor LE10, Tsui JI11, Pericot-Valverde I12, Page K3; HERO Study Group. Contemp Clin Trials. 2019 Dec;87:105859. doi: 10.1016/j.cct.2019.105859. Epub 2019 Oct 24.
 
349.A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments
 

Radley A1,2, Robinson E3, Aspinall EJ4, Angus K5, Tan L3, Dillon JF3. BMC Health Serv Res. 2019 Oct 28;19(1):765. doi: 10.1186/s12913-019-4635-7.
 
350.Provision of and Barriers to Integrating Reproductive and Sexual Health Services for Reproductive-age Women in Opioid Treatment Programs
 

Klaman SL1, Lorvick J, Jones HE. J Addict Med. 2019 Nov/Dec;13(6):422-429. doi: 10.1097/ADM.0000000000000519.
 
351.Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study
 

Bajis S1, Grebely J1, Hajarizadeh B1, Applegate T1, Marshall AD1,2, Harrod ME3, Byrne J4, Bath N3, Read P5, Edwards M6, Gorton C7, Hayllar J8, Cock V9, Peterson S10, Thomson C11, Weltman M12, Jefferies M13, Wood W14, Haber P15, Ezard N16,17, Martinello M1, Maher L1,18, Dore GJ1; LiveRLife Study Group. J Viral Hepat. 2019 Nov 7. doi: 10.1111/jvh.13233. [Epub ahead of print]
 
352.Sustained virological response rates with direct-acting antivirals in black subjects with HCV genotype 1 infection: systematic analysis of clinical trials
 

Struble K1, Chan-Tack K1, Qi K2, Valappil T2, Connelly S1, Mishra P1, Price D2, Murray J1, Birnkrant D1. J Virus Erad. 2019 Sep 18;5(3):138-144.
 
353.Nurse practitioner interventions for smokers with chronic hepatitis C
 

Reid C1, Fenech M2, Jones L3, Salehi N4. J Am Assoc Nurse Pract. 2019 Nov 5. doi: 10.1097/JXX.0000000000000311. [Epub ahead of print]
 
354.Cost-Effectiveness of One-Time Birth Cohort Screening for Hepatitis C as Part of the National Health Service Health Check Program in England
 

Williams J1, Miners A2, Harris R3, Mandal S4, Simmons R4, Ireland G4, Hickman M5, Gore C6, Vickerman P7. Value Health. 2019 Nov;22(11):1248-1256. doi: 10.1016/j.jval.2019.06.006. Epub 2019 Aug 19.
 
355.Liver and Kidney Recipient Selection of HCV-Viremic Donors - Meeting Consensus Report from the 2019 Controversies in Transplantation
 

Burton JR Jr, Terrault NA, Goldberg DS, Bloom RD, Gilroy R, Heimbach JK, Brown RS Jr, Everson GT, Rubin E, Wiesner R, Pomfret EA. Transplantation. 2019 Oct 18. doi: 10.1097/TP.0000000000003014. [Epub ahead of print]
 
356.Motivation to Quit Drinking in Individuals Coinfected with HIV and Hepatitis C
 

Hayaki J1, Anderson BJ2, Herman DS2,3, Moitra E3, Pinkston MM3,4, Kim HN5,6, Stein MD7. AIDS Behav. 2019 Oct 23. doi: 10.1007/s10461-019-02709-z. [Epub ahead of print]
 
357.Efficacy of Direct-Acting Antivirals for Chronic Hepatitis C in a Large Cohort of Older Adults in the United States
 

Pan CQ1,2, Gayam V3, Rabinovich C4, Normatov M4, Fidman B4, Wang D5, Garlapati P3. J Am Geriatr Soc. 2019 Oct 24. doi: 10.1111/jgs.16206. [Epub ahead of print]
 
358.HCV in the Hemodialysis Population: treat now or later?
 

Martin P1, Jadoul M2, Pol S3. J Viral Hepat. 2019 Oct 24. doi: 10.1111/jvh.13224. [Epub ahead of print]
 
359.Project ECHO Revisited: Propensity Score Analysis And HCV Treatment Outcomes
 

Page K1,2, Qeadan F1,2, Qualls C2, Thornton K1, Arora S1. Hepat Med. 2019 Oct 7;11:149-152. doi: 10.2147/HMER.S212855. eCollection 2019.
 
360.The Impact of Hepatitis C Virus Infection on Buprenorphine Dose in Pregnancy
 

McDowell ML1, Tonismae TR1, Slaven JE2, Abernathy MP1, Shanks AL1, Benjamin TD3, Quinney SK1. Am J Perinatol. 2019 Oct 26. doi: 10.1055/s-0039-1698838. [Epub ahead of print]
 
361.Medication Non-adherence in a Prospective, Multi-center Cohort Treated with Hepatitis C Direct-Acting Antivirals
 

Serper M1, Evon DM2, Stewart PW3, Lok AS4, Amador J3, Reeve BB5, Golin CE6, Fried MW7, Reddy KR1, Sterling RK8, Sarkar S9, Di Bisceglie AM10, Lim JK11, Nelson DR12, Reau N13. J Gen Intern Med. 2019 Oct 28. doi: 10.1007/s11606-019-05394-9. [Epub ahead of print]
 
362.Adherence to once-daily and twice-daily direct acting antiviral therapy for hepatitis C infection among people with recent injection drug use or current opioid agonist therapy
 

Cunningham EB1, Hajarizadeh B1, Amin J1,2, Litwin AH3,4,5, Gane E6, Cooper C7, Lacombe K8, Hellard M9,10, Read P1,11, Powis J12, Dalgard O13,14, Bruneau J15, Matthews GV1,16, Feld JJ17, Dillon JF18, Shaw D19, Bruggmann P20, Conway B21, Fraser C22, Marks P1, Dore GJ1,16, Grebely J1. Clin Infect Dis. 2019 Nov 2. pii: ciz1089. doi: 10.1093/cid/ciz1089. [Epub ahead of print]
 
363.Characteristics and current clinical practices of opioid treatment programs in the United States
 

Jones CM1, Byrd DJ2, Clarke TJ3, Campbell TB2, Ohuoha C4, McCance-Katz EF5. Drug Alcohol Depend. 2019 Oct 17;205:107616. doi: 10.1016/j.drugalcdep.2019.107616. [Epub ahead of print]
 
364.Glecaprevir/pibrentasvir for 8?weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial
 

Brown RS Jr1, Buti M2, Rodrigues L3, Chulanov V4, Chuang WL5, Aguilar H6, Horváth G7, Zuckerman E8, Carrion BR9, Rodriguez-Perez F10, Urbánek P11, Abergel A12, Cohen E3, Lovell SS3, Schnell G3, Lin CW3, Zha J3, Wang S3, Trinh R3, Mensa FJ3, Burroughs M3, Felizarta F13. J Hepatol. 2019 Nov 2. pii: S0168-8278(19)30647-6. doi: 10.1016/j.jhep.2019.10.020. [Epub ahead of print]
 
365.The role of stigma and trauma in hepatitis C virus treatment in veterans: Applying the common-sense model
 

Garvey CM1, Jones R1. Public Health Nurs. 2019 Nov;36(6):829-835. doi: 10.1111/phn.12665. Epub 2019 Oct 3.
 
366.Hepatitis C Virus in Children: Trying to Overcome the Domestic and Global Challenges of Cases and Cost
 

Perfect C1, Jhaveri R2,3. J Pediatric Infect Dis Soc. 2019 Oct 16. pii: piz069. doi: 10.1093/jpids/piz069. [Epub ahead of print]
 
367.A Simplified Algorithm for the Management of Hepatitis C Infection
 

Dieterich DT1. Gastroenterol Hepatol (N Y). 2019 May;15(5 Suppl 3):1-12.
 
368.Patients with Alcoholic Liver Disease Have Worse Functional Status at Time of Liver Transplant Registration and Greater Waitlist and Post-transplant Mortality Which Is Compounded by Older Age
 

McCabe P1, Galoosian A2, Wong RJ3. Dig Dis Sci. 2019 Oct 22. doi: 10.1007/s10620-019-05891-1. [Epub ahead of print]
 
369.Efficacy and Safety of 8 Weeks of Glecaprevir/Pibrentasvir in Treatment-Naïve, HCV-Infected Patients with APRI?=?1 in a Single-Arm, Open-Label, Multicenter Study.
 

Fontana RJ1, Lens S2, McPherson S3, Elkhashab M4, Ankoma-Sey V5, Bondin M6, Dos Santos AGP6, Xue Z6, Trinh R6, Porcalla A6, Zeuzem S7. Adv Ther. 2019 Oct 23. doi: 10.1007/s12325-019-01123-0. [Epub ahead of print]
 
370.Hepatitis C Screening: Barriers to Linkage to Care
 

Saab S1,2, Challita YP1, Najarian LM1, Guo R3, Saggi SS1, Choi G1,2. J Clin Transl Hepatol. 2019 Sep 28;7(3):226-231. doi: 10.14218/JCTH.2018.00063. Epub 2019 Apr 12.
 
371.Real-world experiences with direct-acting antiviral agents for chronic hepatitis C treatment
 

Daniel KE1,2, Saeian K1, Rizvi S1. J Viral Hepat. 2019 Oct 10. doi: 10.1111/jvh.13218. [Epub ahead of print]
 
372.Electronic Clinical Decision Support Intervention to Increase Hepatitis C Screening and Linkage to Care Among Baby Boomers in Urban Safety Net Health Systems
 

Armstrong H1, Gonzalez-Drigo M1, Norels G1, Taussig D1, Trick W2, Diep L2, Zhang H2, Catrambone JC1, Adeyemi O1. Popul Health Manag. 2019 Oct 8. doi: 10.1089/pop.2019.0105. [Epub ahead of print]
 
373.Medical Burden of Disease Among Individuals in Recovery From Alcohol and Other Drug Problems in the United States: Findings From the National Recovery Survey
 

Eddie D1, Greene MC, White WL, Kelly JF. J Addict Med. 2019 Sep/Oct;13(5):385-395. doi: 10.1097/ADM.0000000000000512.
 
374.Hepatitis C remains leading indication for listings and receipt of liver transplantation for hepatocellular carcinoma
 

Singal AK1, Satapathy SK2, Reau N2, Wong R2, Kuo YF2. Dig Liver Dis. 2019 Sep 30. pii: S1590-8658(19)30785-6. doi: 10.1016/j.dld.2019.08.022. [Epub ahead of print]
 
375.Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol)
 

Hickman M1, Dillon JF2, Elliott L3, De Angelis D4, Vickerman P5, Foster G6,7, Donnan P8, Eriksen A9, Flowers P3, Goldberg D3,10, Hollingworth W5, Ijaz S11, Liddell D12, Mandal S11, Martin N13, Beer LJZ14, Drysdale K6,7, Fraser H5, Glass R11, Graham L15, Gunson RN16, Hamilton E17, Harris H11, Harris M18, Harris R11, Heinsbroek E11, Hope V19, Horwood J5, Inglis SK14, Innes H3,10, Lane A5, Meadows J5, McAuley A3,10, Metcalfe C5, Migchelsen S11, Murray A17, Myring G5, Palmateer NE3,10, Presanis A4, Radley A2,20, Ramsay M11, Samartsidis P4, Simmons R11, Sinka K11, Vojt G3, Ward Z5, Whiteley D21, Yeung A3,10, Hutchinson SJ3,10. BMJ Open. 2019 Sep 24;9(9):e029538. doi: 10.1136/bmjopen-2019-029538.
 
376.Prevalence of viremic HCV infection by age, race/ethnicity, birthplace and disease awareness among viremic persons in the U.S., 1999-2016
 

Zou B1, Yeo YH1, Le MH1, Henry L1, Chang ET2,3, Lok AS4, Cheung R1,5, Nguyen MH1. J Infect Dis. 2019 Sep 27. pii: jiz479. doi: 10.1093/infdis/jiz479. [Epub ahead of print]
 
377.Eradicating hepatitis C virus: The APRN
 

Pozza R1, McCoy-Hill C, Hall K, Hefner A, Wilgers K, Tapelband J, Masroor M, Hassanein T. Nurse Pract. 2019 Nov;44(11):16-27. doi: 10.1097/01.NPR.0000586008.23422.2c.
 
378.Adherence to pan-genotypic glecaprevir/pibrentasvir and efficacy in HCV-infected patients: A pooled analysis of clinical trials
 

Brown A1, Welzel TM2, Conway B3, Negro F4, Bräu N5, Grebely J6, Puoti M7, Aghemo A8, Kleine H9, Pugatch D10, Mensa FJ10, Chen YJ10, Lei Y10, Lawitz E11, Asselah T12. Liver Int. 2019 Sep 30. doi: 10.1111/liv.14266. [Epub ahead of print]
 
379.Hepatitis C Virus Epidemiology and the Impact of Interferon-Free Hepatitis C Virus Therapy
 

Lazarus JV1, Roel E1,2, Elsharkawy AM3. Cold Spring Harb Perspect Med. 2019 Sep 30. pii: a036913. doi: 10.1101/cshperspect.a036913. [Epub ahead of print]
 
380.Challenges and Promise of a Hepatitis C Virus Vaccine
 

Cox AL1. Cold Spring Harb Perspect Med. 2019 Sep 23. pii: a036947. doi: 10.1101/cshperspect.a036947. [Epub ahead of print]
 
381."That Can't Be!": Perceptions of HIV and Hepatitis C Screening during Admission to an Acute Care Surgery Service
 

Privette AR1, Ferguson PL1, Olsen J1, Gay S1, Richey LE2. J Emerg Trauma Shock. 2019 Jul-Sep;12(3):185-191. doi: 10.4103/JETS.JETS_103_18.
 
382.Missed opportunities for prevention and treatment of hepatitis C among persons with HIV/HCV coinfection
 

Millman AJ1, Luo Q2, Nelson NP1, Vellozzi C1, Weiser J3. AIDS Care. 2019 Sep 23:1-9. doi: 10.1080/09540121.2019.1668533. [Epub ahead of print]
 
383.Glecaprevir/Pibrentasvir: The First 8-Week, Pangenotypic HCV Treatment Regimen for Patients 12 Years of Age and Older
 

Huff J1, Andersen R1. Ann Pharmacother. 2019 Sep 19:1060028019877128. doi: 10.1177/1060028019877128. [Epub ahead of print]
 
384.Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C Virus Infection in Chronic Kidney Disease: Synopsis of the Kidney Disease: Improving Global Outcomes 2018 Clinical Practice Guideline
 

Gordon CE1, Berenguer MC2, Doss W3, Fabrizi F4, Izopet J5, Jha V6, Kamar N7, Kasiske BL8, Lai CL9, Morales JM10, Patel PR11, Pol S12, Silva MO13, Balk EM14, Earley A15, Di M16, Cheung M15, Jadoul M17, Martin P18. Ann Intern Med. 2019 Sep 24. doi: 10.7326/M19-1539. [Epub ahead of print]
 
385.The case for a universal hepatitis C vaccine to achieve hepatitis C elimination
 

Scott N1,2, Wilson DP3,4, Thompson AJ5,6, Barnes E7,8, El-Sayed M9, Benzaken AS10, Drummer HE3,11,12, Hellard ME3,4,12,13. BMC Med. 2019 Sep 18;17(1):175. doi: 10.1186/s12916-019-1411-9.
 
386.Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis
 

Graf C1, Mücke MM1, Dultz G1, Peiffer KH1, Kubesch A1, Ingiliz P2, Zeuzem S1, Herrmann E3, Vermehren J1. Clin Infect Dis. 2019 Sep 12. pii: ciz696. doi: 10.1093/cid/ciz696. [Epub ahead of print]
 
387.Hepatitis C Virus Infection in the Dallas County Jail: Implications for Screening, Prevention, and Linkage to Care
 

Abe CM1, Aguwa M2, Zhao M2, Sullivan J3, Porsa E3, Nijhawan AE4. Public Health Rep. 2019 Sep 17:33354919874081. doi: 10.1177/0033354919874081. [Epub ahead of print]
 
388.Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
 

Cotter TG1, Jensen DM2. Drug Des Devel Ther. 2019 Jul 29;13:2565-2577. doi: 10.2147/DDDT.S172512. eCollection 2019.
 
389.Hepatitis C Treatment Cascade in a Federally Qualified Health Center
 

Hachey DM1, Holmes JT2, Aubuchon-Endsley NL3. J Community Health. 2019 Sep 11. doi: 10.1007/s10900-019-00736-4. [Epub ahead of print]
 
390.Metabolic Changes in Chronic Hepatitis C Patients who Carry IFNL4-?G and Achieve Sustained Virologic Response with Direct-Acting Antiviral Therapy
 

Emmanuel B1, El-Kamary SS2, Magder LS2, Stafford KA1,2, Charurat ME3, Chairez C4, McLaughlin M4, Hadigan C4, Prokunina-Olsson L5, O'Brien TR5, Masur H6, Kottilil S1. J Infect Dis. 2019 Aug 26. pii: jiz435. doi: 10.1093/infdis/jiz435. [Epub ahead of print]
 
391.Defining the hepatitis C cure cascade in an Urban health system using the electronic health record
 

Miller LS1, Millman AJ2, Lom J1, Osinubi A2, Ahmed F3, Dupont S1, Rein D3, Vellozzi C2, Harris AM2. J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13199. [Epub ahead of print]
 
392.Defining the hepatitis C cure cascade in an Urban health system using the electronic health record
 

Miller LS1, Millman AJ2, Lom J1, Osinubi A2, Ahmed F3, Dupont S1, Rein D3, Vellozzi C2, Harris AM2. J Viral Hepat. 2019 Sep 10. doi: 10.1111/jvh.13199. [Epub ahead of print]

 
 
393.Hepatitis C Virus: 30 Years after Its Discovery
 

Houghton M1. Cold Spring Harb Perspect Med. 2019 Sep 9. pii: a037069. doi: 10.1101/cshperspect.a037069. [Epub ahead of print]
 
394.HCV-infected individuals have higher prevalence of comorbidity and multimorbidity: a retrospective cohort study
 

Cooper CL1,2,3, Galanakis C4, Donelle J5, Kwong J5,6,7, Boyd R8, Boucher L9, Kendall CE4,5,9,10,11. BMC Infect Dis. 2019 Aug 23;19(1):712. doi: 10.1186/s12879-019-4315-6.
 
395.Community Perceptions of Comprehensive Harm Reduction Programs and Stigma Towards People Who Inject Drugs in Rural Virginia
 

Baker LS1, Smith W2, Gulley T3, Tomann MM2. J Community Health. 2019 Sep 9. doi: 10.1007/s10900-019-00732-8. [Epub ahead of print]
 
396.Cascade of Care for Alaska Native People with Chronic Hepatitis C Virus Infection: Statewide Program with High Linkage to Care
 

McMahon BJ1,2, Townshend-Bulson L1, Homan C1, Gounder P2, Barbour Y1, Hewitt A1, Bruden D2, Espera H1, Plotnik J1, Gove J1, Stevenson TJ1, Luna SV1, Simons BC1,2. Clin Infect Dis. 2019 Aug 28. pii: ciz832. doi: 10.1093/cid/ciz832. [Epub ahead of print]
 
397.Hepatitis C Virus: 30 Years after Its Discovery
 

Houghton M1. Cold Spring Harb Perspect Med. 2019 Sep 9. pii: a037069. doi: 10.1101/cshperspect.a037069. [Epub ahead of print]
 
398.Hepatitis C Virus Structure: Defined by What It Is Not
 

Dearborn AD1,2, Marcotrigiano J1. Cold Spring Harb Perspect Med. 2019 Sep 9. pii: a036822. doi: 10.1101/cshperspect.a036822. [Epub ahead of print]
 
399.Eliminating Structural Barriers: The Impact of Unrestricted Access on Hepatitis C Treatment Uptake among People Living with HIV
 

Saeed S1,2, Strumpf E1,3, Moodie EEM1, Wong L2, Cox J1,2, Walmsley S4,5, Tyndall M6, Cooper C5,7, Conway B8, Hull M5,9, Martel-Laferriere V10, Gill J11, Wong A12, Vachon ML13, Klein MB2,5; Canadian Co-Infection Cohort Study Investigators. Clin Infect Dis. 2019 Aug 28. pii: ciz833. doi: 10.1093/cid/ciz833. [Epub ahead of print]
 
400.Screening for Chronic Hepatitis C Virus: Occupational Health Nurses Interpreting the Titers
 

Cadet MJ1. Workplace Health Saf. 2019 Sep;67(9):495-496. doi: 10.1177/2165079919865560.
 
401.Impact of Direct Acting Antiviral Agent Therapy upon Extrahepatic Manifestations of Hepatitis C Virus Infection
 

Mohanty A1, Salameh S2, Butt AA3,4,5,6. Curr HIV/AIDS Rep. 2019 Sep 4. doi: 10.1007/s11904-019-00466-1. [Epub ahead of print]
 
402.Immunomodulation of CXCL10 Secretion by Hepatitis C Virus: Could CXCL10 Be a Prognostic Marker of Chronic Hepatitis C?
 

Ferrari SM1, Fallahi P2, Ruffilli I1, Elia G1, Ragusa F1, Paparo SR1, Patrizio A1, Mazzi V1, Colaci M3, Giuggioli D4, Ferri C4, Antonelli A1. J Immunol Res. 2019 Aug 8;2019:5878960. doi: 10.1155/2019/5878960. eCollection 2019.
 
403.Hepatitis C Core-Antigen Testing from Dried Blood Spots
 

Biondi MJ1,2,3, van Tilborg M4,5, Smookler D6,7, Heymann G8, Aquino A9, Perusini S10, Mandel E11,12, Kozak RA13, Cherepanov V14, Kowgier M15, Hansen B16,17, Goneau LW18, Janssen HLA19,20, Mazzulli T21,22, Cloherty G23, de Knegt RJ24, Feld JJ25,26,27. Viruses. 2019 Sep 6;11(9). pii: E830. doi: 10.3390/v11090830.
 
404.The Cost Effectiveness of Birth-Cohort Hepatitis C Screening During Pre-Admission Testing for Elective Procedures at a Single Specialty Orthopedic Hospital
 

Sibley RA, Pham V, Moynihan AM, Hutzler LH, Bosco JA. Bull Hosp Jt Dis (2013). 2019 Sep;77(3):206-210.
 
405.Technology preferences to enhance HIV and HCV care among patients with substance use disorders
 

Tofighi B1,2,3, Hein P1, Carvalho AMS4, Lee JD1,2,3, Leonard NR3,5. J Addict Dis. 2019 Aug 5:1-3. doi: 10.1080/10550887.2019.1640056. [Epub ahead of print]
 
406.Modelling the potential prevention benefits of a treat-all hepatitis C treatment strategy at global, regional and country levels: A modelling study
 

Trickey A1,2, Fraser H1, Lim AG1, Walker JG1, Peacock A3, Colledge S3, Leung J3,4,5, Grebely J5,6, Larney S3, Martin NK1,7, Degenhardt L3, Hickman M1,2, May MT1,2,8, Vickerman P1,2. J Viral Hepat. 2019 Aug 7. doi: 10.1111/jvh.13187. [Epub ahead of print]
 
407.Promoting treatment for hepatitis C in people who inject drugs: A review of the barriers and opportunities
 

Pedlar A1, Sandhu PJ1. J Am Assoc Nurse Pract. 2019 Aug 14. doi: 10.1097/JXX.0000000000000269. [Epub ahead of print]
 
408.Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities
 

Moorman AC1, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.
 
409.Global burden of atherosclerotic cardiovascular disease in people with hepatitis C virus infection: a systematic review, meta-analysis, and modelling study
 

Lee KK1, Stelzle D2, Bing R1, Anwar M1, Strachan F1, Bashir S1, Newby DE1, Shah JS3, Chung MH3, Bloomfield GS4, Longenecker CT5, Bagchi S6, Kottilil S6, Blach S7, Razavi H7, Mills PR8, Mills NL9, McAllister DA10, Shah ASV11. Lancet Gastroenterol Hepatol. 2019 Oct;4(10):794-804. doi: 10.1016/S2468-1253(19)30227-4. Epub 2019 Jul 31.
 
410.We know DAAs work, so now what? Simplifying models of care to enhance the hepatitis C cascade
 

Lazarus JV1, Pericàs JM2, Picchio C1, Cernosa J3, Hoekstra M1, Luhmann N4, Maticic M5,6, Read P7, Robinson EM8, Dillon JF8. J Intern Med. 2019 Aug 31. doi: 10.1111/joim.12972. [Epub ahead of print]
 
411.Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities
 

Moorman AC1, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.
 
412.No evidence for higher rates of hepatocellular carcinoma after direct-acting antiviral treatment: a meta-analysis
 

Rutledge SM1,2, Zheng H2, Li DK1,2, Chung RT1,2. Hepatoma Res. 2019;5. pii: 31. doi: 10.20517/2394-5079.2019.19. Epub 2019 Aug 7.
 
413.Initial uptake, time to treatment, and real-world effectiveness of all-oral direct-acting antivirals for hepatitis C virus infection in the United States: A retrospective cohort analysis
 

Kwo PY1, Puenpatom A2, Zhang Z3, Hui SL4, Kelley AA5, Muschi D6. PLoS One. 2019 Aug 22;14(8):e0218759. doi: 10.1371/journal.pone.0218759. eCollection 2019.
 
414.Relationships among neurotransmitters, cytokines and cognitive performance for individuals with hepatitis C achieving sustained virologic response: A pilot study
 

Weinstein AA1, Estep JM2, de Avila L2, Curry M3, Golabi P2, Escheik C2, Birerdinc A2, Stepanova M4, Price JK2, Gerber L5, Younossi ZM6. J Neuroimmunol. 2019 Oct 15;335:577022. doi: 10.1016/j.jneuroim.2019.577022. Epub 2019 Aug 14.
 
415.Decreased warfarin sensitivity among patients treated with elbasvir and grazoprevir for hepatitis C infection
 

DeCarolis DD1, Chen YC2, Westanmo AD3, Conley C4, Gravely AA5, Khan FB6. Am J Health Syst Pharm. 2019 Sep 1;76(17):1273-1280. doi: 10.1093/ajhp/zxz127.
 
416.Promoting treatment for hepatitis C in people who inject drugs: A review of the barriers and opportunities
 

Pedlar A1, Sandhu PJ1. J Am Assoc Nurse Pract. 2019 Aug 14. doi: 10.1097/JXX.0000000000000269. [Epub ahead of print]
 
417.Infectious complications of addiction: A call for a new subspecialty within infectious diseases
 

Serota DP1, Barocas JA2,3, Springer SA4. Clin Infect Dis. 2019 Aug 17. pii: ciz804. doi: 10.1093/cid/ciz804. [Epub ahead of print]
 
418.Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities
 

Moorman AC1, Xing J, Rupp LB, Gordon SC, Lu M, Spradling PR, Boscarino JA, Schmidt MA, Daida YG, Teshale EH; CHeCS Investigators. Am J Manag Care. 2019 Aug;25(8):369-374.
 
419.Short-Term Outcomes and Lessons Learned From the Federal HIV Health Improvement Affinity Group for State Medicaid/Children
 

Davies C1, Klein PW2, Okoye ID3, Heitgerd J4, Shapatava E4, Ihiasota I4, Browne MNC5, Viall A6, Stockmann D5, Hauck H7. J Acquir Immune Defic Syndr. 2019 Sep 1;82 Suppl 1:S62-S68. doi: 10.1097/QAI.0000000000002021.
 
420.Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population
 

Stevens ER1,2, Nucifora KA1, Hagan H2,3, Jordan AE3,4, Uyei J1, Khan B5, Dombrowski K5, des Jarlais D2, Braithwaite RS1,3. Clin Infect Dis. 2019 Aug 11. pii: ciz726. doi: 10.1093/cid/ciz726. [Epub ahead of print]
 
421.Estimated Impact of Hepatitis C Positive Lung Donor Utilization on US Donor Lung Supply
 

Mooney JJ1, Purington N2, Mohabir P1, Dhillon GS1. Am J Transplant. 2019 Aug 8. doi: 10.1111/ajt.15558. [Epub ahead of print]
 
422.Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct-Acting Antivirals
 

Ioannou GN1,2, Green PK2, Berry K2, Graf SA3,4. Hepatol Commun. 2019 Jun 11;3(8):1124-1136. doi: 10.1002/hep4.1389. eCollection 2019 Aug.
 
423.Efficacy of Glecaprevir and Pibrentasvir in Patients with Genotype 1 Hepatitis C Virus Infection with Treatment Failure after NS5A Inhibitor Plus Sofosbuvir Therapy
 

Lok AS1, Sulkowski MS2, Kort JJ3, Willner I4, Reddy KR5, Shiffman ML6, Hassan MA7, Pearlman BL8, Hinestrosa F9, Jacobson IM10, Morelli G11, Peter JA12, Vainorius M13, Michael LC14, Fried MW15, Wang GP16, Lu W17, Larsen L18, Nelson DR19. Gastroenterology. 2019 Aug 8. pii: S0016-5085(19)41199-2. doi: 10.1053/j.gastro.2019.08.008. [Epub ahead of print]
 
424.Direct-Acting Antiviral Treatment of Patients with Hepatitis C Resolves Serologic and Histopathologic Features of Autoimmune Hepatitis
 

Simoes CC1, Saldarriaga OA1, Utay NS2, Stueck AE3, Merwat SK4, Merwat SN4, Schiano TD5, Fiel MI6, Stevenson HL1. Hepatol Commun. 2019 Jun 8;3(8):1113-1123. doi: 10.1002/hep4.1388. eCollection 2019 Aug.
 
425.What Matters Most for Treatment Decisions in Hepatitis C: Effectiveness, Costs, and Altruism
 

Mattingly TJ 2nd1, Slejko JF2, Perfetto EM2,3, Kottilil S4, Mullins CD2. Patient. 2019 Jul 26. doi: 10.1007/s40271-019-00378-7. [Epub ahead of print]
 
426.Advancing Public Health in Indian Country for Over 20 Years:S97-S100. doi: 10.1097/PHH.0000000000001061
 

An Evaluation of Hepatitis C Virus Telehealth Services Serving Tribal Communities: Patterns of Usage, Evolving Needs, and Barriers.

Stephens D1, Leston J, Terrault NA, Gailloux K, Mera J, Essex W, Reilley B. J Public Health Manag Pract. 2019 Sep/Oct;25 Suppl 5, Tribal Epidemiology Centers:
 
427.Elimination of hepatitis C virus infection among people who use drugs: Ensuring equitable access to prevention, treatment, and care for all
 

Grebely J1, Hajarizadeh B2, Lazarus JV3, Bruneau J4, Treloar C5; International Network on Hepatitis in Substance Users. Int J Drug Policy. 2019 Jul 23. pii: S0955-3959(19)30194-X. doi: 10.1016/j.drugpo.2019.07.016. [Epub ahead of print]
 
428.Point-of-care Hepatitis C virus testing and linkage to treatment in an Australian inner-city emergency department
 

Hutton J1, Doyle J2, Zordan R3, Weiland T3, Cocco A4, Howell J5, Iser S6, Snell J7, Fry S8, New K8, Sloane R8, Jarman M7, Phan D7, Tran S7, Pedrana A9, Williams B9, Johnson J10, Glasgow S8, Thompson A7. Int J Drug Policy. 2019 Jul 24. pii: S0955-3959(19)30176-8. doi: 10.1016/j.drugpo.2019.06.021. [Epub ahead of print]
 
429.The Consensus Hepatitis C Cascade of Care: standardized reporting to monitor progress toward elimination
 

Safreed-Harmon K1, Blach S2, Aleman S3,4, Boe Kielland K5, Bollerup S6, Cooke G7, Dalgard O8,9, Dillon JF10, Dore GJ11, Duberg AS12, Grebely J11, Midgard H13, Porter K14, Razavi H2, Tyndall M15, Weis N6,16, Lazarus JV1,17. Clin Infect Dis. 2019 Jul 28. pii: ciz714. doi: 10.1093/cid/ciz714. [Epub ahead of print]
 
430.Efficacy of direct-acting antivirals: UK real-world data from a well-characterised predominantly cirrhotic HCV cohort
 

Macken L1,2, Gelson W3, Priest M4, Abouda G5, Barclay S4,6, Fraser A7, Healy B8, Irving W9, Verma S1,2. J Med Virol. 2019 Jul 22. doi: 10.1002/jmv.25552. [Epub ahead of print]
 
431.Patterns and Correlates of Prescription Opioid Receipt Among US Veterans: A National, 18-Year Observational Cohort Study
 

Rentsch CT1,2, Edelman EJ3,4, Justice AC5,3,4, Marshall BDL6, Xu K7, Smith AH7, Crystal S8, Gaither JR9,10, Gordon AJ11, Smith RV12, Kember RL13,14, Polimanti R7, Gelernter J7,15, Fiellin DA3,4, Tate JP5,3, Kranzler HR14,16, Becker WC3,10; VACS Project Team. AIDS Behav. 2019 Jul 17. doi: 10.1007/s10461-019-02608-3. [Epub ahead of print]
 
432.Maternal hepatitis B or C status and the long-term risk of gastrointestinal morbidity for offspring: A population-based cohort study
 

Yoles I1,2, Sheiner E2, Abu-Freha N3, Wainstock T4. Liver Int. 2019 Jul 18. doi: 10.1111/liv.14193. [Epub ahead of print]
 
433.Evidence-making hepatitis C cure: Towards a science that knows more carefully
 

Rhodes T1, Lancaster K2. Int J Drug Policy. 2019 Jul 12. pii: S0955-3959(19)30178-1. doi: 10.1016/j.drugpo.2019.06.023. [Epub ahead of print]
 
434.Sociodemographic and clinical characteristics of persons who experienced spontaneous hepatitis C viral clearance
 

Kimble MM1, Javanbakht M2, Chew KW1, Stafylis C3, He D2, Ramirez S4, Baik Y2, Saab S4, Klausner JD1,2. BMC Infect Dis. 2019 Jul 15;19(1):626. doi: 10.1186/s12879-019-4223-9.
 
435.Cost-effectiveness of scaling-up HCV prevention and treatment in the United States for people who inject drugs
 

Barbosa C1, Fraser H2, Hoerger TJ1, Leib A3, Havens JR4, Young A4, Kral A1, Page K5, Evans J6, Zibbell J1, Hariri S7, Vellozzi C8, Nerlander L7, Ward JW7, Vickerman P2. Addiction. 2019 Jul 15. doi: 10.1111/add.14731. [Epub ahead of print]
 
436.Interprofessional team-based approach to patients with chronic hepatitis C and personality disorder: Three case studies
 

Gardenier D1, Woody A2, Amory C3, Weiss JJ4. Arch Psychiatr Nurs. 2019 Aug;33(4):352-357. doi: 10.1016/j.apnu.2019.02.001. Epub 2019 Feb 11.
 
437.Hepatitis C Screening in Mothers and Infants Exposed to Opioids
 

Bell R1, Wolfe I2, Cox D3, Thakarar K3, Lucas L3, Craig A3. Hosp Pediatr. 2019 Aug;9(8):639-642. doi: 10.1542/hpeds.2018-0225. Epub 2019 Jul 10.
 
438.Risk for malignancies of infectious etiology among adult survivors of specific non-Hodgkin lymphoma subtypes
 

Herr MM1, Schonfeld SJ1, Dores GM1,2, Engels EA3, Tucker MA4, Curtis RE1, Morton LM1. Blood Adv. 2019 Jul 9;3(13):1961-1969. doi: 10.1182/bloodadvances.2019030924.
 
439.The remarkable history of the hepatitis C virus
 

Pol S1, Lagaye S2. Microbes Infect. 2019 Jul 8. pii: S1286-4579(19)30068-1. doi: 10.1016/j.micinf.2019.06.008. [Epub ahead of print]
 
440.The Role of Zinc in Antiviral Immunity
 

Read SA1,2, Obeid S3, Ahlenstiel C3, Ahlenstiel G1,2. Adv Nutr. 2019 Jul 1;10(4):696-710. doi: 10.1093/advances/nmz013.
 
441.Efficacy and safety of interferon-free regimens in patients affected by chronic hepatitis C and psychiatric disorders
 

Boglione L1, Lupia T2, Cariti G2, Di Perri G2. J Infect Chemother. 2019 Jul 10. pii: S1341-321X(19)30173-4. doi: 10.1016/j.jiac.2019.06.004. [Epub ahead of print]
 
442.Early improvement of glycaemic control after virus clearance in patients with chronic hepatitis C and severe liver fibrosis: a cohort study
 

Lanini S1, Bartolini B1, Taibi C1, Agresta A1, Garbuglia AR1, Montaldo C1, Pisapia R1, D'Offizi G1, Scognamiglio P1, Capobianchi MR1, Zumla A2, Ippolito G1. New Microbiol. 2019 Jul 15;42(2). [Epub ahead of print]
 
443.Exploring the emotions of patients undergoing therapy for hepatitis C
 

Montague S1, Agarwal K2, Cannon M3. Br J Nurs. 2019 Jul 11;28(13):824-828. doi: 10.12968/bjon.2019.28.13.824.
 
444.HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics
 

Chehl N1, Maheshwari A, Yoo H, Cook C, Zhang T, Brown S, Thuluvath PJ. Medicine (Baltimore). 2019 Jul;98(28):e16242. doi: 10.1097/MD.0000000000016242.
 
445.HCV treatment access among Latinxs who inject drugs: qualitative findings from Boston, Massachusetts, 2016
 

Mittal A1, Kosinski KC2, Stopka TJ3. Harm Reduct J. 2019 Jul 9;16(1):44. doi: 10.1186/s12954-019-0314-6.
 
446.Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners
 

Crowley D1,2, Murtagh R3, Cullen W3, Keevans M4, Laird E5, McHugh T6, McKiernan S7, Miggin SJ7, O'Connor E3,6, O'Reilly D4, Betts-Symonds G8, Tobin C9, Van Hout MC10, Lambert JS3,6. Harm Reduct J. 2019 Jul 5;16(1):42. doi: 10.1186/s12954-019-0313-7.
 
447.HCV screening, linkage to care, and treatment patterns at different sites across one academic medical center
 

Calner P1, Sperring H2, Ruiz-Mercado G3, Miller NS4, Andry C4, Battisti L5, Scrudder K3, Shea F3, Chan A3, Schechter-Perkins EM1. PLoS One. 2019 Jul 10;14(7):e0218388. doi: 10.1371/journal.pone.0218388. eCollection 2019.
 
448.A Decade On: Systematic Review of ClinicalTrials.gov Infectious Disease Trials, 2007-2017
 

Jaffe IS1, Chiswell K2, Tsalik EL1. Open Forum Infect Dis. 2019 Apr 15;6(6):ofz189. doi: 10.1093/ofid/ofz189. eCollection 2019 Jun.
 
449.Cost-effectiveness of pan-genotypic direct-acting antiviral regimens for treatment of chronic Hepatitis C in the United States
 

Gordon S1, Lee J2, Smith N3, Dieterich D4. Expert Rev Pharmacoecon Outcomes Res. 2019 Jun 17:1-7. doi: 10.1080/14737167.2019.1629291. [Epub ahead of print]
 
450.Evaluating peer-supported screening as a hepatitis C case-finding model in prisoners
 

Crowley D1,2, Murtagh R3, Cullen W3, Keevans M4, Laird E5, McHugh T6, McKiernan S7, Miggin SJ7, O'Connor E3,6, O'Reilly D4, Betts-Symonds G8, Tobin C9, Van Hout MC10, Lambert JS3,6. Harm Reduct J. 2019 Jul 5;16(1):42. doi: 10.1186/s12954-019-0313-7.
 
451.Risk-Based Prenatal Hepatitis C Testing Practices and Results, Alaska 2013-2016
 

Nolen LD1, Gustin C2, Seeman S1, Murphy N2, Truitt S2, Schillie S3, Bruce MG1, Bruden D1, Tiesinga J4, McMahon B4. Can J Gastroenterol Hepatol. 2019 Jun 2;2019:8654741. doi: 10.1155/2019/8654741. eCollection 2019.
 
452.Overdose Deaths and Acute Hepatitis Infections among American Indians in North Carolina
 

Cox ME1, Dzialowy N2, Armstrong L3, Proescholdbell S4. N C Med J. 2019 Jul-Aug;80(4):197-203. doi: 10.18043/ncm.80.4.197.
 
453.The Massachusetts Hepatitis C Testing Cascade, 2014-2016
 

Vo QT1, Onofrey S1, Church D1, Cranston K1, DeMaria A1, Klevens RM1. Microbiol Insights. 2019 Jun 21;12:1178636119857961. doi: 10.1177/1178636119857961. eCollection 2019.
 
454.Observed Changes in Natural Killer and T cell Phenotypes with Evaluation of Immune Outcome in a Longitudinal Cohort Following Sofosbuvir-Based Therapy for Chronic Hepatitis C Infection
 

Stevenson TJ1, Barbour Y1, McMahon BJ1, Townshend-Bulson L1, Hewitt AM1, Espera HGF1, Homan C1, Holck P1, Luna SV1, Knall C2, Simons BC1,2. Open Forum Infect Dis. 2019 May 17;6(6):ofz223. doi: 10.1093/ofid/ofz223. eCollection 2019 Jun.
 
455.Making sense of 'side effects': Counterpublic health in the era of direct-acting antivirals
 

Bryant J1, Rance J2, Hull P3, Mao L4, Treloar C5. Int J Drug Policy. 2019 Jun 17. pii: S0955-3959(19)30157-4. doi: 10.1016/j.drugpo.2019.06.002. [Epub ahead of print]
 
456.Treatment Adherence and Support for People who Inject Drugs Taking Direct Acting Antiviral Therapy for Hepatitis C Infection
 

Read P1,2, Gilliver R1, Kearley J1, Lothian R1, Cunningham EB2, Chronister KJ1, Dore GJ2. J Viral Hepat. 2019 Jul 12. doi: 10.1111/jvh.13175. [Epub ahead of print]
 
457.Ledipasvir-Sofosbuvir for 12 Weeks in Children 3 to <6 Years Old With Chronic Hepatitis C
 

Schwarz KB1, Rosenthal P2, Murray KF3, Honegger JR4, Hardikar W5, Hague R6, Mittal N7, Massetto B8, Brainard DM8, Hsueh CH8, Shao J8, Parhy B8, Narkewicz MR9, Rao GS10, Whitworth S11, Bansal S12, Balistreri WF13. Hepatology. 2019 Jun 20. doi: 10.1002/hep.30830. [Epub ahead of print]
 
458.A Success Story: Advances in Treatment and Lower Disease Prevalence of Hepatitis C has a Large Impact on Medical Plan Costs
 

Leung N1, Bernacki SE, Bernacki EJ. J Occup Environ Med. 2019 Jun 13. doi: 10.1097/JOM.0000000000001633. [Epub ahead of print]
 
459.Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid
 

Roebuck MC1, Liberman JN. Am J Manag Care. 2019 Jun;25(8 Suppl):S131-S139.
 
460.Effectiveness and Safety of Sofosbuvir/Velpatasvir/ Voxilaprevir in Patients with Chronic Hepatitis C Previously Treated with DAAs
 

Llaneras J1, Riveiro-Barciela M2, Lens S3, Diago M4, Cachero A5, García-Samaniego J6, Conde I7, Arencibia A8, Arenas J9, Gea F10, Torras X11, Luis Calleja J12, Antonio Carrión J13, Fernández I14, María Morillas R15, Miguel Rosales J16, Carmona I17, Fernández-Rodríguez C18, Hernández-Guerra M19, Llerena S20, Bernal V21, Turnes J22, González-Santiago JM23, Montoliu S24, Figueruela B25, Badia E26, Delgado M27, Fernández-Bermejo M28, Iñarrairaegui M29, Manuel Pascasio J30, Esteban R2, Mariño Z3, Buti M31. J Hepatol. 2019 Jun 13. pii: S0168-8278(19)30345-9. doi: 10.1016/j.jhep.2019.06.002. [Epub ahead of print]
 
461.Influence of social determinants of health and substance use characteristics on persons who use drugs pursuit of care for hepatitis C virus infection
 

Williams N1, Bossert N1, Chen Y2, Jaanimägi U1, Markatou M3, Talal AH4. J Subst Abuse Treat. 2019 Jul;102:33-39. doi: 10.1016/j.jsat.2019.04.009. Epub 2019 May 2.
 
462.Clinical evaluation of a hepatitis C antibody rapid immunoassay on self-collected oral fluid specimens
 

Kimble MM1, Stafylis C2, Treut P1, Saab S3, Klausner JD4. Diagn Microbiol Infect Dis. 2019 May 25. pii: S0732-8893(19)30117-8. doi: 10.1016/j.diagmicrobio.2019.05.010. [Epub ahead of print]
 
463.Hepatitis C Competency and Outreach of Occupational Health Nurses
 

Surjadi M1, Nuchols B2, Souza D, Wolfe L3, Burgel B1. Workplace Health Saf. 2019 Jun 10:2165079919841637. doi: 10.1177/2165079919841637. [Epub ahead of print]
 
464.Heart Transplantation for Hepatitis C Virus Non-Viremic Recipients From Hepatitis C Virus Viremic Donors
 

Frager SZ1, Dhand A2, Gass A3, Levine A3, Spielvogel D4, Nog R2, Wolf DC5, Bodin RI5. Cardiol Rev. 2019 Jul/Aug;27(4):179-181. doi: 10.1097/CRD.0000000000000255.
 
465.Assessing the Safety of Direct-Acting Antiviral Agents for Hepatitis C
 

McGlynn EA1, Adams JL2, Kramer J2, Sahota AK3, Silverberg MJ4, Shenkman E5, Nelson DR6. JAMA Netw Open. 2019 Jun 5;2(6):e194765. doi: 10.1001/jamanetworkopen.2019.4765.
 
466.A Pilot Study of Safety and Efficacy of HCV Retreatment with sofosbuvir/velpatasvir/voxilaprevir in Patients With or Without HIV (RESOLVE STUDY)
 

Wilson E1, Covert E2, Hoffmann J1, Comstock E1, Emmanuel B1, Tang L1, Husson J1, Chua J1, Price A1, Mathur P1, Rosenthal E1, Kattakuzhy S1, Masur H3, Kottilil S1. J Hepatol. 2019 Jun 4. pii: S0168-8278(19)30307-1. doi: 10.1016/j.jhep.2019.05.021. [Epub ahead of print]
 
467.Willingness to participate in hepatitis C vaccine trials among socially marginalized people who use drugs
 

Yakovenko I1, Hyshka E1, Tyrrell L2, Wild TC3. J Subst Abuse Treat. 2019 Jun;101:67-71. doi: 10.1016/j.jsat.2019.03.010. Epub 2019 Mar 27.
 
468.Gaps in HCV Knowledge and Risk Behaviors among Young Suburban People Who Inject Drugs
 

Jost JJ1, Tempalski B2, Vera T3, Akiyama MJ4, Mangalonzo AP5, Litwin AH6,7. Int J Environ Res Public Health. 2019 Jun 2;16(11). pii: E1958. doi: 10.3390/ijerph16111958.
 
469.Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL Study
 

Persico M1, Aglitti A1, Milella M2, Coppola C3, Messina V4, Claar E5, Gentile I6, Sogari F7, Pierri P8, Surace LA9, Morisco F10, Tundo P11, Brancaccio G12, Serviddio G13, Gatti P14, Termite AP15, Di Costanzo GG16, Caroleo B17, Cozzolongo R18, Coppola N19, Longo A20, Fontanella L21, Federico A22, Rosato V1,5, Terrenato I23, Masarone M1. Liver Int. 2019 Jun 7. doi: 10.1111/liv.14170. [Epub ahead of print]
 
470.The opioid epidemic in rural northern New England: An approach to epidemiologic, policy, and legal surveillance
 

Stopka TJ1, Jacque E2, Kelso P3, Guhn-Knight H4, Nolte K5, Hoskinson R Jr4, Jones A3, Harding J6, Drew A7, VanDonsel A3, Friedmann PD4. Prev Med. 2019 May 31:105740. doi: 10.1016/j.ypmed.2019.05.028. [Epub ahead of print]
 
471.Randomized feasibility trial of directly observed versus unobserved hepatitis C treatment with ledipasvir-sofosbuvir among people who inject drugs
 

Coffin PO1,2, Santos GM1,2, Behar E1, Hern J1, Walker J1, Matheson T1, Kinnard EN1,3, Silvis J1, Vittinghoff E2, Fox R2, Page K2. PLoS One. 2019 Jun 3;14(6):e0217471. doi: 10.1371/journal.pone.0217471. eCollection 2019.
 
472.Increasing Prevalence of Chronic Hepatitis C Virus Infection in a Southern Academic Obstetrical Clinic
 

Lazenby GB1, Orr C1, Guille C1, Meissner EG1. South Med J. 2019 Jun;112(6):325-330. doi: 10.14423/SMJ.0000000000000988.
 
473.Scaling-up Hepatitis C Prevention and Treatment Interventions for Achieving Elimination in the United States - a Rural and Urban Comparison
 

Fraser H1, Vellozzi C2, Hoerger TJ3, Evans JL4, Kral AH3, Havens J5, Young AM5,6, Stone J1, Handanagic S7, Hariri S8, Barbosa C3, Hickman M1, Leib A9, Martin NK1,10, Nerlander L7, Raymond HF11, Page K12, Zibbell J3, Ward JW8,13, Vickerman P1. Am J Epidemiol. 2019 May 31. pii: kwz097. doi: 10.1093/aje/kwz097. [Epub ahead of print]
 
474.Point-of-care hepatitis C testing from needle and syringe programs: An Australian feasibility study
 

Williams B1, Howell J2, Doyle J3, Thompson AJ4, Draper B5, Layton C6, Latham N7, Bramwell F6, Membrey D6, Mcpherson M8, Roney J9, Stoové M5, Hellard ME10, Pedrana A11. Int J Drug Policy. 2019 May 22. pii: S0955-3959(19)30134-3. doi: 10.1016/j.drugpo.2019.05.012. [Epub ahead of print]
 
475.Staying hepatitis C negative: A systematic review and meta-analysis of cure and reinfection in people who inject drugs
 

Latham NH1,2, Doyle JS1,3, Palmer AY1, Vanhommerig JW1, Agius P1,4, Goutzamanis S1,4, Li Z1, Pedrana A1,5, Gottfredsson M6,7,8, Bouscaillou J9, Luhmann N9, Mazhnaya A10,11, Altice FL12,13, Saeed S14, Klein M15, Falade-Nwulia OO16, Aspinall E17,18, Hutchinson S17,18, Hellard ME1,3,5,19, Sacks-Davis R1,4,20. Liver Int. 2019 May 24. doi: 10.1111/liv.14152. [Epub ahead of print]
 
476.Community Screening, Identification, and Referral to Primary Care, for Hepatitis C, B, and HIV Among Homeless Persons in Los Angeles
 

Fuster D1, Gelberg L2,3. J Community Health. 2019 May 24. doi: 10.1007/s10900-019-00679-w. [Epub ahead of print]
 
477.Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project
 

Rojas Rojas T1, Di Beo V1, Delorme J2, Barre T1, Mathurin P3, Protopopescu C1, Bailly F4, Coste M1, Authier N2, Carrieri MP5, Rolland B6, Marcellin F1. Int J Drug Policy. 2019 May 22. pii: S0955-3959(19)30135-5. doi: 10.1016/j.drugpo.2019.05.013. [Epub ahead of print]
 
478.The Swiss Hepatitis Strategy as a model for facing future health policy challenges
 

Blindenbacher R1, Maeschli B2, Bruggmann P3. Health Policy. 2019 May 16. pii: S0168-8510(18)30417-2. doi: 10.1016/j.healthpol.2019.05.010. [Epub ahead of print]
 
479.Cost-effectiveness of HCV Treatment Models for People Who Inject Drugs in Opioid Agonist Treatment Programs
 

Gutkind S1, Schackman BR1, Morgan JR2, Leff JA1, Agyemang L3, Murphy SM1, Akiyama MJ3, Norton BL3, Litwin AH4,5, Linas BP2,6. Clin Infect Dis. 2019 May 16. pii: ciz384. doi: 10.1093/cid/ciz384. [Epub ahead of print]
 
480.Cost-effectiveness and budgetary impact of HCV testing, treatment and linkage to care in U.S. prisons
 

Assoumou SA1,2, Tasillo A1, Vellozzi C3, Yazdi GE1, Wang J1, Nolen S1, Hagan L4, Thompson W4, Randall LM5, Strick L6,7, Salomon JA8, Linas BP1,2,9.
 
481.Telementoring of primary care providers delivering hepatitis C treatment in New York City: Results from Project INSPIRE
 

Teixeira PA1, Bresnahan MP2, Laraque F2, Litwin AH3, Shukla SJ3, Schwartz JM3, Reynoso S3, Perumalswami PV4, Weiss JM4, Wyatt B4, Schackman BR1. Learn Health Syst. 2018 Jul;2(3). pii: e10056. doi: 10.1002/lrh2.10056. Epub 2018 May 10.
 
482.Efficacy and safety of direct-acting antiviral therapy for chronic hepatitis C genotype 6: A meta-analysis
 

Luo A1, Xu P, Wang J, Li Z, Wang S, Jiang X, Ren H, Luo Q. Medicine (Baltimore). 2019 May;98(20):e15626. doi: 10.1097/MD.0000000000015626.
 
483.Utilizing Electronic Laboratory Reporting Data to Assess the Burden of Hepatitis C in Arizona
 

Tsang CA1, Khan MA, Brady SM, Erhart LM, Komatsu KK. J Public Health Manag Pract. 2019 May 14. doi: 10.1097/PHH.0000000000001011. [Epub ahead of print]
 
484.Real-world Australian data reflect very high sustained virologic response at 12 weeks with direct acting antiviral therapy for hepatitis C and suggests highly achievable even in those without an end-of-treatment response
 

Williams J1, Lucarelli N2, Nicoll A1,2, Lubel J1,2. Intern Med J. 2019 May;49(5):666-669. doi: 10.1111/imj.14279.
 
485.Sleep disturbances in HIV-HCV coinfected patients: indications for clinical management in the HCV cure era (ANRS CO13 HEPAVIH cohort)
 

Costa M1,2, Rojas Rojas T1,2, Lacoste D3, Villes V1,2, Aumaitre H4, Protopopescu C1,2, Yaya I1,2, Wittkop L5,6, Krause J7, Salmon-Céron D8,9, Marcellin F1,2, Sogni P8,10,11, Carrieri MP1,2; ANRS CO13 HEPAVIH Study Group. Eur J Gastroenterol Hepatol. 2019 May 14. doi: 10.1097/MEG.0000000000001441. [Epub ahead of print]
 
486.The Global State of Harm Reduction in Prisons
 

Sander G1, Shirley-Beavan S1, Stone K1. J Correct Health Care. 2019 Apr;25(2):105-120. doi: 10.1177/1078345819837909.
 
487.Comprehensive nationwide chronic hepatitis C surveillance is necessary for accurate state-level prevalence estimates
 

Moore MS1, Greene SK2, Bocour A3, Brown CM4, Coyle JR5, Kuncio D6, Onofrey S7, Patel MT8, Winters A9. J Viral Hepat. 2019 May 13. doi: 10.1111/jvh.13124. [Epub ahead of print]
 
488.Balancing the risk and rewards of utilizing organs from hepatitis C viremic donors
 

Sise ME1, Strohbehn IA2, Bethea E2, Gustafson JL2, Chung RT2. Curr Opin Organ Transplant. 2019 Jun;24(3):351-357. doi: 10.1097/MOT.0000000000000651.
 
489.Treatment of patients with HIV or hepatitis C by pharmacist clinicians in a patient-centered medical home
 

Ryan KL1, Jakeman B2, Conklin J3, Pineda LJ4, Deming P5, Mercier RC5. Am J Health Syst Pharm. 2019 May 4. pii: zxz059. doi: 10.1093/ajhp/zxz059. [Epub ahead of print]
 
490.Hepatitis C Update and Expanding the Role of Primary Care
 

Simoncini GM1, Koren DE2. J Am Board Fam Med. 2019 May-Jun;32(3):428-430. doi: 10.3122/jabfm.2019.03.180286.
 
491.Integration of Hepatitis C Treatment in a Primary care Federally Qualified Health Center; Philadelphia, Pennsylvania, 2015-2017
 

Bartholomew TS1,2, Grosgebauer K2, Huynh K3, Cos T3,4. Infect Dis (Auckl). 2019 Apr 28;12:1178633719841381. doi: 10.1177/1178633719841381. eCollection 2019.
 
492.Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection
 

Pearlman B1, Perrys M2, Hinds A3. Am J Gastroenterol. 2019 May 8. doi: 10.14309/ajg.0000000000000248. [Epub ahead of print]
 
493.Epidemiologic features of a large hepatitis C cohort evaluated in a major health system in the western United States
 

Mukhtar NA1, Ness EM1, Jhaveri M1, Fix OK1, Hart M1, Dale C1, Pratt C2, Kowdley KV3. Ann Hepatol. 2019 Mar - Apr;18(2):360-365. doi: 10.1016/j.aohep.2018.12.003. Epub 2019 Apr 17.
 
494.Role of HCV Viremia in Corroborated HCV Transmission Events Within Young Adult Injecting Partnerships
 

Hahn JA1, Tully DC2, Evans JL3, Morris MD3, Briceno A3, Bean DJ4, Allen TM4, Page K5. Open Forum Infect Dis. 2019 Apr 25;6(4):ofz125. doi: 10.1093/ofid/ofz125. eCollection 2019 Apr.
 
495.The Costs of Hepatitis C by Liver Disease Stage: Estimates from the Veterans Health Administration
 

Gidwani-Marszowski R1,2,3, Owens DK4,5, Lo J6, Goldhaber-Fiebert JD5, Asch SM4,7, Barnett PG6,4,5. Appl Health Econ Health Policy. 2019 Apr 27. doi: 10.1007/s40258-019-00468-5. [Epub ahead of print]
 
496.Retreatment of Hepatitis C Virus-Infected Patients with Direct-Acting Antiviral Failures
 

Pawlotsky JM1,2. Semin Liver Dis. 2019 Apr 30. doi: 10.1055/s-0039-1687823. [Epub ahead of print]
 
497.High versus low mean arterial pressures in hepatorenal syndrome: A randomized controlled pilot trial
 

Varajic B1, Cavallazzi R2, Mann J2, Furmanek S3, Guardiola J2, Saad M2. J Crit Care. 2019 Apr 15;52:186-192. doi: 10.1016/j.jcrc.2019.04.006. [Epub ahead of print]
 
498.Content Validity and Reliability of a Self-Report Measure of Medication Nonadherence in Hepatitis C Treatment
 

Voils CI1,2, King HA3,4,5, Thorpe CT6,7, Blalock DV3,8, Kronish IM9, Reeve BB4, Boatright C3, Gellad ZF3,10. Dig Dis Sci. 2019 Apr 29. doi: 10.1007/s10620-019-05621-7. [Epub ahead of print]
 
499.The contribution of injection drug use to hepatitis C virus transmission globally, regionally, and at country level: a modelling study
 

Trickey A1, Fraser H2, Lim AG2, Peacock A3, Colledge S3, Walker JG2, Leung J4, Grebely J5, Larney S3, Martin NK6, Hickman M7, Degenhardt L3, May MT8, Vickerman P7. Lancet Gastroenterol Hepatol. 2019 Apr 10. pii: S2468-1253(19)30085-8. doi: 10.1016/S2468-1253(19)30085-8. [Epub ahead of print]
 
500.Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs
 

E Williams B1, Nelons D2, Seaman A3, Witkowska M4, Ronan W5, Wheelock H5, Zaman A3, Garcia J2. Int J Drug Policy. 2019 Apr 15. pii: S0955-3959(19)30074-X. doi: 10.1016/j.drugpo.2019.03.015. [Epub ahead of print]
 
501.Hepatitis C virus testing, liver disease assessment and direct-acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study
 

Bajis S1, Grebely J1, Cooper L2, Smith J2, Owen G2, Chudleigh A2, Hajarizadeh B1, Martinello M1, Adey S3, Read P4, Gilliver R4, Applegate T1, Treloar C5, Maher L1, Dore GJ1. J Viral Hepat. 2019 Apr 13. doi: 10.1111/jvh.13112. [Epub ahead of print]
 
502.Quantitative evaluation of an integrated nurse model of care providing hepatitis Ctreatment to people attending homeless services in Melbourne, Australia
 

Harney BL1, Whitton B2, Lim C3, Paige E2, McDonald B4, Nolan S5, Pemberton D5, Hellard ME6, Doyle JS6. Int J Drug Policy. 2019 Apr 10. pii: S0955-3959(19)30077-5. doi: 10.1016/j.drugpo.2019.02.012. [Epub ahead of print]
 
503.Liver Fibrosis Determination
 

Lai M1, Afdhal NH2. Gastroenterol Clin North Am. 2019 Jun;48(2):281-289. doi: 10.1016/j.gtc.2019.02.002. Epub 2019 Apr 1.
 
504.Direct-Acting Oral Anticoagulants (DOACs) in Cirrhosis and Cirrhosis-Associated Portal Vein Thrombosis
 

Weinberg EM1, Palecki J1, Reddy KR1. Semin Liver Dis. 2019 May;39(2):195-208. doi: 10.1055/s-0039-1679934. Epub 2019 Apr 12.
 
505.Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients with Chronic HCV Infection and Psychiatric Disorders: An Integrated Analysis
 

Back D1, Belperio P2, Bondin M3, Negro F4, Talal AH5, Park C3, Zhang Z3, Pinsky B3, Crown E3, Mensa FJ3, Marra F1. J Viral Hepat. 2019 Apr 12. doi: 10.1111/jvh.13110. [Epub ahead of print]
 
506.Drug-Drug Interaction Studies of Methadone and Antiviral Drugs: Lessons Learned
 

Younis IR1,2, Lakota EA1,3, Volpe DA1, Patel V1, Xu Y1, Sahajwalla CG1. J Clin Pharmacol. 2019 Apr 11. doi: 10.1002/jcph.1405. [Epub ahead of print]
 
507.Hepatitis C Virus Treatment with Directly Acting Agents Reduces the Risk of Incident Diabetes - Results from ERCHIVES
 

Butt AA1,2,3, Yan P1, Aslam S1, Shaikh OS1, Abou-Samra AB2,3. Clin Infect Dis. 2019 Apr 12. pii: ciz304. doi: 10.1093/cid/ciz304. [Epub ahead of print]
 
508.Hepatitis C in pregnant American Indian and Alaska native women; 2003-2015
 

Nolen LD1, O'Malley JC2, Seeman SS1, Bruden DJT1, Apostolou A3,4, McMahon BJ5, Bruce MG1. Int J Circumpolar Health. 2019 Dec;78(1):1608139. doi: 10.1080/22423982.2019.1608139.
 
509.HIV and HCV screening among trauma patients
 

Simoncini GM1, Oyola-Jimenez J1, Singleton D1, Volgraf J2, Ramsey FV3, Goldberg A4. Int J STD AIDS. 2019 Apr 8:956462419829590. doi: 10.1177/0956462419829590. [Epub ahead of print]
 
510.Longitudinal assessment of the association between implementation strategy use and the uptake of hepatitis C treatment: Year 2
 

Rogal SS1,2,3, Yakovchenko V4, Waltz TJ5,6, Powell BJ7, Gonzalez R8, Park A9, Chartier M10, Ross D10, Morgan TR8, Kirchner JE11, Proctor EK12, Chinman MJ13,14. Implement Sci. 2019 Apr 8;14(1):36. doi: 10.1186/s13012-019-0881-7.
 
511.Health implications of sex trading characteristics in Long Beach, California, USA
 

Clingan SE1, Fisher DG2,3, Hardan-Khalil K4, Reynolds GL3,5, Huckabay L4, Costa C4, Pedersen WC2, Johnson ME6. Int J STD AIDS. 2019 Apr 8:956462419828138. doi: 10.1177/0956462419828138. [Epub ahead of print]
 
512.Outcomes of a nurse-led model of care for hepatitis C assessment and treatment with direct-acting antivirals in the custodial setting
 

Overton K1, Clegg J2, Pekin F2, Wood J2, McGrath C2, Lloyd A3, Post JJ4. Int J Drug Policy. 2019 Apr 6. pii: S0955-3959(19)30078-7. doi: 10.1016/j.drugpo.2019.02.013. [Epub ahead of print]
 
513.Hepatitis C treatment outcomes among homeless-experienced individuals at a community health centre in Boston
 

Beiser ME1, Smith K2, Ingemi M3, Mulligan E4, Baggett TP5. Int J Drug Policy. 2019 Apr 5. pii: S0955-3959(19)30079-9. doi: 10.1016/j.drugpo.2019.03.017. [Epub ahead of print]
 
514.Hepatitis C virus screening trends: A 2016 update of the National Health Interview Survey
 

Kasting ML1, Giuliano AR2, Reich RR3, Roetzheim RG4, Duong LM5, Thomas E6, Nelson DR7, Shenkman E8, Vadaparampil ST9. Cancer Epidemiol. 2019 Apr 3;60:112-120. doi: 10.1016/j.canep.2019.03.007. [Epub ahead of print]
 
515.Identifying Areas with Disproportionate Local Health Department Services Relative to Opioid Overdose, HIV and Hepatitis C Diagnosis Rates: A Study of Rural Illinois
 

McLuckie C1,2, Pho MT3,4, Ellis K5, Navon L6,7, Walblay K8, Jenkins WD9, Rodriguez C10, Kolak MA11, Chen YT12, Schneider JA13, Zahnd WE14,15. Int J Environ Res Public Health. 2019 Mar 19;16(6). pii: E989. doi: 10.3390/ijerph16060989.
 
516.Causes of death among persons diagnosed with hepatitis C infection in the pre and post DAA era in England: a record linkage study
 

Simmons R1,2, Ireland G1,2, Ijaz S3,2, Ramsay M1, Mandal S1,2; National Institute for Health Research Health Protection Research Unit (NIHR HPRU) in Blood Borne and Sexually Transmitted Infections. J Viral Hepat. 2019 Mar 21. doi: 10.1111/jvh.13096. [Epub ahead of print]
 
517.Quality of Life, Functioning, and Coping in HCV Patients Continuing Versus Ceasing Alcohol Use
 

Sims OT1,2, Oh H3, Pollio DE1, Hong BA4, Pollio EW1, North CS5,6. Health Promot Pract. 2019 Mar 21:1524839919837968. doi: 10.1177/1524839919837968. [Epub ahead of print]
 
518.Restoration of HCV-Specific Immune Responses with Antiviral Therapy: A Case for DAA Treatment in Acute HCV Infection
 

Casey JL1, Feld JJ2,3, MacParland SA4,5. Cells. 2019 Apr 5;8(4). pii: E317. doi: 10.3390/cells8040317.
 
519.Treatment cascade for hepatitis C virus in young adult people who inject drugs in San Francisco: Low number treated
 

Morris MD1, Mirzazadeh A2, Evans JL3, Briceno A3, Coffin P4, Hahn JA5, Page KA6. Drug Alcohol Depend. 2019 Feb 27;198:133-135. doi: 10.1016/j.drugalcdep.2019.02.008. [Epub ahead of print]
 
520.Age-related Differences in Past or Present HCV Infection among People Who Inject Drugs - National HIV Behavioral Surveillance, Eight U.S Cities, 2015
 

Abara WE1, Trujillo L2, Broz D2, Finlayson T2, Teshale E1, Paz-Bailey G2, Glick S3, Al-Tayyib AA4, Robinson WT5, Masiello-Schuette S6, Sey EK7, Anderson BJ8, Poe J Infect Dis. 2019 Mar 27. pii: jiz142. doi: 10.1093/infdis/jiz142. [Epub ahead of print]

J9, Braunstein S10.
 
521.Preoperative Treatment of Hepatitis C Is Associated With Lower Prosthetic Joint Infection Rates in US Veterans
 

Bendich I1, Takemoto S2, Patterson JT1, Monto A3, Barber TC1, Kuo AC2. J Arthroplasty. 2019 Mar 9. pii: S0883-5403(19)30208-6. doi: 10.1016/j.arth.2019.02.052. [Epub ahead of print]
 
522.Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital
 

Eckardt P1, Niu J2, Savage A1, Griffin T1, Sherman E1,3. J Int Assoc Provid AIDS Care. 2019 Jan-Dec;18:2325958219835590. doi: 10.1177/2325958219835590.
 
523.Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia
 

Doyle JS1,2, Scott N2,3, Sacks-Davis R2, Pedrana AE2,3, Thompson AJ4,5, Hellard ME1,2,3; Eliminate Hepatitis C Partnership. Aliment Pharmacol Ther. 2019 Mar 25. doi: 10.1111/apt.15210. [Epub ahead of print]

Collaborators (10)
 
524.Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy
 

Thabut D1, Bureau C2, Layese R3, Bourcier V4, Hammouche M4, Cagnot C5, Marcellin P6, Guyader D6, Pol S7, Larrey D8, De Lédinghen V9, Ouzan D10, Zoulim F11, Roulot D12, Tran A13, Bronowicki JP14, Zarski JP15, Goria O16, Calès P17, Péron JM18, Alric L19, Bourlière M20, Mathurin P21, Blanc JF22, Abergel A23, Serfaty L24, Mallat A3, Grangé JD25, Attali P26, Bacq Y27, Wartelle-Bladou C28, Dao T29, Pilette C30, Silvain C31, Christidis C32, Capron D33, Bernard-Chabert B34, Hillaire S35, Di Martino V36, Sutton A37, Audureau E3, Roudot-Thoraval F3, Nahon P4; ANRS CO12 CirVir group.

Collaborators (38) Gastroenterology. 2019 Feb 13. pii: S0016-5085(18)35303-4. doi: 10.1053/j.gastro.2018.11.053. [Epub ahead of print]
 
525.Comparative effectiveness of pharmacist care delivery models for hepatitis Cclinics
 

Naidjate SS1, Zullo AR2, Dapaah-Afriyie R1, Hersey ML1, Marshall BDL3, Winkler RM1, Berard-Collins C4. Am J Health Syst Pharm. 2019 Mar 15. pii: zxz034. doi: 10.1093/ajhp/zxz034. [Epub ahead of print]
 
526.Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia
 

Younossi ZM1, Henry L1, P Ong J2, Tanaka A3, Eguchi Y4, Mizokami M3, Lim YS5, Dan YY6, Yu ML7, Stepanova M8. Aliment Pharmacol Ther. 2019 Mar;49(6):644-653. doi: 10.1111/apt.15131. Epub 2019 Feb 13.
 
527.The health equity implementation framework: proposal and preliminary study of hepatitis C virus treatment
 

Woodward EN1,2, Matthieu MM3,4, Uchendu US5, Rogal S6,7,8, Kirchner JE3,9,10. Implement Sci. 2019 Mar 12;14(1):26. doi: 10.1186/s13012-019-0861-y.
 
528.Budgetary impact analysis of a primary care-based hepatitis C treatment program: Effects of 340B Drug Pricing Program
 

Jones EA1, Linas BP2, Truong V3, Burgess JF1, Lasser KE2,3. PLoS One. 2019 Mar 14;14(3):e0213745. doi: 10.1371/journal.pone.0213745. eCollection 2019.
 
529.Increasing access for veterans with hepatitis C by enhancing use of clinical pharmacy specialists
 

Ourth HL, Groppi JA, Morreale AP, Jorgenson T, Himsel AS, Jacob DA. J Am Pharm Assoc (2003). 2019 Mar 7. pii: S1544-3191(19)30028-7. doi: 10.1016/j.japh.2019.01.018. [Epub ahead of print]
 
530.Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy
 

Thabut D1, Bureau C2, Layese R3, Bourcier V4, Hammouche M4, Cagnot C5, Marcellin P6, Guyader D6, Pol S7, Larrey D8, De Lédinghen V9, Ouzan D10, Zoulim F11, Roulot D12, Tran A13, Bronowicki JP14, Zarski JP15, Goria O16, Calès P17, Péron JM18, Alric L19, Bourlière M20, Mathurin P21, Blanc JF22, Abergel A23, Serfaty L24, Mallat A3, Grangé JD25, Attali P26, Bacq Y27, Wartelle-Bladou C28, Dao T29, Pilette C30, Silvain C31, Christidis C32, Capron D33, Bernard-Chabert B34, Hillaire S35, Di Martino V36, Sutton A37, Audureau E3, Roudot-Thoraval F3, Nahon P4; ANRS CO12 CirVir group.

Collaborators (38) Gastroenterology. 2019 Feb 13. pii: S0016-5085(18)35303-4. doi: 10.1053/j.gastro.2018.11.053. [Epub ahead of print]
 
531.Family Practitioner-Directed Hepatitis C Therapy With Direct-Acting Antivirals Achieves High-Sustained Virologic Response in Prison Population
 

Mokkarala S1,2, Johnson C3, Sarkar S3, Rudas RJ4. J Correct Health Care. 2019 Mar 13:1078345819832875. doi: 10.1177/1078345819832875. [Epub ahead of print]
 
532.Hepatitis B and C virus infections transmitted through organ transplantation investigated by CDC, United States, 2014-2017
 

Bixler D1, Annambholta P2, Abara WE1, Collier MG1, Jones J2, Mixson-Hayden T1, Basavaraju SV2, Ramachandran S1, Kamili S1, Moorman A1. Am J Transplant. 2019 Mar 12. doi: 10.1111/ajt.15352. [Epub ahead of print]
 
533.Fibrosis reversal after hepatitis C virus elimination
 

Rockey DC1. Curr Opin Gastroenterol. 2019 Mar 6. doi: 10.1097/MOG.0000000000000524. [Epub ahead of print]
 
534.Screening and Treating Hepatitis C in the VA: Achieving Excellence Using Lean and System Redesign
 

Park A1, Gonzalez R1, Chartier M1, Rogal S1, Yakovchenko V1, Ross D1, Morgan TR1. Fed Pract. 2018 Jul;35(7):24-29.
 
535.Understanding how, why, for whom, and under what circumstances opt-out blood-borne virus testing programmes work to increase test engagement and uptake within prison: a rapid-realist review
 

Francis-Graham S1,2,3, Ekeke NA4, Nelson CA5, Lee TY5, Haj SE4, Rhodes T6, Vindrola C7, Colbourn T8, Rosenberg W9,4,10. BMC Health Serv Res. 2019 Mar 8;19(1):152. doi: 10.1186/s12913-019-3970-z.
 
536.Short-term budget affordability of hepatitis C treatments for state Medicaid programs
 

Chou JW1, Silverstein AR2, Goldman DP2. BMC Health Serv Res. 2019 Feb 28;19(1):140. doi: 10.1186/s12913-019-3956-x.
 
537.Treatment strategies for patients with decompensated liver cirrhosis due to hepatitis C virus infection eligible for liver transplantation: real-life data from five German transplant centers
 

Sandmann L1,2, Dörge P1,2, Wranke A1,2, Vermehren J3,2, Welzel TM3,2, Berg CP4,2, Grottenthaler JM4,2, Weiss KH5,2, Langel J5,2, Sterneck M6,2, von Wulffen M6,2, Manns MP1,2, Wedemeyer H1,7,2, Hardtke S1,2, von Hahn T1,2. Eur J Gastroenterol Hepatol. 2019 Feb 21. doi: 10.1097/MEG.0000000000001386. [Epub ahead of print]
 
538.Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection
 

Dellay B1, Sexter A2, Wang JH3, Hess GP4,5, Kim WR6, Israni AK3,7. Pharmacotherapy. 2019 Feb 18. doi: 10.1002/phar.2237. [Epub ahead of print]
 
539.Direct-acting antiviral agents do not increase the incidence of hepatocellular carcinoma development: a prospective, multicenter study
 

Ide T1, Koga H2, Nakano M1, Hashimoto S3, Yatsuhashi H3, Higuchi N4, Nakamuta M4, Oeda S5, Eguchi Y5, Shakado S6, Sakisaka S6, Yoshimaru Y7, Sasaki Y7, Honma Y8, Harada M8, Seike M9, Maeshiro T10, Miuma S11, Nakao K11, Mawatari S12, Ido A12, Nagata K13, Matsumoto S14, Takami Y15, Sohda T16, Kakuma T17, Torimura T1. Hepatol Int. 2019 Feb 28. doi: 10.1007/s12072-019-09939-2. [Epub ahead of print]
 
540.Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis CVirus Genotypes 1 and 4 Infection
 

Wei L1, Kumada H2, Perumalswami PV3, Tanwandee T4, Cheng W5, Heo J6, Cheng PN7, Hwang P8, Mu SM9, Zhao XM9, Asante-Appiah E8, Caro L8, Hanna GJ8, Robertson MN8, Haber BA8, Talwani R8. J Gastroenterol Hepatol. 2019 Feb 19. doi: 10.1111/jgh.14636. [Epub ahead of print]
 
541.Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis CVirus Genotype 1 or 4 Infection and Advanced Kidney Disease
 

Lawitz E1, Gane E2, Cohen E3, Vierling J4, Agarwal K5, Hassanein T6, Mantry PS7, Pockros PJ8, Bennett M9, Kemmer N10, Morelli G11, Zha J3, Wang D3, Shulman NS3, Cohen DE3, Reddy KR12. Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.
 
542.Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation
 

Latt NL1. Gastroenterol Hepatol (N Y). 2018 Dec;14(12):687-705.
 
543.Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
 

Bernstein DE1, Tran A2, Martin P3, Kowdley KV4, Bourliere M5, Sulkowski MS6, Pockros PJ7, Renjifo B8, Wang D8, Shuster DL8, Cohen DE8, Jacobson IM9. Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.

 
 
544.Screening and Treating Hepatitis C in the VA: Achieving Excellence Using Lean and System Redesign
 

Park A1, Gonzalez R1, Chartier M1, Rogal S1, Yakovchenko V1, Ross D1, Morgan TR1. Fed Pract. 2018 Jul;35(7):24-29.
 
545.Impact of Sofosbuvir-Based Therapy on Liver Transplant Candidates with Hepatitis C Virus Infection
 

Dellay B1, Sexter A2, Wang JH3, Hess GP4,5, Kim WR6, Israni AK3,7. Pharmacotherapy. 2019 Feb 18. doi: 10.1002/phar.2237. [Epub ahead of print]
 
546.Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants with Hepatitis CVirus Genotypes 1 and 4 Infection
 

Wei L1, Kumada H2, Perumalswami PV3, Tanwandee T4, Cheng W5, Heo J6, Cheng PN7, Hwang P8, Mu SM9, Zhao XM9, Asante-Appiah E8, Caro L8, Hanna GJ8, Robertson MN8, Haber BA8, Talwani R8. J Gastroenterol Hepatol. 2019 Feb 19. doi: 10.1111/jgh.14636. [Epub ahead of print]
 
547.Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis CVirus Genotype 1 or 4 Infection and Advanced Kidney Disease
 

Lawitz E1, Gane E2, Cohen E3, Vierling J4, Agarwal K5, Hassanein T6, Mantry PS7, Pockros PJ8, Bennett M9, Kemmer N10, Morelli G11, Zha J3, Wang D3, Shulman NS3, Cohen DE3, Reddy KR12. Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.
 
548.Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease
 

Bernstein DE1, Tran A2, Martin P3, Kowdley KV4, Bourliere M5, Sulkowski MS6, Pockros PJ7, Renjifo B8, Wang D8, Shuster DL8, Cohen DE8, Jacobson IM9. Kidney Int Rep. 2018 Oct 16;4(2):245-256. doi: 10.1016/j.ekir.2018.10.005. eCollection 2019 Feb.
 
549.Vitamin D deficiency and health-related quality of life in chronic hepatitis C
 

Palazzo D1, Biliotti E1, Esvan R1, Volpicelli L1, Franchi C1, Fontanelli Sulekova L1, Spaziante M1, Santori M1, Rugova A1, Rucci P2, Taliani G1. J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13076. [Epub ahead of print]
 
550.Priorities and recommended actions for how researchers, practitioners, policy makers, and the affected community can work together to improve access to hepatitis C care for people who use drugs
 

Day E1, Broder T2, Bruneau J3, Cruse S1, Dickie M4, Fish S4, Grillon C5, Luhmann N5, Mason K6, McLean E7, Trooskin S8, Treloar C9, Grebely J10. Int J Drug Policy. 2019 Feb 8;66:87-93. doi: 10.1016/j.drugpo.2019.01.012. [Epub ahead of print]
 
551.Evidence-based and guideline-concurrent responses to narratives deferring HCV treatment among people who inject drugs
 

Childs E1, Assoumou SA2, Biello KB3,4,5, Biancarelli DL1,6, Drainoni ML1,2,6,7, Edeza A3,4, Salhaney P3, Mimiaga MJ3,4,5,8, Bazzi AR9. Harm Reduct J. 2019 Feb 11;16(1):14. doi: 10.1186/s12954-019-0286-6.
 
552.Impact of hepatitis C treatment on pain intensity, prescription opioid use and arthritis
 

Kumthekar A1, Shull S2, Lovejoy TI2,3, Morasco BJ2,3, Chang M2,3, Barton J2,3. Int J Rheum Dis. 2019 Feb 6. doi: 10.1111/1756-185X.13479. [Epub ahead of print]
 
553.Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries
 

Ferenci P1, Bourgeois S2, Buggisch P3, Norris S4, Curescu M5, Larrey D6, Marra F7, Kleine H8, Dorr P9, Charafeddine M9, Crown E9, Bondin M9, Back D7, Flisiak R10. J Viral Hepat. 2019 Feb 10. doi: 10.1111/jvh.13080. [Epub ahead of print]
 
554.Stereotactic body radiation therapy for hepatocellular carcinoma: Practice patterns, dose selection and factors impacting survival
 

Robbins JR1,2, Schmid RK2, Hammad AY3, Gamblin TC3, Erickson BA2. Cancer Med. 2019 Jan 31. doi: 10.1002/cam4.1948. [Epub ahead of print]
 
555.Universal Screening for HIV and Hepatitis C Infection: A Community-Based Pilot Project
 

Kempf MC1, Ott C2, Wise JM2, Footman AP3, Araya BY3, Hardy CM4, Walker C4, Latham C5, Stockett R5, Daniels G5, Alexander M5, Lanzi RG3. Am J Prev Med. 2018 Nov;55(5S1):S112-S121. doi: 10.1016/j.amepre.2018.05.015.
 
556.Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection
 

Lawitz E1, Poordad F1, Anderson LJ2, Vesay M2, Kelly MM2, Liu H2, Gao W2, Fernsler D2, Asante-Appiah E2, Robertson MN2, Hanna GJ2, Barr E2, Butterton J2, Kowdley KV3, Hassanein T4, Sahota A5, Gordon SC6, Yeh WW2. J Viral Hepat. 2019 Feb 9. doi: 10.1111/jvh.13079. [Epub ahead of print]
 
557.Safety and efficacy of glecaprevir/pibrentasvir in patients with chronic hepatitis C genotypes 1-6 receiving opioid substitution therapy
 

Grebely J1, Dore GJ2, Alami NN3, Conway B4, Dillon JF5, Gschwantler M6, Felizarta F7, Hézode C8, Tomasiewicz K9, Fredrick LM3, Dumas EO3, Mensa FJ3. Int J Drug Policy. 2019 Feb 5;66: